

CURRICULUM VITAE

PART I: General Information

Date Prepared: December 21, 2015

Name: Andrew Alan Nierenberg, M.D.

Office Address: Massachusetts General Hospital
Bipolar Clinical and Research Program
Suite 580
50 Staniford Street
Boston, MA 02114

Home Address: 113 Oxbow Road
Wayland, MA 01778

Work Email: anierenberg@partners.org **Work Fax:** (617)726-6768

Place of Birth: Bronx, New York

Education:

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1976	B.A.	State University of New York at Buffalo, Buffalo NY
1980	M.D.	Albert Einstein College of Medicine of Yeshiva University, Bronx, New York
2007	Honorary Masters	Harvard University, Cambridge, MA

Post-Doctoral Training:

1980-1981 Intern in Medicine and Psychiatry, New York University/Bellevue Hospital, New York, NY

1981-1983 Resident in Psychiatry, New York University/Bellevue Hospital, New York, NY

1983-1984 Chief Resident in Psychiatry, New York University/Bellevue Hospital, New York, NY

Research Fellowships:

1984-1986 Robert Wood Johnson Clinical Scholar, Postdoctoral Fellow in Internal Medicine and Psychiatry (Clinical Epidemiology), Yale University, New Haven, CT

1985-1986 Research Psychiatrist, Connecticut Mental Health Center; Abraham Ribicoff Clinical Neuroscience Research Unit, New Haven, CT

Licensure and Certification:

1981 New York State license registration

1984 Connecticut State license registration

1985 American Board of Psychiatry and Neurology (Psychiatry)
1986 Massachusetts State license registration #56066

Academic Appointments:

1982-1984 Clinical Instructor in Psychiatry, New York University, New York NY
1984-1986 Clinical Instructor in Psychiatry, Yale University, New Haven CT
1986-1993 Instructor in Psychiatry, Harvard Medical School, Boston MA
1993-1996 Assistant Professor of Psychiatry, Harvard Medical School, Boston, MA
1997-2006 Associate Professor of Psychiatry, Harvard Medical School, Boston MA
2007- Professor of Psychiatry, Harvard Medical School, Boston MA

Hospital Appointments:

1983-1984 Chief Resident, New York University Medical Center/Bellevue Hospital, New York NY
1984-1986 Postdoctoral Fellow in Medicine and Psychiatry, Yale New Haven Hospital, New Haven CT
1985-1986 Research Psychiatrist, Connecticut Mental Health Center, New Haven CT
1986-1994 Assistant Psychiatrist, McLean Hospital, Belmont MA
1992-1995 Assistant Psychiatrist, Massachusetts General Hospital, Boston MA
1995-1997 Associate Psychiatrist, Massachusetts General Hospital, Boston MA
1997- Psychiatrist, Massachusetts General Hospital, Boston MA

Other Professional and Major Visiting Appointments:

1997- Co-Founder and Co-Director, Depression and Anxiety Associates Group Practice, Outpatient Psychiatry Division, Massachusetts General Hospital, Boston, Massachusetts

Hospital and Health Care Organization Service Responsibilities:

1986-1988 Psychiatrist-in-Charge, Codman I, Affective Disorders Unit, McLean Hospital, Belmont, MA
1988-1989 Psychiatrist-in-Charge, South Belknap I, Affective Disorders Unit, McLean Hospital, Belmont, MA
1989-1991 Psychiatrist-in-Charge, South Belknap II, Affective Disorders Research Unit, McLean Hospital, Belmont, MA
1989-1992 Psychiatrist, Biological Psychiatry Program, McLean Hospital
1992-1995 Staff Member, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA

Major Administrative Responsibilities:

1989-1992 Founder and Director, Treatment Resistant Depression Program, McLean Hospital, Belmont, MA
1990-1992 Director, Affective Disorders Outpatient Services, McLean Hospital, Belmont, MA
1992-1995 Associate Director and Research Psychiatrist, Depression Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA

1995-	Associate Director, Depression Clinical and Research Program, Massachusetts General Hospital, Boston MA
1998-	Co-Founder, Co-Director, MGH Depression and Anxiety Associates Group Practice
2000- 2008	Medical Director, Bipolar Programs (Harvard Bipolar Research Program and Partners Bipolar Mood Disorder Treatment Center), Massachusetts General Hospital, Boston MA
2001-2004	Co-Director, Stanley Bipolar Center, Massachusetts General Hospital, Boston MA
2008-2010	Co-Director, Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston MA
2010-2011	Director, Bipolar Research Program, MGH
2010-	Director, Clinical Research Support Office, MGH Clinical Research Program
2011-	Director, Bipolar Clinic and Research Program, MGH
2011-	Director of Education, Clinical Trials Network and Institute, MGH
2013-	Co-Director, Clinical Research Education Unit, MGH Clinical Research Program
2014	Director, Clinical Research Education Unit, MGH Clinical Research Program
2014	Director, Research Education and Training, MGH Research Institute

Major Committee Assignments:

Medical School:

2002-2004	Member, Scientific Advisory Board, Bernard Osher Institute, Division for Research and Education in Complementary and Integrative Medical Therapies, Harvard Medical School
2004	Member, Harvard Medical School 2 nd Year Psychopathology Task Force
2004	Charter Member, Seminars in Brain and Behavior, Harvard Medical School (Director: Edward Kravitz, PhD)
2004	Invited Participant, Harvard Medical School Program on Leadership Development for Physicians and Scientists, Boston MA
2009	Ad Hoc Committee for Professors

Affiliated Institution:

1983-1984	Curriculum Committee, Psychiatry, New York University/Bellevue, New York NY
1987-1991	Informed Consent Committee, McLean Hospital, Belmont MA
1988-1989	Case Conference Committee, McLean Hospital, Belmont MA
1992	Mental Health Special Projects Review Committee: Clinical Subcommittee, National Institute of Mental Health
1993-2000	Cingulotomy Assessment Committee, Massachusetts General Hospital, Boston MA
1994-1995	Physician's Review Committee, Department of Psychiatry, Massachusetts General Hospital, Boston MA
1994-1998	Subcommittee on Review of Research Proposals (SRRP), Committee on Research, Massachusetts General Hospital, Boston MA
1995-	Depression Clinical and Research Program Evaluation Committee, Massachusetts General Hospital, Boston MA
2000	Steering Committee, Department of Psychiatry, Massachusetts General Hospital

2000 NIMH Systematic Treatment Enhancement Program Coordinating Center Steering Committee, Massachusetts General Hospital

2000 Research Directors Executive Committee, Department of Psychiatry, Massachusetts General Hospital

2000 Steering Committee Task Force: Interface Between Clinical Services and Research, Massachusetts General Hospital

2003 Executive Committee for Academic Promotions, Department of Psychiatry, Massachusetts General Hospital

2003 Chair, NIMH Data Safety Monitoring Board, Pramipexole in Treatment-Resistant Depression (K23 MH67060; PI: Roy H. Perlis, MD), Massachusetts General Hospital

2004 MGH Joyce and Richard Tedlow Award Committee, Massachusetts General Hospital

2004 Module Director, Mood Disorders, Massachusetts General Hospital
Psychiatric Academy CME

2005 Massachusetts General Hospital Psychiatry Academy CME Executive Committee

2006 Steering Committee for Psychiatry Research, Massachusetts General Hospital

2010 Advisory Committee for the MGH-McLean Psychiatry Residency Research Concentration Opportunity

2012 Clinical Research Council, Massachusetts General Hospital

2013 Search committee for the DCRP/CTNI junior faculty position

2014 DSMB member, DOD grant "Prevention of Stimulant Induced Euphoria with an Opioid Receptor Antagonist"

2014 Search Committee for the Medical Director of the Stress and Anxiety Program at McLean Hospital

2014 Member, The Football Players Health Study at Harvard University
Social and Behavioral Advisory Group

2015 Committee on Clinical Research

2015 Chair, MGH Research Institute Training and Education Committee

2015 Member, Partners Learning System Steering Committee

Regional:

2005 Chair, Psychiatric Interest Group, Massachusetts Psychiatric Society

2005 Psychopharmacology Annual Conference Planning Committee, Massachusetts Psychiatric Society

2005- Massachusetts Department of Mental Health Psychopharmacology Expert Advisory Group

National:

1990 National Institute of Mental Health Planning Meeting on Treatment Resistant Depression

1993 International Psychopharmacology Algorithm Project

1994 International Advisory Board, Third International Conference on Refractory Depression

1994 Peer Review Team, Consultation Service, American Psychiatric Association

1995 Planning Workshop Group for 1996 NCDEU meeting, National Institute of Mental Health

1995 Expert Phase Participant, MacArthur General Reliability Field Trial for DSM-IV

1995 Expert Advisory Panel on Psychiatric Disease, United States Pharmacopeial Convention, Inc.(1995-2000)

1996 Advisor, American Psychiatric Association Handbook of Psychiatric Measures and Outcomes, Mood Disorders Section

1996 Consultant, Meeting on Integration of Treatment Strategies for Depression, National Institute of Mental Health, National Institutes of Health, Bethesda MD

1996 Special Emphasis Panel, National Institute of Mental Health, National Institutes of Health, Bethesda MD

1997 Special Emphasis Panel, National Institute of Mental Health, National Institutes of Health, Bethesda MD

1998 Consultant, NIMH R21 MH52737 Cognitive and Drug Therapy for Drug-Resistant Depression, PI Karla Moras, Department of Psychology University of Pennsylvania

2000-2001 National Institute of Mental Health Special Emphasis Panel Interventions Review Committee (ITV)

2001 Planning meeting member, NIMH Interventions Review Committee (ITV), "Effectiveness Research"

2001-2005 Initial Review Group Member, National Institute of Mental Health, Interventions Review Committee (ITV)

2001 NIMH, Special Emphasis Panel, T-32 Reviews

2000-2005 DSMB member and external expert safety monitor for NIMH RO1 Fluoxetine for Bipolar II Depression (Amsterdam J, PI)

2002 Publications Committee, NIMH, Systematic Treatment Enhancement Program-Bipolar Disorder (STEP-BD)

2003 Scientific Advisor, National Institute of Mental Health cooperative agreement "Research Units on Pediatric Psychopharmacology and Psychosocial Interventions: Treatment of Adolescent Suicide Attempters Study"

2004 Planning Committee, NIMH Systematic Treatment Enhancement Project for Bipolar Disorder (STEP-BD) Publication Planning Workshop

2004 Chair, National Institute of Mental Health ZMH1 BRB-S (04) Interventions Committee Special Emphasis Panel on Perinatal Mental Health

2004 Planning Committee, NIMH Workshop: Blurring the Boundary Between Clinical and Statistical Expertise in the Review of Treatment Related Applications

2004 Planning Committee, 2004 National Institute of Mental Health New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting

2004 Planning Committee, National Institute of Mental Health Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Data Analysis

2004 Communications Committee, National Institute of Mental Health Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

2004 Study Design Task Force, National Institute of Mental Health Depression Treatment Network

2004 Project Management Team, National Institute of Mental Health Depression Network

2005 Planning Committee, National Institute of Mental Health Depression Treatment Network

2005 Measurements/Clinical Methods Task Force, National Institute of Mental Health Depression Treatment Network

2005 National Institute of Mental Health Systematic Treatment Enhancement Project for Bipolar Disorder (STEP-BD) Network Leadership Group

2005 Medication Management Pilot Study Team for NIMH Antidepressant Sequences/Combinations to Enhance Depression Treatment (ASCEND)

2005 Education Committee, International Society for Bipolar Disorders

2006 Discussion Leader, Study Design, NIAA/NIDA/NIMH Workshop

Methodology of Conducting Pharmacologic Clinical Trials in Patients with Alcohol/Drug Dependence and Psychiatric Comorbidity

2006 National Alliance of the Mentally Ill (NAMI) Selection Committee for Mind of America Scientific Research Award

2006 Executive Advisory Board for the NIMH Career Development Institute (CDI) for Bipolar Disorder at University of Pittsburgh

2007 Medical Committee, Ryan Licht Sang Bipolar Foundation

2007 Discussion Facilitator, Scientific Advisory Board, Improving Psychotropic Prescribing Practices Planning Meeting, Bipolar Subgroup, New York State Office of Mental Health

2007 Member, Scientific Advisory Board, California Bipolar Foundation

2007 Scientific Advisor, American Society for the Prevention of Suicide

2007 Member, Board of Councilors, International Society for Bipolar Disorders

2008 Scientific Planning and Organizing Committee, Bipolar Statistical Summit Conference, NIMH

2008-2010 American College of Neuropsychopharmacology (ACNP) Advocacy Committee

2008 American Psychiatric Association Ad Hoc Workgroup on Relationships between Psychiatry and Medical Industries

2008 NIMH New Clinical Drug Evaluation Unit (NCDEU) 2009 Annual Meeting Review Committee

2009 National Network of Depression Centers, Research Committee

2009 Member, DSMB NIMH R01 MH080097BP I: Prevention and relapse and recurrence of bipolar depression

2009 Member, DSMB NIMH R01 MH060353-02 BP II: Treatment of Bipolar Type II major depression

2010 Training Awards Committee, International Society for Bipolar Disorder (ISBD)

2010-2011 Chair, Bipolar Interest Group, National Network of Depression Centers

2011-2012 Vice Chair, Research Domain Committee, National Network of Depression Centers

2011 Member, DSMB CDDG-TND trial "A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to Nicotine Replacement Therapy for Prevention of Very Early Relapse to Smoking."

2012 Chair, DSMB, Data Safety and Monitoring Board.
NIMH 1R21DA030808-01 Cognitive Remediation with D-Cycloserine to Improve Smoking Cessation Outcomes

2012 Medical Monitor for "A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation and Prevention of Early Relapse to Smoking"

2012 Reviewer, NARSAD grants

2012 Reviewer, American Society for the Prevention of Suicide grants

2012 Member, DSMB, "Efficacy and Safety of Cranial Electrical Stimulation (CES) for the Treatment of Major Depressive Disorder: A Pilot Study"

2012 Reviewer, NIMH Adult Psychopathology and Aging Initial Review Group

2012 Member, DSMB, "Quantification of Outcome Measures for Mind Body Interventions"

2012 Reviewer, NIMH 2012/05 ZRG1 BBBP-V (10) Initial Review Group
2012 Reviewer, AHRQ, Comparative Effectiveness Review entitled
"Nonpharmacologic Interventions for Treatment-Resistant Depression
in Adults" (EHC-2009-02-0012.R3)
2012 Reviewer, NIMH 2012/05 ZMH1 ERB-M (05) S ITVA, Initial Review
Group
2012 NCDEU Steering Committee
2012 NIMH National Action Alliance for Suicide Prevention Research
Prioritization Task Force Expert Presenter
2013 Reviewer, Brain and Behavior Research Foundation NARSAD grants
2013 Reviewer, International Bipolar Foundation Research grants
2014 Patient Centered Outcomes Research Institute (PCORI) PCORnet
Steering Committee
2014 Co-Chair, Clinical Trials Task Force, PCORnet
2014 Klerman Awards Committee, Depression Bipolar Support Alliance
2014 Reviewer, Anxiety Depression Association of America annual meeting
symposia
2015 Clinical Endpoints Working Group of the Neuroscience Steering
Committee of the Biomarkers Consortium of the Foundation for the
National Institutes of Health
2015 External reviewer of the Institute of Medicine Workshop Summary
Enabling Discovery, Development, and Translation of Treatments for
Cognitive Dysfunction in Depression.
2015 Member, Life Science Industry-PCORnet Coordinating Committee,
Patient Centered Outcomes Research Institute Network
2015 Member, ISCTM Suicide Ideation Behavior Consensus Meeting
2015 ACNP Annual Meeting Scientific Program Committee for 2016
2015 Member, Patient Centered Outcomes Research Network Research
Committee

International

2013 Steering Committee, International Society for Bipolar Disorder Annual
Meeting, Seoul Korea 2014
2013-2014 Interim Vice President for Research, International Society for Bipolar
Disorder
2015 Steering Committee, International Society for Bipolar Disorder Annual
Meeting, Amsterdam 2016
2015 Participant, MQ Conference on Research Priorities for Bipolar Disorder
9th & 10th November 2015, London England

Professional Societies:

1985-2012 American Psychiatric Association
1985-1988 Connecticut Psychiatric Society
1987-1990 Association for Health Services Research
1988-1994 New York Academy of Sciences
1988-2012 Massachusetts Psychiatric Society
1992-1995 American Association for the Advancement of Science
1992-1995 American Association of Suicidology
1992 Society of Biological Psychiatry
1992-2000 American Society of Clinical Psychopharmacology (founding member)
2005 American College of Neuropsychopharmacology (ACNP)
2005 International Society for Bipolar Disorders (ISBD)
2006 Psychiatric Research Society

2008 International Society for Affective Disorders
2010 Collegium Internationale Neuro-Psychopharmacologicum (CINP)
2014 Anxiety Depression Association of America

Editorial Boards:

1994- Psychiatric Annals
1996-1999 Journal of Depressive Disorders: Index and Review
2000-2000 Psychiatric Clinics North America (guest editor)
2001- Harvard Mental Health Letter
2001- Journal of Clinical Psychiatry
2003-2015 International Journal of Neuropsychopharmacology (Collegium
Internationale Neuro-Psychopharmacologicum – CINP)
2004- Journal of Clinical Psychopharmacology
2005- Bipolar Disorders – An International Journal of Psychiatry and
Neuroscience
2006 - Revista de Psiquiatria do Rio Grande do Sul, Brazil
2007- Advances in Schizophrenia and Clinical Psychiatry
2007- Progress in Neuro-Psychopharmacology and Biological Psychiatry
2007 Psychiatric Clinics North America (guest editor)
2009- Depression and Anxiety
2009- Associate Editor, Psychiatric Annals
2009-2010 Editor-in-Chief, CNS Spectrums
2009- Editorial Advisory Board Member, Klinik Psikofarmakoloji Bulteni
(Bulletin of Clinical Psychopharmacology), Turkey
2010- Pharmacopsychiatry
2010- American Professional Society for Attention and Related Disorders
(APSARD) ADHD and Comorbidity Newsletter
2011- Australian New Zealand Journal of Psychiatry
2012- International Journal of Bipolar Disorders
2013- Scientific Reports (Nature)
2014- Clinical Psychopharmacology and Neuroscience (Official Scientific
Journal of the Korean College of Neuropsychopharmacology)
2015- Acta Psychiatrica Scandinavica
2015- Journal of Affective Disorders

Editorial Boards: Ad Hoc Reviewer:

1985-1986 Journal of Clinical Epidemiology
1987- Psychopharmacology
1989- Journal of Clinical Psychiatry
1991- Biological Psychiatry
1991- Journal of Affective Disorders
1991- American Medical Association Drug Evaluation Subscription
(Consultant- Mood Disorders Section)
1992- American Journal of Medicine
1993- Journal of Clinical Psychopharmacology
1993- Harvard Review of Psychiatry
1994- Psychiatric Annals (Guest Editor)
1994- General Hospital Psychiatry
1994- Journal of Geriatric Psychiatry and Neurology
1995- Journal of Gerontology: Medical Sciences
1995- Progress in Neuro-Psychopharmacology & Biological Psychiatry
1996- The Medical Letter

1997- Drug Safety
 1997- Psychiatry Research
 1997- Cognitive Therapy and Research
 1997- Depression and Anxiety
 1998- Archives of General Psychiatry
 1999- Progress in Neuro-Psychopharmacology & Biological Psychiatry
 2000- Journal of Psychosomatic Research
 2000- International Journal of Neuropsychopharmacology
 2000- Psychotherapy and Psychosomatics
 2001- American Journal of Psychiatry
 2001- CNS Drugs
 2001- Psychiatry Research
 2001- Psychopharmacology
 2002- Psychiatric Annals
 2002- The American Journal of Managed Care
 2003- Bipolar Disorders
 2003- Psychotherapy and Psychosomatics
 2003- Cognitive Therapy and Research
 2003- Journal of Psychiatric Research
 2005- Clinical Trials: The Journal of the Society for Clinical Trials
 2006- Journal of the American Medical Association (JAMA)
 2010- Archives of Internal Medicine
 2012- Trends in Pharmacological Sciences

Non-Profit Boards

2009 American Professional Society for ADHD and Related Disorders (APSARD)
 2009 Sean Costello Foundation
 2009 Ryan Licht Sang Bipolar Foundation Medical Committee
 2009 American Foundation for Suicide Prevention Scientific Advisory Board
 2010 Scientific Council, Brain and Behavior Research Foundation (formerly NARSAD)
 2013 MitoAction Foundation
 2014 American Foundation for Suicide Prevention Board, Boston Chapter
 2015 International Bipolar Foundation

Awards and Honors:

1976 Magna Cum Laude, State University of New York at Buffalo
 1992 NIMH R-29 FIRST Award
 1994 Selected by peers for Woodward/White, Inc. The Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 2nd edition, Woodward/White, Inc., Aiken, SC
 1996 Residents Teaching Award as a member of the Massachusetts General Hospital Psychopharmacology Unit (award to entire unit)
 1997 Selected by peers for Woodward/White, Inc. The Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 3rd edition, Woodward/White, Inc., Aiken, SC
 1997 The Best Doctors in Boston, (Suicide), Boston Magazine
 1998 Selected by peers for Woodward/White, Inc. The Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 4th edition, Woodward/White, Inc., Aiken, SC
 1999 The Best Doctors in Boston, Boston Magazine

- 1999 Gerald L. Klerman Young Investigator Award, National Depressive and Manic Depressive Association (NDMDA; now Depression and Bipolar Support Alliance)
- 2000 Selected by peers for Woodward/White, Inc. The Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 5th edition, Woodward/White, Inc., Aiken, SC
- 2000 National Association for Research in Schizophrenia and Depression (NARSAD) Independent Investigator Award
- 2003 National Association for Research in Schizophrenia and Depression (NARSAD) Independent Investigator Award (Second Award)
- 2003 Selected by peers for Woodward/White, Inc. Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 6th edition, Woodward/White, Inc., Aiken, SC
- 2005 Selected by peers for Woodward/White, Inc. Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 7th edition, Woodward/White, Inc., Aiken, SC
- 2006 Distinguished Fellow of the American Psychiatric Association
- 2007 Selected by peers for Woodward/White, Inc. Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 8th edition, Woodward/White, Inc., Aiken, SC
- 2007 Peer Review Circle of Honor, Journal of Clinical Psychiatry
- 2008 Selected by peers for Woodward/White, Inc. Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 9th edition, Woodward/White, Inc., Aiken, SC
- 2009 Selected by peers for Woodward/White, Inc. Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 10th edition, Woodward/White, Inc., Aiken, SC
- 2010 Selected by peers for Woodward/White, Inc. Best Doctors in America (Psychiatry Section: Mood and Anxiety Disorders) 11th edition, Woodward/White, Inc., Aiken, SC
- 2011 Selected by peers for Woodward/White, Inc. Best Doctors® in America (Psychiatry Section: Mood and Anxiety Disorders) 12th edition, Woodward/White, Inc., Aiken, SC
- 2012 Selected by peers for Woodward/White, Inc. Best Doctors® in America (Psychiatry Section: Mood and Anxiety Disorders) 13th edition, Woodward/White, Inc., Aiken, SC
- 2013 Colvin Prize for Outstanding Mood Disorder Research, Brain and Behavior Research Foundation (NARSAD)
- 2013 Selected by peers for Woodward/White, Inc. Best Doctors® in America (Psychiatry Section: Mood and Anxiety Disorders) 14th edition, Woodward/White, Inc., Aiken, SC
- 2014 Inaugural incumbent of the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at Massachusetts General Hospital.
- 2014 Included in "The World's Most Influential Scientific Minds 2014" by Thomson Reuters (Highly cited papers rank in the top 1% by citations for their field and year of publication 2002-2012; among the top 93 psychiatrists/psychologists worldwide).
- 2014 Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong, Australia
- 2015 Exceptional Mentorship in the Research Arena, Massachusetts General Hospital Department of Psychiatry
- 2015 Gerald L Klerman Senior Investigator Award, Depression Bipolar Support Alliance (DBSA)

2015

Selected by peers for Woodward/White, Inc. Best Doctors® in America (Psychiatry Section: Mood and Anxiety Disorders) 15th edition, Woodward/White, Inc., Aiken, SC

PART II: Research, Teaching and Clinical Contributions

A. Narrative Report:

I am a patient-oriented, clinical research psychiatrist who focuses on depression and bipolar disorder. I am the Director of the MGH Bipolar Clinic and Research Program as well as the Associate Director of the Depression Clinical and Research Program. My academic appointment is Professor of Psychiatry at Harvard Medical School. Prior to joining the staff at MGH, I was the director of a mood disorders research inpatient unit and the founder and Director of the Treatment Resistant Depression Program at McLean Hospital from 1986 to 1992. Since joining the Depression Program at MGH in 1992, I have helped grow the Depression program and facilitate the research of junior faculty as well as continuing my focus on treatment resistant depression. Since my additional appointment as Medical Director (and subsequently Director) of the Bipolar Clinic and Research Program at MGH, I have led the day-to-day operation of an internationally known clinical and research service. In 2011, I became the overall Director of the Bipolar Program. Additionally, in 2010, I became the Director of the Clinical Research Services Unit and in 2013 Co-Director of the Education Unit of the Clinical Research Program for the entire hospital and have been providing guidance to the clinical research community of MGH. In 2015, the CRP transitioned to the Division Clinical Research for the MGH Research Institute where I continue to direct the Services Unit and the Training and Education Committee.

Clinical

My current outpatient practice includes patients suffering from a variety of psychiatric disorders, and focuses on bipolar disorder, major depressive disorder, and treatment resistant depression. I have an active clinical practice and have conducted over 500 in-depth complex consultations. I am frequently sought out by peers for consultation regarding the clinical care of patients with difficult-to-treat mood disorders. My clinical expertise has been noted by my colleagues through my inclusion in "The Best Doctors in America" that lists the top 5% of physicians nominated by their peers. I have been listed in every edition of "Best Doctors" since 1994.

Teaching

I have a strong interest in teaching, mentoring, and training junior clinical investigators. I have been part of the faculty of local and nationwide training seminars in clinical research and beginning investigator workshops at the MGH, the annual meetings of the NIMH sponsored New Clinical Drug Evaluation Unit (NCDEU), American Society of Clinical Psychopharmacology and National Institute of Mental Health (ASCP/NIMH) Clinical Trial Workshops, Grant Workshop at the Annual American Association of Behavioral Therapy (AABT), and American Psychiatric Association (APA) Research Colloquium for Junior Investigators. I am on the executive committee of the Massachusetts General Hospital Psychiatric Academy (MGPA) and develop content for live symposia and webcasts. The MGPA now includes over 30,000 academy members and is growing at a rate of about 1,500 per month. I have been a mentor or co-mentor on 16 NIMH training K Awards, one KL2 Award and 5 National Association of Research in Schizophrenia and Depression (NARSAD) Awards. I am the senior author (last in the author list) for over 25 papers with junior colleagues as first author. In 2015, I received the MGH Mentorship Award in for exceptional mentorship in

the research arena. I have been invited to organize symposia and present at numerous national and international conferences and consistently receive top ratings.

Research

The focus of my patient-oriented research has been on difficult-to-treat mood disorders, with a special focus on treatment resistant depression, and further research into depressive residual symptoms, and minor depression. My work in the area of treatment resistant depression helped to establish treatment resistance as a legitimate field for systematic inquiry. Since 2000, my interests expanded to include bipolar disorder, specifically bipolar depression, comorbidity of bipolar disorder with attention deficit hyperactivity disorder, and children-at-risk of bipolar disorder (funded by two consecutive Independent NARSAD Awards). I was the overall principal investigator for a NIH collaborative RO-1 for the study of pharmacotherapy of minor depression. Additionally, I was the MGH site PI for the approximately \$30 million Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) NIMH contract. I was also on the Project Management Team of the more than \$25 million Sequenced Treatment Enhancement Program to Relieve Depression (STAR*D) NIMH contract. My roles in these two large NIMH contracts (that each entered over 4000 patients) range from design, to implementation, and oversight. I am among the very few intimately associated with both of these studies. I was the Regional Center Director of the NIMH Depression Trials Network, the follow up contract to STAR*D, as well as a member of the study design team. As of October 2005, I have been the overall PI and Director of nationwide NIMH Bipolar Trials Network (BTN; the follow up contract to STEP-BD) that provides an infrastructure for large effectiveness clinical trials of interventions for bipolar disorder. I was the PI on a \$7 million study to assess the effectiveness of lithium as a component of the treatment of bipolar disorder (Lithium Moderate Dose Use Study – LiTMUS) that ran on the network. In 2010, I obtained a competitive \$10 million multi-site comparative effectiveness study funded by the AHRQ to run on the expanded 10-site BTN. In 2014, I became the PI of the Patient Centered Outcomes Research Institute (PCORI) Mood Patient Powered Research Network. Overall, I have had leadership roles in about \$88 million of federally funded clinical research.

As far as academic productivity, I have authored or coauthored over 370 peer-reviewed papers, over 50 review papers, and 15 chapters, with over 18,000 citations and h-index of 70 according to ISI. Collectively, these papers have had a major impact on the clinical practice of psychopharmacology, including treatment of residual insomnia in depression, evidence-based management of treatment resistant depression, the recognition of depressive residual symptoms after treatment, the conditional probability of response to antidepressants during treatment, and the importance of comorbid attention deficit disorder in adults with bipolar disorder. I published the only randomized trial of competing options for the management of bipolar treatment resistant depression. In 2014, I was listed as one of "The World's Most Influential Scientific Minds 2014" by Thomson Reuters (Highly cited papers rank in the top 1% by citations for their field and year of publication 2002-2012).

Major Research Interests:

1. Pharmacologic treatment and course of bipolar disorder.
2. Comparative effectiveness studies.
3. Phenomenology, longitudinal course, and treatment of mood disorders

B. Research Funding Information:

Past:

Foundations and Federal Government Sources

1984-1986	Robert Wood Johnson Clinical Scholar	PI
	Longitudinal Course of Major Depression After Lithium Augmentation	
1992-1997	NIMH R29 MH46952	PI
	The Course of Treatment Resistant Depression.	
1992-1997	RO-1 NIMH Grant	Co-Investigator
	Double-Blind Study of Fluoxetine Adjuncts in Refractory Depression	
1993-1995	Stanely Award	Co-Investigator
	MRI and MRS in Patients with Major Depression	
1997-2002	R10 NIMH Grant	Co-Investigator
	Prediction of Outcome during Fluoxetine Continuation	
1999-2004	NIDA/NIH Contract	Co-Investigator
	Bupropion as an Adjunct to the Nicotine Patch Plus CBT	
1999-2005	NIMH Contract	Pathway Leader
	Treatment Resistant Bipolar Depression: Systematic Treatment Enhancement Program-Bipolar Disorder (STEP-BD)	
1999-2005	NIMH Contract	Co-Pathway Leader
	Bipolar Depression: Systematic Treatment Enhancement Program-Bipolar Disorder	
1999-2005	NIMH Contract	Associate Site Director
	Project Management Committee/Executive Committee/ Project Director/ Safety Officer/Communications Committee/Ancillary Studies Committee	
	Sequential Treatment Alternatives to Relieve Depression (STAR*D)	
2000-2002	NARSAD Independent Investigator Award	PI
	Identifying Children at Risk for Bipolar Disorder	
2001-2005	NIMH Contract	Site PI
	Systematic Treatment Enhancement Program-Bipolar Disorder (STEP-BD)	
2001-2004	Stanley Foundation Bipolar Research Center	Co-PI
	\$450,000	
2001-2006	NIH (Collaborative RO1)	
	Pharmacotherapy of Minor Depression	Overall PI and Site PI
	NIMH RO1MH61758-01A2	
2003-2005	NARSAD Independent Investigator Award II	PI
	Identifying Children at Risk for Bipolar Disorder	
2003-2005	NIMH R01MH61758-03S1	PI
	Re-entry Supplement (for M. Ostacher)	
	Pharmacotherapy for Minor Depression	
2004-2009	NIMH Contract	Regional Site Director
	Depression Trials Network	and Member Project Management Team
2010-2012	Wyss Institute	PI
	Biomarkers for Mood Disorders	
2005-2011	NIMH Contract	
	Bipolar Trials Network	Overall PI and Director of the National Coordinating Center
		Director and Overall PI
2006-2011	NIMH Contract	
	Lithium Moderate Use Dose Study (LiTMUS)	
2005-2010	NIH RO1	Co-Investigator
	Omega-3 Fatty Acids for Treatment of Major Depression	
	NIMH R01 MH074085-01	
2010-2011	NIH K18	PI
	Complex Dynamic Systems in Mood Disorders	

2010-2013	AHRQ RO1 Bipolar Comparative Effectiveness Study \$9,784,863	PI
-----------	--	----

Industry Funding

1991-1993	Wyeth-Ayerst Grant An Open Evaluation of the Safety and Efficacy of Venlafaxine for Treatment Resistant Depression	Co-PI
1992-1993	Pfizer Grant Double-Blind, Parallel Comparisons of Sertraline, Imipramine, and Placebo in Outpatients with Atypical Depression	Co-Investigator
1992-1994	Pfizer Grant Double-Blind, Parallel Comparisons of Sertraline, Imipramine, and Placebo in Outpatients with Dysthymia	Co-Investigator
1991-1994	Pfizer Grant Double-Blind, Parallel Comparisons of Sertraline, Imipramine, and Placebo in Outpatients with Dysthymia: Follow-up Phase	Co-Investigator
1993-1994	Pfizer Grant Sertaline for Depressed Patients Resistant to Lithium Augmentation	PI
1993-1994	IRI Institute Grant Levels of CRF, Thymopoietin, and HPA-axis Derived Hormones in Untreated Patients with Depression	Co-Investigator
1994-1995	SmithKline-Beecham Double-Blind, Placebo-Controlled, Parallel Group Study of Paroxetine in the Treatment of Dysthymia	Co-Investigator
1994-1995	American Cyanamid A Phase III, 28-Day, Multicenter, Randomized Double-Blind, Comparative and Placebo-Controlled, Parallel Group Safety, Tolerance, and Efficacy Study of 5, 10, and 20 mg of CL 284,846 Compared with 10 mg of Zolpidem or Placebo in Adult Outpatients with Insomnia	Co-Investigator
1993-1994	IRI Institute Grant Levels of CRF, Thymopoietin, and HPA-axis Derived Hormones in Untreated Patients with Depression	Co-Investigator
1994-1995	Wyeth-Ayerst Double-Blind, Placebo-Controlled Study of Extended-Release Venlafaxine in Major Depressive Disorder	Co-Investigator
1994-1995	American Cyanamid PI: Jerrold Rosenbaum, M.D. A Phase III, 28-Day, Multicenter, Randomized Double-Blind, Comparative and Placebo-Controlled, Parallel Group Safety, Tolerance, and Efficacy Study of 5, 10, and 20 mg of CL 284,846 Compared with 10 mg of Zolpidem or Placebo in Adult Outpatients with Insomnia	Co-Investigator
1994-1995	Smithkline-Beecham Double-Blind, Placebo-Controlled, Parallel Group Study of Paroxetine in the Treatment of Dysthymia	Co-Investigator
1995-1997	Synthelabo A Pilot, Phase II, Double-Blind, Placebo-Controlled Dose Escalation (5, 10, and 20 mg) Befloxatone Study of Nine Weeks Duration in Outpatients with Major Depressive Disorder	Co-Investigator
1995-1997	Hoffmann-La Roche Open Study of the Central Nervous System Effects of Tolcapone in Patients with Major Depressive Disorder	Co-Investigator
1996-1997	Pfizer Pharmaceuticals	Co-Investigator

	A Phase II, Ten-Week, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate Efficacy and Safety of Oral CP-93,393-1 in Outpatients with Major Depressive Disorder	
1996-1997	Lorex Pharmaceuticals	Co-Investigator
	Management of Persistent Insomnia in Adult Outpatients on SSRI Therapy: Hypnotic Efficacy and Safety Study of Zolpidem	
1996-1997	Smithkline-Beecham	Co-Investigator
	A Double-Blind, Placebo-Controlled Trial to Evaluate the Clinical Effects of Immediate-Release Paroxetine and Modified-Release Paroxetine in the Treatment of Major Depression	
1996-1998	Solvay Pharmaceuticals	Co-Investigator
	An Open Study of Fluvoxamine in Anxious Depression	
1996-1998	Eli Lilly and Company	Co-Investigator
	Fluoxetine versus Sertraline and Paroxetine in MDD: Comparison of Discontinuation-Emergent Symptoms	
1997-1998	Pfizer Pharmaceuticals	Co-Investigator
	Depression Disease Management Strategy Program in Primary Care: A Validation Study	
1997-1998	Sanofi	Co-Investigator
	A Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of SR46349B in Outpatients with Major Depression	
1997-1999	Eli Lilly and Company	Co-Investigator
	Fluoxetine, Paroxetine, and Sertraline in the Treatment of Major Depression: Physiological Correlates of SSRI Withdrawal	
1997-1999	Organon, Inc.	Co-Investigator
	Remeron's Efficacy in Subjects with Major Depressive Disorder who are SSRI Treatments Failures	
1997-1999	Organon, Inc.	PI
	A Multicenter, Placebo-Controlled Study of Relapse Prevention by Long-Term Treatment with the Recommended dose of Remeron in Outpatients with Major Depressive Episode	
1997-1999	Eli Lilly and Company	Co-Investigator
	Weekly Enteric-Coated Fluoxetine Hydrochloride vs. Daily Fluoxetine or Placebo in the Continuation Treatment of Major Depressive Disorder	
1998-1999	Pfizer Pharmaceuticals	Co-Investigator
	A Six Week, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral CP122,721 in Outpatients with Major Depressive Disorder	
1998-1999	Pharmacia and Upjohn	Co-Investigator
	Reboxetine vs. Placebo and Fluoxetine in a Controlled, Randomized, Double-Blind, Multicenter Study of Treatment in Major Depressive Disorders	
1993-1999	Eli Lilly and Company Grant	Co-Investigator
	Fluoxetine and Cognitive Maintenance Therapies in Depression	
1997-2000	Bristol-Myers Squibb	Co-Investigator
	An Open Study of Nefazodone in Depression with Anger Attacks	
1998-2001	Lichtwer Pharma U.S., Inc.	Co-PI
	A Double-Blind, Parallel Comparison of Hypericum, Fluoxetine, and Placebo in Major Depressive Disorder	
1998-2002	Glaxo-Wellcome, Inc. Grant	Co-Investigator
	An Open Study of Bupropion SR in the Treatment of Major Depressive Disorder Patients who Fail to Respond or to Maintain Response to Fluoxetine Treatment	
1998-2003	Bristol-Myers Squibb	PI

1998-2002	A Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled, Randomized, Flexible-Dose Trial of Nefazadone ER in the Treatment of Depressed Patients Eli Lilly and Company	Co-Investigator
1999-2000	The Combination of Olanzapine and Antidepressants in Psychotic Major Depression: Relapse Rates Following Antidepressant Discontinuation Pharmacia & Upjohn	Co-Investigator
1999-2001	Reboxetine versus Placebo in the Treatment of Major Depressive Disorder Resistant to Fluoxetine Pharmacia & Upjohn	Co-Investigator
1999-2002	Open-Label Reboxetine Rescue and Continuation Therapy Eli Lilly and Company	Co-Investigator
1999-2002	The Combination of Olanzapine and Fluoxetine in Treatment Resistant Depression without Psychotic Features Pfizer, Inc	Co-Investigator
2000-2005	A Double-Blind, Placebo-Controlled Study of Sildenafil for the Treatment of SSRI-Induced Sexual Dysfunction Cyberonics	PI
2000- 2003	A Multicenter, Pivotal, Safety, and Efficacy Study of the NeuroCybernetic Prosthesis (NCP) System in Patients with Depression Organon, Inc	Co-Investigator
2000- 2002	A Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel Group Study of Efficacy and Safety of Org 33062 ER and Paroxetine in Subjects who Suffer from Major Depressive Disorder with Atypical Features Organon, Inc.	Co-Investigator

**Research Funding Information:
Current:**

2008-2014	NIH RO1 Galantamine for Cognitive Deficits in Bipolar Disorder	Co-PI
2013-2016	NIH RO1 Multi level Analysis of Positive Valence Systems Across Mood Disorders	Co-Investigator
2013-2015	American Foundation for Suicide Prevention Distinguished Investigator Grant Reconceptualizing Suicide as Impaired Temporal Discounting: An fMRI Study in Bipolar Disorder \$100,000	PI
2013-2014	Brain and Behavior Research Foundation Distinguished Investigator Award \$100,000	PI
2014-2015	Pan-PPAR Agonist Treatment for Bipolar Depression: A Proof of Concept Study Patient Centered Outcomes Research Institute (PCORI) Contract Mood Patient Powered Research Network (Mood PPRN)	PI
2014-2015	\$1,000,000 Patient Centered Outcomes Research Institute (PCORI) Contract Scalable Collaborative Infrastructure for a Learning Healthcare System, Harvard Medical School \$7,000,000 (K. Mandl, PI)	Co-Investigator

C. Report of Current Research Activities:

1. Project: Patient Centered Outcomes Research Institute (PCORI) Contract
Mood Patient Powered Research Network Role: PI
The ultimate goal of the Mood PPRN is to improve the lives of patients with mood disorders through prospective comparative effectiveness trials embedded within routine care and through patient reported outcomes as well as outcome data from electronic medical records (EMR). The Mood PPRN can be used as a platform to determine the best interventions for mood disorders that lead to the best patient-defined relevant outcomes. The main aim of the Mood PPRN is to bring together at least 50,000 patients with mood disorders who will be willing and able to participate in prospective comparative effectiveness studies and provide longitudinal data through their EMR and patient recorded outcomes.

2. Project: Scalable Collaborative Infrastructure for a Learning Healthcare System Co-Investigator (K. Mandl, PI)
The goal of this PCORI Clinical Data Research Network is to build, test, and deliver our Scalable Collaborative Infrastructure for a Learning Health System (SCILHS) to enable a common data model across 10 health systems, covering more than 8 million patients, plugging universally into the point of care, generating evidence and discovery, and thereby enabling clinician and patient participation in research during the patient encounter. Central to the success of SCILHS is the development of innovative apps to improve patient-centered outcomes research (PCOR) methods and capacitate point-of-care functions such as consent, enrollment, randomization, and outreach for patient-reported outcomes. SCILHS adapts and extends an existing national research network formed on an advanced IT infrastructure built with open source, free, modular components.

D. Report of Teaching:

1983-1984	Clinical Supervision of Medical Students and First Year Residents (Chief Resident), New York University Medical School, New York, NY
1983-1984	Organized Grand Rounds, New York University Medical Center, New York, NY
1984-1985	Clinical Preceptor, Connecticut Mental Health Center, Hill Division, New Haven, CT
1984-1986	Supervision of Medical Students, Yale-New Haven Hospital and Connecticut Mental Health Center, New Haven, CT (15 students, 1 hrs/yr)
1985-1986	Discussion Group Leader, Yale University Medical School Course in Biostatistics, New Haven, CT
1986-1992	Supervisor of Residents and Medical Students, McLean Hospital, Harvard Medical School, Belmont, MA
1989-1990	Supervisor of Residents, Massachusetts Mental Health Center, Boston, MA
1989-1990	Lecturer, Psychopharmacology Extramural Training Program, Massachusetts State Hospital System, Massachusetts Mental Health Research Corporation, Boston, MA (15 students, 10 hrs/yr)
1989-1990	Psychopharmacology Consultant, Danvers State Hospital, Hawthorne, MA

1989-1992 Psychopharmacology Supervisor, McLean Hospital, Harvard Medical School, Belmont, MA

1991-1992 Senior Psychopharmacology Supervisor for inpatient psychopharmacology consultation service, McLean Hospital, Harvard Medical School, Belmont, MA (5 students, 40 hrs/yr)

1992-2004 Curbside consultant at Harvard Psychopharmacology Review Course Massachusetts General Hospital, Boston MA

1993 Chairman, Treatment Resistant Bipolar Depression Symposium, Second International Conference on Refractory Depression, Napa CA (50 students, 3 hrs/yr)

1993-2005 Psychopharmacology supervisor of residents, Massachusetts General Hospital, Boston, MA (4 students, 40 hrs/yr)

1993- Lecturer in Psychiatry Review Course at McLean Hospital, Belmont MA (60 students, 1 hrs/yr)

1993- Study group co-chairman, International Psychopharmacology Algorithm Project, American College of Neuropsychopharmacology Annual Meeting, Honolulu, Hawaii (40 students, 3 hrs/yr)

1994 Co-chairman, course on treatment resistant depression, American Psychiatric Association Annual Meeting 1994, Philadelphia PA (70 students, 4 hrs/yr)

1994 Lecturer in Psychiatry Review Course at McLean Hospital, Belmont MA (50 students, 1 hrs/yr)

1994-2004 Lecturer at Harvard Psychopharmacology Review Course, Antidepressants: Issues and New Drugs, Massachusetts General Hospital, Boston MA (800 students, 1 hrs/yr)

1994 Psychopharmacology Inpatient Resident Lecture Series on antidepressants, Massachusetts General Hospital, Boston, MA (4 students, 1 hrs/yr)

1995 Co-chairman, course on treatment resistant depression, 148th Annual Meeting American Psychiatric Association 1995, Miami, FL (60 students, 4 hrs/yr)

1995 Case conference discussant, Massachusetts General Hospital Inpatient Psychiatry Unit (4 students, 1 hrs/yr)

1995-2005 Individual and group supervisor for PGY-III psychiatry residents, Depression Clinical and Research Program, Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, MA (40 students, 2/yr)

1995 Medical Psychiatry Conference "Treatment Resistant Depression", Massachusetts General Hospital Inpatient Psychiatry Unit, Boston, MA (12 students, 1 hrs)

1996 Workshop on "Treatment of Refractory Affective Disorders", 149th Annual Meeting American Psychiatric Association, New York, NY (100 students, 1 hrs)

1996 Co-chairman, "Advances in the Treatment of Refractory Depression", joint session with the American Society of Clinical Psychopharmacology, 149th Annual Meeting American Psychiatric Association Annual, New York, NY, (152 students, 7 hrs)

1996-1998 Co-leader, "How to give a Lecture", Massachusetts General Hospital Department of Psychiatry, Boston, MA, (10 students, 3 hrs)

1996 Medical Psychiatry Conference, "Pharmacological Management of Treatment Resistant Depression, Massachusetts General

- Hospital Inpatient Psychiatry Unit, Boston, MA, (15 participants, 1 hrs)
- 1997 Co-chairman, "Advances in the Treatment of Refractory Depression", 150th Annual Meeting American Psychiatric Association Annual, San Diego, CA, (144 students, 7 hrs)
- 1997 Lecturer at Harvard Psychopharmacology Review Course, Antidepressants: Issues and New Drugs, Massachusetts General Hospital, Boston, MA, (635 students, 1 hrs)
- 1997 Discussant for Presentation on St. John's Wort, Psychopharmacology Rounds, McLean Hospital, Belmont, MA (12 students, 1 hrs)
- 1997 Discussant for Presentation on St. John's Wort, Psychosomatic Rounds, Massachusetts General Hospital, Boston, MA (10 students, 1 hrs)
- 1998 Proposal Evaluator, "Course on Clinical Research", Massachusetts General Hospital, Division of Research, Boston, MA, (4 participants, 2 hrs)
- 1998 Discussant, Psychosomatic Conference, "An Update of ECT", Massachusetts General Hospital, Boston, MA, (15 participants, 2 hrs)
- 1998 Symposium Chairman, "Cutting Edge Polypharmacy", American Psychiatric Association Annual Meeting, Toronto, Canada, (150 participants, 4 hrs)
- 1998 Symposium Co-Chairman, "Predictors of Response in Depression", American Psychiatric Association Annual Meeting, Toronto, Canada, (1200 participants, 4 hrs)
- 1998 Conference Chairman, "Antidepressants and Sexual Dysfunction Symposium, New York, NY, (500 participants, 4 hrs)
- 1998 Lecturer, Harvard Medical Student Psychiatry Rotation, "An Overview of Depression", Cambridge, MA, (10 participants, 1 hrs)
- 1999 Symposium Chairman, "Time and Antidepressants", American Psychiatric Association Annual Meeting, Washington, D.C., (350 participants, 3 hrs)
- 1999 Lecturer, "Serotonin: The First Decade", Boston, MA, 92 participants, 3 hours
- 1999 Lecturer, MGH Primary Care Ambulatory Conference, Depressive Spectrum Disorders, Boston, MA, 12 participants, 1 hour
- 1999-2005 Lecturer, "How to give a presentation", Clinical Research Program of Massachusetts General Hospital, Boston, MA, (97 participants, 1.5 hrs)
- 1999 Discussant, "Repetitive Transcranial Magnetic Stimulation: A new procedure for psychiatry?", Psychosomatic Rounds, Massachusetts General Hospital, Boston, MA, (12 participants, 1.5 hrs)
- 1999 Discussant, ECT, rTMS, and VMS. Association for Convulsive Therapy Annual Meeting, Washington, D.C. (100 participants 1 hrs)
- 1999 Lecturer, "Antidepressants", Harvard Medical School 10th Annual Psychiatry Course, North Falmouth, MA, (75 participants, 1.5 hrs)
- 2000 Symposium Chairman, "Evidence Based Management of Refractory Depression", American Psychiatric Association Annual Meeting, Chicago, Il, (1200 participants, 3 hrs)

2001	Lecturer, "Vagus Nerve Stimulation", Blake 11 Medical-Psychiatry Conference, Massachusetts General Hospital, Boston MA, (12 participants, 1 hrs)
2001	Symposium Chairman, Novel Approaches to the Patient with Treatment Resistant Depression, Boston MA, (100 participants, 4 hrs)
2001	Lecturer, ECT, rTMS, and VNS at Novel Approaches to the Patient with Treatment Resistant Depression, Boston MA, (100 participants, 1 hour)
	Invited Presentations: Local
2001 -	Co-Coordinator PGY-II Depression Module MGH-McLean Adult Residency Training Program Biomedical Seminar Series
2002	Presented "Antidepressants: Current Issues and New Drugs", Palliative Care Grand Rounds, Massachusetts General Hospital
2002	Lecturer, "Psychopharmacology: A focus on depression for Internists", presented at Internal Medicine Review Course, Harvard University Medical School, Cambridge MA, (300 participants, 1 hrs)
2002	Vagus Nerve Stimulation for Depression, Presented at Psychopharmacology Series, Massachusetts General Hospital, (20 participants, 1 hrs)
2002-2005	Lecturer, "How to give a presentation", Harvard Medical School PASTEUR, Massachusetts General Hospital, Boston, MA, (20 participants, 1 hrs)
2002-2004	Lecturer, "Major Depression: Pathophysiology and Treatment", Revisiting biomedical sciences and pathology: the elucidation of biomedical sciences at the cellular and molecular levels of the etiopathology of human diseases. Harvard Medical School, Boston MA (20 participants, 1.5 hrs)
2004	"Alternative Medications for Depression" Presented at Harvard Alumni Association Symposium Alumni College program, Living Healthier, Living Longer, Harvard Medical School, Boston MA (50 participants, 1 hrs)
2004-2005	"Treatment of Mood Disorders 2004" Presented at Psychiatry 700J Psychopathology Course, Harvard Medical School (75 participants, 1 hr)
2005	"Research in Mood Disorders" Presented at the Harvard Medical Student Psychiatry Interest Group, Harvard Medical School (40 participants, 1 hr)
2006	"Developmental perspective in studies of adult bipolar disorder" Presented to the Child Psychiatry Fellows, MGH
2006-2011	"How to Give a Talk" Presented at the MGH Clinical Research Program Seminar
2010-present	Introduction to Research Module for PGY-2 class, MGH
2010-present	Developing a Strategy for Your Research Career, Clinical Research Fellows Orientation Part I: Starting Your Clinical Research Career at MGH, MGH Clinical Research Program
2011-present	Seminar Leader, Applying for an NIH Career Development Award, MGH Clinical Research Program
2013	"Methods of Clinical Trials for Mood Disorders" MGH, Global Psychiatric Clinical Research Fellowship
2013	Phase IV Trials: Goals, issues, and examples Presented at Design and Conduct of Clinical Trials
2014	Course Director, Chinese Society of Psychiatry Program, MGH

2015 Keynote Address
Good Clinical Practice at an Academic Research Institution
MGH Clinical Research Program

Invited Presentations: Local

Additional 90 Presentations between 1989 and 2000 (see appendix)

2001 "An Update on Treatment Resistant Depression"
Presented at Grand Rounds, Department of Psychiatry,
Massachusetts Mental Health Center, Boston, MA (50
participants, 1 hrs)

2001 "Non-Pharmacological Treatments for Treatment Resistant
Depression:
Presented at CME Symposium "Treatment Resistant
Depression", Boston, MA (60 participants, 1 hrs)

2001 "Vagus Nerve Stimulation for Treatment Resistant Depression"
Presented at Grand Rounds, Department of Psychiatry,
Massachusetts General Hospital, Boston, MA (50 participants, 1
hrs)

2001 "Depressive Breakthrough"
Presented at Grand Rounds, Department of Psychiatry,
University of Massachusetts Medical School, Worcester MA (100
participants, 1 hrs)

2002 STAR*D: An Innovative Study of Resistant Depression,
Presented at Grand Rounds, Lahey Clinic, Burlington MA (20
participants, 1 hrs)

2002 Treatment of Depression and Related Symptoms
Grand Rounds, Haywood Hospital, Gardner MA (20 participants,
1 hrs)

2003 STAR*D: The study that will change your practice
Grand Rounds, Salem Hospital, Salem, MA (40 participants, 1
hrs)

2003 Management of Depression and Associated Symptoms
Grand Rounds, Haywood Hospital, Gardner, MA (20
participants, 1 hrs)

2003 Treatment Resistant Depression
Grand Rounds, Health Alliance Hospital, Leominster, MA (25
participants, 1 hrs)

2003 STAR*D: An Innovative Study of Resistant Depression,
Presented at Grand Rounds, Boston Medical Center, Boston, MA
(70 participants, 1 hrs)

2004 "Natural Treatments for Mental Health"
Presented at Osher Center Harvard Medical School Grand
Rounds, Boston MA (40 participants, 1 hrs)

2004 "Depression"
Presented at Mental Health Legal Advisors Symposium, Boston
MA (200 participants, 1 hrs)

2004 "Alternative Medications for Depression"
Presented at Harvard Alumni Association Symposium Alumni
College program, Living Healthier, Living Longer, Harvard
Medical School, Boston MA (75 participants, 1 hrs)

2004 "The Use of Mood Stabilizers for Bipolar Disorder"

- Presented at Massachusetts Mental Health Center Symposium on Uses of Mood Stabilizers in Special Populations, Boston MA (10 participants, 1 hrs)
- 2004 "First-Line Antidepressant Treatment: Does Mechanism Matter?" Presented at Massachusetts Psychiatric Society Annual Psychopharmacology Update, Boston MA (30 participants, 1 hrs)
- 2005 "Treatment of Depression" Presented at Grand Rounds, Harvard-Longwood Psychiatry Program (70 participants, 1 hrs)
- 2006 "The Psychology of Risk in Prescribing" Presented at the 16th Annual Psychopharmacology Update of the Massachusetts Psychiatry Society "Evidence-Supported, Risk-Minimizing, Cost Conscious Approaches in Psychopharmacology", Waltham MA
- 2006 "Development of Bipolar Disorder" Presented at New England Child and Adolescent Psychiatry Annual Meeting
- 2006 "Major Depressive Disorder: An Overview and Gaps in Practice" Presented at Massachusetts Medical Society CME Outcomes Measurement Institute
- 2007 "Lessons from STAR*D". Presented at Grand Rounds, Mercy Hospital, Springfield, MA
- 2007 "Advances in Major Depressive Disorder" Presented at Grand Rounds, Emerson Hospital, Concord MA
- 2007 "Depression Update: From Neurogenesis to STAR*D" Presented at Medical Grand Rounds, North Shore Medical Center, Salem MA
- 2007 "Bipolar Disorder Hot Topics: Summary of the Clinical Side" Presented at Stanley Center for Psychiatric Research, Broad Institute, Cambridge MA
- 2008 "Lessons from STEP-BD" Presented at Grand Rounds, Brockton VA Medical Center Department of Psychiatry
- 2008 "What's Mitochondria Got to Do with Bipolar Disorder?" Presented at Grand Rounds, MGH
- 2009 Discussant. Resident Journal Club, McLean Hospital
- 2010 "Refutation of Anatomy of an Epidemic" Presented at Grand Rounds, MGH
- 2011 "What Can We Learn About Pediatric Bipolar Disorder From Adults?" Presented at the Annual Bipolar Pediatric Symposium, Boston MA
- 2011 "An Overview of the Treatment of Depression" Presented at the Annual Meeting of College Counselors, Assumption College, Worcester MA
- 2011-Present "Introduction to Clinical Research" Presented at the Clinical Research Program Seminar for Incoming Fellows, MGH

Invited Presentations: 1985-2000 121 National Presentations (see appendix)

- 2001 Discussant, "State of the Science of Relapse Prevention in Major Depression: A National Institute of Mental Health Workshop", May 21-22, 2001, Potomac MD (35 participants, 1 hrs)
- 2001 Presenter and Participant, "Methodology in Bipolar Disorder Research: The Search for Gold Standards". National Institute of Mental Health, Pittsburgh PA (50 participants, 1 hrs)
- 2001 "An Update of Treatment Resistant Depression"
Presented Grand Rounds at the University of Chicago, Chicago, IL (120 participants, 1 hrs)
- 2002 "Bridging the Gap to Wellness"
4 hour seminar, University of Minnesota, Minneapolis, MN (100 participants, 1 hrs)
- 2002 "Methodologic considerations for the Development of Antidepressants and Mood Stabilizers"
Presented at the NIMH/ASCP Workshop on Clinical Trials in Psychopharmacology, New York, NY (75 participants, 1 hrs)
- 2002 STAR*D: An Innovative Study of Resistant Depression,
Presented at Grand Rounds, Hampstead Hospital, Hampstead NH (25 participants, 1 hrs)
- 2002 "The Astrology of Treatment Resistant Depression: STAR*D Gazing"
Presented at the Psychopharmacology Conference, University of Wisconsin, Madison WI (100 participants, 1 hrs)
- 2002 "Psychopharmacology and Long Term Treatment of Bipolar Disorder"
Presented at "The Neurobiology of Bipolar Disorder: Research Workshop", Clinical Neuroscience Research Branch, NIMH and the Office of Rare Diseases, NIH, Rockville MD (40 participants, 1 hrs)
- 2003 STAR*D: A Novel Study for Resistant Depression
Presented at Grand Rounds, Zucker Hillside Hospital, Hillside, NY (100 participants, 1 hrs)
- 2003 STAR*D: An Innovative Study of Resistant Depression,
Presented at Grand Rounds, Southern New Hampshire Memorial Hospital, Nashua NH (25 participants, 1 hrs)
- 2003 Recognition and Clinical significance of Difficult to Treatment Mood Disorders. Presented at difficult to treat Mood and Anxiety Disorders Symposium, Washington DC (50 participants, 1 hrs)
- 2003 STAR*D: A Novel Study for Resistant Depression
Presented at Grand Rounds, Syracuse University, New York (120 participants, 1 hrs)
- 2003 Generally Well Tolerated: Comparative Adverse-Event Profiles of Newer Antidepressants. Presented at 2003 American Psychiatric Association Annual Meeting, San Francisco, CA (500 participants, 1 hrs)
- 2003 Treatment Matters.
Presented at 2003 American Psychiatric Association Annual Meeting San Francisco, CA (500 participants, 1 hrs)
- 2003 Chairman, "Treating Depression: What Matters?" Symposium at 2003 APA Annual Meeting, San Francisco, CA (500 participants, 3 hrs)

- 2004 Faculty, American Psychiatric Association Research Colloquium for Junior Investigators: Mood Disorders (40 participants, 3 hrs)
- 2004 Development of Bipolar Disorder
Presented at Grand Rounds, New York State Psychiatric Institute, Columbia University Department of Psychiatry, New York, NY (100 participants, 1 hrs)
- 2004 Overcoming Treatment Resistant Depression,
Presented at the American Society of Clinical Psychopharmacology, Annual Psychopharmacology Meeting, New York, NY (80 participants, 1 hrs)
- 2004 Invited Presenter, "Grant reviews from the Clinical Researcher's Perspective", NIMH Workshop: Blurring the Boundary Between Clinical and Statistical Expertise in the Review of Treatment Related Applications, Washington D.C. (70 participants, 1 hr)
- 2005 Invited Presenter and Panelist, "Clinical Research of Antidepressants and Mood Stabilizers", American Society of Clinical Psychopharmacology and NIMH, A Workshop on Clinical Trials in Psychopharmacology, New York, NY. (90 participants, 3 hrs)
- 2005 Invited Presenter, "Relationship between Bipolar Parental Childhood Comorbid Conditions and Offspring", National Institute of Mental Health Pediatric Bipolar Conference, Coral Gables, FL (100 participants, 1/2 hrs)
- 2005 Invited Presenter and Panelist, "Antidepressants and Suicide: Treatments or Cause?", New Clinical Drug Evaluation Unit (NCDEU), Boca Raton FL (300 participants 2 1/2 hrs)
- 2006 Invited Participant and Panelist, "Clinical Significance Conference", University of Pittsburgh, Pittsburgh PA
- 2006 Invited Presenter and Panelist, "Clinical Research of Antidepressants and Mood Stabilizers", American Society of Clinical Psychopharmacology and NIMH, A Workshop on Clinical Trials in Psychopharmacology, New York, NY. (90 participants, 3 hrs)
- 2007 Invited Presenter, "Lessons Learned from STEP-BD: Collaborative Care, Pharmacotherapy, and Psychotherapy", Presented at Grand Rounds, University of Michigan Medical School Department of Psychiatry, Ann Arbor, MI
- 2007 Invited Presenter, "Bipolar Depression", Presented at Nevada Psychiatric Society Psychopharmacology Conference, Las Vegas, NV
- 2007 Invited Presenter and Faculty, "Clinical Research in Bipolar Disorder: Where to Start?", Presented at the Career Development Institute for Bipolar Disorder, Pittsburgh, PA
- 2007 Plenary Speaker, "Congruence between retrospective reports from bipolar adults and developmental data from bipolar youth", Presented at NIMH Pediatric Bipolar Disorder Conference, Bethesda, MD
- 2007 Plenary Speaker, "Lessons from STEP-BD", Presented at the International Bipolar Disorders Meeting, Pittsburgh PA
- 2007 Invited Speaker, "Implications of a randomized placebo-controlled study of adjunct antidepressants for bipolar disorder: A STEP-BD study", Presented at the New Clinical Drug Evaluation Unit Meeting, Boca Raton FL

- 2007 Invited Presenter and Panelist, "Clinical Research of Antidepressants and Mood Stabilizers", American Society of Clinical Psychopharmacology and NIMH, A Workshop on Clinical Trials in Psychopharmacology, New York, NY. (90 participants, 3 hrs)
- 2008 Invited Speaker, "STAR*D: Recruiting Community Physicians as Investigators for a Clinical Trial", Presented at the Parkinson's Disease Foundation, New York NY
- 2008 Invited Presenter and Panelist, "Clinical Research of Antidepressants and Mood Stabilizers", American Society of Clinical Psychopharmacology and NIMH, A Workshop on Clinical Trials in Psychopharmacology, New York, NY. (90 participants, 3 hrs)
- 2008 "Monitoring Antidepressants and Suicidal Ideation"
Presented at the UT Southwestern Medical Center, Depression Treatment: Is the Glass Half Full or Half Empty? 4th Annual Depression Update for the Primary Care Physician, Dallas Tx
- 2008 "Depression: New Treatments, Remission and Response, Comorbidities"
Presented at 1st Annual Scientific Seminar Meetings on Psychiatry, New York, NY
- 2008 "Next Step Treatment for Depression"
Fifth Psychiatry Congress, Bayamon Region, San Juan, PR
- 2009 Invited Presenter and Panelist, "Clinical Research of Antidepressants and Mood Stabilizers", American Society of Clinical Psychopharmacology and NIMH, A Workshop on Clinical Trials in Psychopharmacology, New York, NY. (90 participants, 3 hrs)
- 2009 "Case Study Presentation/Discussion Workshop"
Presented at Conference for Consensus on Treatment Resistant Depression, Baltimore, MD
- 2009 "Evidence-based Treatment for Unipolar and Bipolar Depression: What are the Options?"
Presented at Clinical Dialogue: Update on Psychopharmacology 2009, New York, NY
- 2009 "Treatment Resistant Depression"
Presented at the State University at Buffalo Fifth Annual Comprehensive Review of Psychiatry Conference, Niagra Falls, NY
- 2009 "The Complexity of Bipolar Disorder and its Management"
Presented at the American Drug Utilization Review Society, Scottsdale AZ
- 2010 Invited Presenter and Panelist, "Clinical Research of Antidepressants and Mood Stabilizers", American Society of Clinical Psychopharmacology and NIMH, A Workshop on Clinical Trials in Psychopharmacology, New York, NY. (90 participants, 3 hrs)
- 2010 "Switch or Augment? Lessons from STAR*D"
Presented at American Academy of Clinical Psychiatrists 2010 Current Psychiatry Symposium
- 2010 "Mitochondrial Modulators for Bipolar Disorder"
Presented at the Annual NCDEU Conference, Boca Raton FL
- 2010 "Bipolar Disorder and ADHD"
Presented at the APSARD Annual Conference, Washington D.C.

- 2011 "Who Put the Evidence in Evidence-Based Psychiatry?"
Presented at Grand Rounds, Dartmouth Medical School
- 2011 "Evidence Based Medicine in Psychiatry"
Presented at Grand Rounds, John Hopkins Medical School
Department of Psychiatry, Baltimore MD
- 2011 Invited Presenter and Panelist, "Clinical Research of
Antidepressants and Mood Stabilizers", American Society of
Clinical Psychopharmacology and NIMH, A Workshop on Clinical
Trials in Psychopharmacology, New York, NY. (90 participants, 3
hrs)
- 2011 "An Update on the Treatment of Treatment Resistant
Depression"
Laressa Gribbons Memorial Lecture, University of Florida,
Gainesville FL.
- 2012 Invited Presenter and Panelist, "Clinical Research of
Antidepressants and Mood Stabilizers", American Society of
Clinical Psychopharmacology and NIMH, A Workshop on Clinical
Trials in Psychopharmacology, New York, NY. (60 participants, 3
hrs)
- 2013 Invited Presenter and Panelist, "Clinical Research of
Antidepressants and Mood Stabilizers", American Society of
Clinical Psychopharmacology and NIMH, A Workshop on Clinical
Trials in Psychopharmacology, New York, NY. (90 participants, 3
hrs)
- 2013 "Making the Impossible Possible: The Challenges of Practicing
Evidence Based Psychiatry with a Focus on Bipolar Depression",
The 2013 Gloria Neidorf Memorial Lecture, 25th Annual New
York Mental Health Symposium, Brain and Behavior Research
Foundation, New York, NY
- 2014 "A Clinical Approach to Treatment Resistant Bipolar Depression"
And "Consideration of Special Depressed Populations, Geriatric
and Bipolar Depression"- Workshop *with J. Craig Nelson MD*
Presented at the 4th Annual Yale Psychopharmacology Master
Class: Focus on Depression, New Haven, CT
- 2014 Discussant, "Advances in Pediatric Bipolar Disorder Research",
167th Meeting of the American Psychiatric Association
- 2014 Discussant, "Cognitive Therapy and Medications in the
Treatment of Depression and the Prevention of Subsequent
Recurrence", 167th Meeting of the American Psychiatric
Association
- 2014 "Bipolar CHOICE (Clinical Health Outcomes Initiative in
Comparative Effectiveness): A Pragmatic Trial of Lithium vs. a
Second Generation Antipsychotic for Bipolar Disorder"
Symposium Co-chair, American Society for Clinical
Psychopharmacology Annual Meeting
- 2014 "Practical, Pragmatic, and Possible Psychopharmacology Clinical
Trials: Lessons Learned from the from AHRQ Bipolar CHOICE
Study, Presenter, American Society for Clinical
Psychopharmacology Annual Meeting
- 2015 Moderator and Panelist, *Forum on Neuroscience and Nervous
System Disorders*. Enabling Discovery, Development, and
Translation for Cognitive Dysfunction in Depression: A
Workshop Institute of Medicine, Washington, D.C.

International Contributions

- 1993 "Bipolar Treatment Resistant Depression"
Presented at the Second International Conference on Refractory Depression, Amsterdam, The Netherlands
- 1995 "Venlafaxine for Depression: Clinical Aspects"
Presented at the Swiss Psychiatric Congress, Berne, Switzerland
- 1996 "Depression in Medically Ill Patients"
Presented at Grand Rounds, Makati Medical Center, Manila, Philippines
- 1996 "Depression in Medically Ill Patients"
Presented at Grand Rounds, Philippine Heart Center, Manila, Philippines
- 1996 "Depression in Medically Ill Patients"
Presented at Grand Rounds, St. Lukes Medical Center, Manila, Philippines
- 1996 "Depression in Clinical Practice"
Presented at Grand Rounds, University of Sto. Thomas Hospital, Manila, Philippines
- 1996 "A Rational Approach to Antidepressant Drug Selection"
Presented at Philippine Psychiatric Association Annual Meeting, Davao, Philippines
- 1996 "How to Choose an Antidepressant"
Presented at Grand Rounds Universitätsspital Inselspital Psychiatrische Poliklinik, Bern, Switzerland
- 1996 "Chronic Depression"
Presented at Grand Rounds Psychiatrische Universitätsklinik, Basel, Switzerland
- 1996 "Treatment Resistant Depression: a US Perspective"
Presented at Grand Rounds Psychiatrische Universitätsklinik Burghölzi, Zurich, Switzerland
- 1996 "Treatment Resistant Depression: an Update for the 90's"
Presented at Grand Rounds, Alborg Hospital, Alborg, Denmark
- 1996 "Pharmacological Management of Treatment Resistant Depression"
Presented at Grand Rounds, Viborg Hospital, Viborg, Denmark
- 1996 "An Update of Treatment Resistant Depression"
Presented at Grand Rounds, Bispebjerg Hospital (Copenhagen County Hospital in Glostrup), Copenhagen, Denmark
- 1997 "Treatment Resistant Depression"
Presented at Update of Depression, Lisbon, Portugal
- 1998 "Refractory Depression"
Presented at the First Annual Boston to Denmark Psychiatric Symposium, Copenhagen, Denmark
- 1998 "Treatment Resistant Depression"
Presented at the Harvard Psychiatric Symposium, Buenos Aires, Argentina
- 1998 "Long-Term Treatment of Depression"
Presented at the Harvard Psychiatric Symposium, Buenos Aires, Argentina
- 1998 "Long-term Treatment of Depression"
Presented at the First Annual Boston to Denmark Psychiatric Symposium, Copenhagen, Denmark
- 1998 "Atypical Depression"

- 1998 Presented at New Issues in Psychiatry, Bodo, Norway
"Augmentation Strategies in Treatment Resistant Depression"
- 1998 Presented at New Issues in Psychiatry, Bodo, Norway
"Switching Strategies in Treatment Resistant Depression"
- 1998 Presented at New Issues in Psychiatry, Bodo, Norway
"Depressive Spectrum Disorders"
- 1999 Presented at New Issues in Psychiatry, Bodo, Norway
"Depressive Subtypes"
- 1999 Presented at International Symposium on Depression:
Perspectives for the New Millenium, Sao Paulo, Brazil
"Treatment Resistant Depression"
- 2000 Presented at International Symposium on Depression:
Perspectives for the New Millenium, Sao Paulo, Brazil
"Can we predict what initial Treatment to Select and When to
Change Treatment"
- 2000 Presented at Collegium International
Neuropsychopharmacologicum, Brussels, Belgium
"Treatment Resistant Depression"
- 2001 Presented at American Society of Clinical Psychopharmacology,
Winter Meeting Puerto Rico
"The Clinical and Research Challenges of Refractory Depression"
- 2002 Presented at the World Congress of Biological Psychiatry, Berlin,
Germany
"Treatment Resistant Depression"
- 2003 Presented at the World Psychiatric Association Congress,
Yokohama, Japan
"Major Depression: Is there a first choice treatment?"
- 2003 Simposio Internacional Sobre Transtrornos do Humor, Sao
Paulo, Brazil
- 2003 "Resisting Depression: Treatment strategies"
Simposio Internacional Sobre Transtrornos do Humor, Sao
Paulo, Brazil
- 2003 "Depressive Subtypes: Validity and therapeutic approach"
Simposio Internacional Sobre Transtrornos do Humor, Sao
Paulo, Brazil
- 2003 "Generally Well Tolerated: Comparative Adverse Event Profiles
of Newer Antidepressants". Presented at New Vistas in the
Treatments of Anxiety and Depression: Better Beginnings for
Better Outcomes. Halifax, Nova Scotia, Canada
- 2003 "Optimal Monotherapy & Successful Combination Treatments"
Presented at Treating the Circle of Depression, Halifax, Nova
Scotia, Canada
- 2004 "Development of Bipolar Disorder"
Presented at Grand Rounds, University of British Columbia
Medical School, Department of Psychiatry
Vancouver, Canada
- 2004 "Critical Decision Points in Antidepressant Treatment"
Presented at Collegium Internationale
Neuropsychopharmacologicum Annual Meeting,
Paris, France
- 2006 "Residual Symptoms of Depression"
Presented at Psychiatrica V
Barcelona, Spain

2008	"Lessons from STEP-BD for the Treatment and Understanding of Bipolar Disorder" Presented at the 11 th Annual East Meets West Psychiatric Conference, Antalya, Turkey
2009	"Depression: clinical aspects and new treatments" Presented at 2 nd Annual Conference, University of Pisa, Pisa Italy
2010	"Evaluating the Evidence for the Treatment of Bipolar Depression" Presented at the International Society for Bipolar Disorder, Sao Paulo, Brazil
2010	"Diagnosis and Treatment of Major Depression" Presented at the Symposium on Anxiety and Depression: An Update on New Developments, Douglas Hospital/McGill University, Montreal CA
2010	"Clinical Considerations: The Neurobiology of the Treatment of MDD" Presented at the Canadian Psychiatric Association Annual Meeting, Toronto CA
2010	"Evaluating the Evidence for Treating Bipolar Depression" Presented at the CINP Annual Meeting, Hong Kong
2011	"Evidence Based Medicine and Bipolar Depression" Presented at the Israel Society for Biological Psychiatry, Hagoshrim, Israel
2016	"Episteme, techne, and Aristotle's practical wisdom (Phronesis) for medical decision making in psychiatry"
2015	Presented at the 4 th National Congress of Clinical Psychopharmacology, Hellenic Society for Clinical Psychopharmacology, Rhodes, Greece
2015	Workshop: Using Aristotle's Phronesis to manage treatment resistant depression. Presented at the 4 th National Congress of Clinical Psychopharmacology, Hellenic Society for Clinical Psychopharmacology, Rhodes, Greece
2015	"Essense of Bipolar Disorder" Presented at World Congress on Brain, Behavior, and Emotions, Porto Alegre, Brazil
2015	"What is the best treatment match for mood stabilization?" Presented at World Congress on Brain, Behavior, and Emotions, Porto Alegre, Brazil

E. Clinical Activities

1. Description of clinical practice: Psychiatry/psychopharmacology, Mood disorders (major depressive disorder and bipolar disorder), MGH-based outpatient practice.
2. Patient load: I have an outpatient practice for about 10 hours a week through the MGH outpatient clinic as well as the MGPO. About 200 patients are under my care. Most have chronic or recurrent major depressive disorder or bipolar disorder with difficult-to-treat or treatment resistant conditions. I also do complex consultations referred from local, national, and international sources.

3. Clinical contributions: I helped establish the use of trazodone for antidepressant-associated insomnia and established conditional probability parameters to determine the acute duration of treatment of antidepressants based on level of response. I have explored systematic psychopharmacologic treatments for treatment resistant depression and treatment resistant bipolar depression.

4. Other relevant information about clinical role: I was selected by my peers to be included among the Best Doctors in America and Best Doctors in Boston.

F. Advisees and Trainees:

2008-2009 Mentor for Michael Ostacher, MD, MPH in the Harvard Medical School Scholars in Clinical Science Program

Mentee	Mentoring Role With Mentee	Duration	Trainee's Accomplishments	Subsequent Career Activity
1. Katherine A. Philips, MD	Supervised as a resident at McLean and NARSAD application	2 yrs	Established body dysmorphic disorder as a legitimate area of research; KO1 Award; K24 Award	International expert on BDD; Chairperson of NIMH ITV IRG; Professor of Psychiatry and Human Behavior Bio Med Psychiatry & Human Behavior Brown U.
2. Tricia Suppes, M.D., Ph.D	Supervised as a resident at McLean	1 yr	Established bipolar disorder research program at U of Texas Southwestern	International expert on bipolar disorder; Directed TMAP Bipolar Project; Professor of Psychiatry Stanford University
3. S. Nassir Ghaemi, M.D	Supervised as a resident at McLean and fellow at MGH	2 yrs	Established bipolar disorder research program at Cambridge Hospital	International expert on bipolar disorder; K23 Award; RO1; Professor of Psychiatry Tufts University
4. Gordon Frankle, M.D	Supervised as 4 th year resident at MGH	1 yr	Published paper on duration of bipolar depression;	Assistant Professor, University of Pittsburgh
5. Aude Henin, Ph.D.	Supervised as junior faculty at MGH	4 yrs	Project Director on NARSAD Child-at-Risk study (A.A.N. PI)	KO1
6. Hadin Huskamp, Ph.D.	Supervise as junior faculty at Harvard Medical School; K Award Co-mentor	1 yr	KO8	Promoted to Assistant Professor at Harvard Medical School
7. Dan Iosefescu, M.D.	Supervised as resident and junior faculty at MGH, K Award Mentor	3 yrs	K23, NARSAD	Director Mood Disorders Program, Associate Professor at Mt. Sinai Medical School
8. David Mischoulon, M.D., Ph.D.	Supervised as resident and junior faculty at MGH, K Award Mentor	4 yrs	K23, NARSAD, RO-1	Promoted to Director of Research, Depression Program; Associate Professor at Harvard

9. Michael Ostacher, M.D., M.P.H.	Supervised as junior faculty at MGH, K Award Mentor	5 yrs	Re-entry Grant (A.A.N., PI), NARSAD, NIH loan repayment, K23 Award	Associate Professor of Psychiatry, Stanford University Medical School
10. George Papakostas, M.D.	Supervised as resident and junior faculty at MGH, K Award Mentor	5 yrs	K23, NARSAD, RO1	Promoted to Director of Treatment Resistant Depression. Associate Professor at Harvard
11. Roy Perlis, M.D.	Supervised as resident and junior faculty at MGH, K Award Mentor	5 yrs	K23, NARSAD	Promoted to Director of Pharmacogenetics. Associate Professor at Harvard
12. Timothy Petersen, Ph.D.	Supervise as junior faculty at MGH	4 yrs	NARSAD	Promoted to Associate Director of Postgraduate Education, MGH
13. Naomi Simon, M.D.	External mentor at MGH, Co-Mentor of NARSAD	4 yrs	K23, NARSAD, RO1	Director of Center for Anxiety Disorders Associate Professor at Harvard Medical School;
14. Albert Yeung, M.D.	Supervised as resident and junior faculty at MGH, K Award Mentor	4 yrs	K23	Director of Community Studies of Depression MGH; Associate Professor, Harvard
15. William Pirl, MD	K Award Co-Mentor at MGH	5 yrs	K23 Award	Instructor of Psychiatry, Psycho-oncology
15. Thilo Deckersbach, Ph.D.	Supervise as junior faculty at MGH, K Award Mentor	5 yrs	K 23 Award, NARSAD	Director of Psychology, Bipolar Disorder, MGH; Associate Professor, Harvard
16. Beny Lafer, MD	Supervised as fellow at MGH	4 yrs	Published 20 papers	Promoted to Associate Professor, U of Sao Paulo, Brazil
17. Leslie Yan, BA	Supervised as Research Coordinator at MGH	2 yrs	Co-authored 2 papers	Graduate student at UCLA focusing on bipolar disorder
18. Stephanie McMurrich, BA	Supervised as Research Coordinator at MGH	2 yrs	Co-authored 1 paper	Psychologist, Bipolar Program, MGH, Instructor, HMS
19. Louisa Grandin Sylvia, Ph.D.	Supervised as Research Coordinator at MGH	7 yrs	K23 Award	Associate Director, MGH Bipolar Program; Assistant Professor, HMS
20. Jaqueline Ogutha, BA	Supervised as Research Coordinator at MGH	2 yrs	Co-authored 2 abstracts	Medical student at University of Chicago Medical School
21. Lisa Uebelacker, PhD	Supervised as Research Coordinator at MGH	2 yrs	Co-authored 5 papers	Assistant Professor of Psychology at Brown University
22. Brent Foster, MD	Consultant to K Award	5 yrs	K23 Award	Instructor in Psychiatry. HMS, Director Mood Disorders Division, Geriatric Psychiatry Research Program,

				McLean Hospital
23. Brian Brennan, MD	Consultant to K Award	5 yrs	K23 Award	Schizophrenia and Bipolar Program, McLean Hospital, Instructor in Psychiatry, HMS
24. Matthew Bianchi, MD	Mentor to Harvard Catalyst KL2 / Medical Research Investigator Training (MeRIT) Program	2 yrs	KL2 Award	Instructor in Neurology, Harvard Medical School
25. Lori Eisner, PhD	Mentor since 2002 as Research Coordinator; Mentor for T32 Harvard Clinical Research Training Program	10 yrs	T32; Kaplen Award; Harvard CRTF Fellowship	Instructor in Psychiatry; Harvard Medical School
26. Kristin Ellard, PhD	Consultant to NIMH F32 Award and Kaplan Award	1 yr	F32; Kaplen Award	Instructor in Psychiatry, Harvard Medical School
27. Sharmin Ghaznavy, MD, PhD	Consultant to Kaplan Award; NARSAD	1 yr	Kaplen Award; NARSAD Young Investigator	Instructor in Psychiatry, Harvard Medical School
28. Krista F. Huybrechts, PhD	Mentor for K Award	2 yrs	KO1 Award	Instructor in Medicine, Harvard Medical School

Bibliography:

Original Reports:

1. Drob S, Bernard H, Lifshutz H, **Nierenberg A**. Brief group psychotherapy for herpes patients: A preliminary study. Behavior Therapy 17:229-238 (1987).
2. **Nierenberg, AA**, Feinstein AR. How to evaluate a diagnostic marker test: Lessons from the rise and fall of dexamethasone suppression test. JAMA 259:1699-1702 (1988).
3. **Nierenberg, AA**, Keck PE. Management of monoamine oxidase inhibitor associated insomnia with trazodone. J Clin Psychopharmacology 9:42-45 (1989).
4. Keck PE, Pope HG, Cohen BM, McElroy SL, **Nierenberg, AA**. Risk factors for neuroleptic malignant syndrome: A case-control study. Arch Gen Psychiatry 46:914-918 (1989).
5. Keck PE, Pope HG, **Nierenberg, AA**. Autoinduction of hypertensive reactions by tranlycypromine? J Clin Psychopharmacology 9:48-51 (1989).
6. Keck PE, Vuckovic A, Pope HG, **Nierenberg, AA**, Gribble GW, White K. Acute cardiovascular response to monoamine oxidase inhibitors: A prospective assessment. J Clin Psychopharmacol 9:203-206 (1989).
7. **Nierenberg, AA**, Price LH, Charney DS, Heninger GR. After lithium augmentation: A retrospective follow-up of patients with antidepressant-refractory depression. J Affective Disorders 18:167-175 (1990).
8. **Nierenberg, AA**. Methodologic problems in treatment resistant depression research. Psychopharmacol Bull 26:461-464 (1990).

9. **Nierenberg, AA**, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. *J Clin Psychiatry* 51 (supple:39-47):48-50 (1990)
10. **Nierenberg, AA**, Amsterdam JD. Treatment resistant depression: Diagnostic criteria and treatment. *J Clin Psychiatry* 5:39-47 (1990)
11. Keck PE, Carter WP, **Nierenberg, AA**, Cooper TB, Potter WZ, Rothschild AJ, Bird MP. Acute cardiovascular effects of tranylcypromine: Correlation with plasma drug, metabolite, norepinephrine and MHPG levels. *J Clin Psychiatry* 52:250-254 (1991).
12. **Nierenberg, AA**, Cole JO. Antidepressant adverse drug reactions. *J Clin Psychiatry* 52:40-47 (1991).
13. **Nierenberg, AA**. Treatment choice after on antidepressant fails: a survey of northeastern psychiatrists. *J Clin Psychiatry* 52:383-385 (1991)
14. Gardos G, Cole JO, Matthews JD, **Nierenberg, AA**, Dugan SJ. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia. *Neuropsychopharmacology* 6:241-247 (1992).
15. **Nierenberg, AA**. The medical consequences of the selection of an antidepressant treatment choice. *J Clin Psychiatry suppl.* 53:19-24 (1992).
16. **Nierenberg, AA**, Cole JO, Glass LA. Possible trazodone potentiation of fluoxetine - a case series. *J Clin Psychiatry* 53:83-85 (1992).
17. **Nierenberg, AA**, Adler LE, Peselow E, Zornberg G. Trazodone for antidepressant associated insomnia. *Am J Psychiatry* 151:1069-1072 (1994).
18. **Nierenberg, AA**, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. *J Clin Psychopharmacology* 14:419-423 (1994).
19. Philips KA, **Nierenberg, AA**. The assessment and treatment of refractory depression. *J Clin Psychiatry Suppl.* 55:20-26 (1994).
20. Rosenbaum JF, Fava M, **Nierenberg, AA**. The pharmacologic treatment of mood disorders. *Psychiatric Clin North America Annual of Drug Therapy* 1:17-50 (1994).
21. **Nierenberg, AA**. The treatment of severe depression: Is there an efficacy gap between SSRIs and TCAs antidepressant generation? *J Clin Psychiatry Suppl.* 55:55-59 (1994)
22. **Nierenberg, AA**. Treatment resistant depression in the age of serotonin. *Psychiatric Annals* 24:217-219 (1994).
23. Fava M, Rappe SM, Pava J, **Nierenberg, AA**, Alpert J, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. *J Clin Psychiatry* 56:52-55 (1995).
24. **Nierenberg, AA**, Grossbard S, Fava M, Rosenbaum JF. Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. *J Affective Disorders* 34:73-77 (1995).
25. **Nierenberg, AA**, McLean N, Fava M, Alpert J, Worthington J, Rosenbaum JF. Early non-response to fluoxetine as a predictor of poor eight week outcome. *Am J Psychiatry*: 152:1500-1503 (1995).
26. Leiter F, **Nierenberg, AA**, Sanders K, Stern T. Discontinuation reactions following sertraline. *Biol Psychiatry*: 38:694-695 (1995).
27. Worthington J, Fava M, Davidson KG, Alpert JE, **Nierenberg, AA**, Rosenbaum JF. Patterns of improvement in depressive symptoms with fluoxetine treatment. *Psychopharmacol Bull* 31:223-226 (1995).
28. Nelson JC, Docherty JP, Henschen GM, **Nierenberg, AA**, Ward NG. Algorithms for the treatment of subtypes of unipolar depression. *Psychopharmacol Bull*: 31:475-482 (1995).
29. Lafer B, **Nierenberg, AA**, Fava M, Rosenbaum JF. Outpatients with DSM-III-R versus DSM-IV melancholic depression. *Comprehensive Psychiatry*: 37;1:37-39 (1996).

30. Baldessano C, Truman T, **Nierenberg, AA**. Paroxetine-induced akathisia: A review and case report following proxetine treatment. *Comprehensive Psychiatry*: 37:122-124 (1996).
31. Fava M, Alpert JE, **Nierenberg, AA**, Ghaemi N, O'Sullivan R, Tedlow J, Worthington J, Rosenbaum JF. Fluoxetine treatment of anger attacks: a replication study *Ann Clin Psychiatry*: 8:7-10 (1996).
32. Philips KA, **Nierenberg, AA**, Fava M, Rosenbaum JF. Prevalence and clinical features of body dysmorphic disorder in atypical major depression. *J Nervous and Mental Dis.* 1996 184;2:125-29 (1996).
33. Fava M, Abraham M, Alpert J, **Nierenberg, AA**, Pava J, Rosenbaum JF: Gender differences in Axis I comorbidity among depressed outpatients. *J Affective Disorders*: 38:129-133 (1996).
34. Alpert JE, Maddocks A, **Nierenberg, AA**, O'Sullivan R, Pava JA, Worthington JJ, Biederman J, Rosenbaum JF, Fava M. Attention deficit hyperactivity disorder in childhood among adults with major depression depression. *Psychiatry Research* 62:213-219 (1996)
35. Fava M, Alpert JE, Borus JF, **Nierenberg, AA**, Pava J, Rosenbaum JF: Patterns of personality disorder comorbidity in early-onset versus late-onset major depression. *Am J Psychiatry* 153:1308-1312 (1996).
36. **Nierenberg, AA**, Ghaemi SN, Clancy K, Rosenbaum JF, Fava M. Cynicism, hostility, and suicidal ideation in depressed outpatients. *J Nervous and Mental Dis*:184:607-610 (1996)
37. **Nierenberg, AA**, Pava JA, Clancy K, Rosenbaum JF, Fava M. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? *Biological Psychiatry*: 40:691-696 (1996)
38. Worthington J, Fava M, Agustin CM, Alpert J, **Nierenberg, AA**, Pava JA, Rosenbaum JF. Consumption of alcohol, nicotine, and caffeine among depressed outpatients: relationship with response to treatment. *Psychosomatics* 37:518-522 (1996).
39. Tedlow J, Fava M, Uebelacker L, Alpert JE, **Nierenberg, AA**, Rosenbaum JF: Are study dropouts different from completers? *Biological Psychiatry* 40:668-670 (1996)
40. Fava M, Davidson K, Alpert JE, **Nierenberg, AA**, Worthington J, O'Sullivan R, Rosenbaum JF: Hostility changes following antidepressant treatment: Relationship to stress and negative thinking. *Journal of Psychiatric Research* 30:459-467 (1996)
41. Spangler WJ, Cosgrove GR, Cassem E, **Nierenberg, AA**, Rauch SC, Price BH, Ballantine HT. Magnetic resonance image-guided stereotactic cingulotomy for intractable psychiatric disease. *Neurosurgery* 38: 1071-1078 (1996)
42. Demopulos C, Fava M, McLean N, Alpert JE, **Nierenberg, AA**, Rosenbaum JF. Hypochondriacal concerns in depressed outpatients. *Psychosomatic Medicine*: 58:314-320 (1996)
43. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, Moore CM, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothschild AJ, **Nierenberg, AA**, Rosenbaum JF, Cohen BM: Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. *Biological Psychiatry* 41:837-843 (1997).
44. Fava M, Borus JS, Alpert JE, **Nierenberg, AA**, Rosenbaum JF, Bottiglieri T: Folate, vitamin B12, and homocysteine in major depressive disorder. *Am J Psychiatry* 154:426-428 (1997).
45. Fava M, **Nierenberg, AA**, Quitkin FM, Zisook S, Pearlstein T, Stone A, Rosenbaum JF: A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. *Psychopharmacology Bulletin* 33:101-103 (1997).

46. Fava M, Uebelacker LA, Alpert JE, **Nierenberg, AA**, Pava J, Rosenbaum JF. Major depressive subtypes and treatment response. *Biological Psychiatry* 42:568-576 (1997).
47. Alpert JE, Uebelacker LA, McLean NE, **Nierenberg, AA**, Pava JA, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M: Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. *Psychological Medicine* 27:627-633 (1997).
48. Fava M, Mulroy R, Alpert JE, **Nierenberg, AA**, Rosenbaum JF: The emergence of adverse events following venlafaxine extended release (ER) discontinuation. *American Journal of Psychiatry* 154:1760-1762 (1997).
49. **Nierenberg, AA**, Mulroy R. Declaration of treatment failures. In: Rush AJ (ed). *Clinical Decision Trees in the Pharmacotherapy of Mood Disorders. Modern Problems in Pharmacopsychiatry*. Basel Switz. Karger 25:17-33 (1997)
50. Tedlow JR, Fava M, Uebelacker L, **Nierenberg, AA**, Alpert JE, Rosenbaum JF: Outcome definitions and predictors in depression. *Psychotherapy and Psychosomatics* 67: 266-270 (1998)
51. **Nierenberg, AA**, Dougherty D, Rosenbaum JR. Dopaminergic agents and stimulants as antidepressant augmentation strategies. *J Clin Psychiatry* 59(suppl 5):60-63 (1998)
52. **Nierenberg, AA**, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. *J Clin Psychiatry* 59 [Suppl] 18:5-9 (1998)
53. Fava M, Rankin MA, Alpert JE, **Nierenberg, AA**, Worthington JJ: An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. *Psychotherapy and Psychosomatics* 67:328-331 (1998)
54. Cannon B, Mulroy R, Otto MW, Rosenbaum JF, Fava M, **Nierenberg, AA**. Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. *J Aff Dis* 55:45-49 (1999)
55. Alpert JE, Fava M, Uebelacker BA, **Nierenberg, AA**, Pava J, Worthington JJ, Rosenbaum JF. Patterns of Axis I comorbidity in early-onset vs. late-onset major depressive disorder. *Biol Psychiatry* 46:202-210 (1999)
56. Crismon ML, Trivedi M, Pigott TA, Rush JA, Hirschfeld RMA, Kahn D, DeBattista C, Nelson JC, **Nierenberg, AA**, Sackeim HA, Thase ME. The Texas medication algorithm project: Report of the Texas consensus conference panel on medication treatment of major depressive disorder. *J Clin Psychiatry* 60;142-156 (1999)
57. **Nierenberg, AA**, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, Rosenbaum JF, Fava M: Residual symptoms in depressed patients who respond acutely with fluoxetine. *Journal of Clinical Psychiatry* 60;221-225 (1999)
58. Tedlow JR, Leslie V, Keefe BR, Alpert JE, **Nierenberg, AA**, Rosenbaum JF, Fava M: Axis I and axis II disorder comorbidity in unipolar depression with anger attacks. *J Aff Dis* 52:217-223 (1999)
59. Sonawalla S, Renshaw PF, Moore CM, Alpert JE, **Nierenberg, AA**, Rosenbaum JF, Fava M. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. *Am J Psychiatry* 156:1648-1640 (1999)
60. Sonawalla S, Spillmann MK, Kolsky AR, Alpert JE, **Nierenberg, AA**, Rosenbaum JF, Fava M: Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. *J Clin Psychiatry* 60:580-583 (1999)
61. Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, **Nierenberg, AA**, Spillmann MK, Moore CM, Renshaw PF, Bottiglieri T, Moroz G, Magni G. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. *J Clin Psychopharmacology* 19;329-335 (1999)
62. Smoller J, **Nierenberg, AA**. Small numbers, big impact. *Harvard Review of Psychiatry*: 7:109-113 (1999)

63. **Nierenberg, AA**, Burt T, Matthews J, Weiss A. Mania associated with St. John's Wort. *Biol Psychiatry* 46;12:1707-1708 (1999)
64. Fava M, Rankin MA, Wright EC, Alpert JE, **Nierenberg, AA**, Pava JA, Rosenbaum JF: Anxiety disorders in major depression. *Comprehensive Psychiatry* 41:97-102 (2000)
65. Newman JR, Ewing SE, McColl RD, Borus JS, **Nierenberg, AA**, Pava JA, Fava M: Tridimensional personality questionnaire and treatment response in major depressive disorder: a negative study. *J Aff Dis* 57:241-247 (2000)
66. Fredman SJ, Fava M, White CN, **Nierenberg, AA**, Rosenbaum JF. Partial response, non-response, and relapse on SSRIs in major depression: A survey of current "next-step" practices. *J Clin Psychiatry* 61:403-408 (2000)
67. Mischoulon D, **Nierenberg, AA**, Kizilbash L, Rosenbaum JF, Fava M: Strategies for management of depression refractory to SSRI treatment: a survey of clinicians. *Canadian Journal of Psychiatry* 45:476-481 (2000)
68. **Nierenberg, AA**, Alpert JE. Depressive breakthrough. *Psychiatric Clin North America* 23: 731-742 (2000).
69. Fava M, Vuolo RD, Wright EC, **Nierenberg, AA**, Alpert JE, Rosenbaum JF. Fenfluramine challenge in unipolar depression with and without anger attacks. *Psychiatry Research* 94:9-18 (2000)
70. **Nierenberg, AA**, Farabaugh AH, Alpert JE, Gordon JA, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. *Am J Psychiatry* 157: 1423-1428 (2000).
71. Alpert JE, Mischoulon D, **Nierenberg, AA**. Nutrition and depression: focus on folate. *Nutrition* 16:544-546 (2000)
72. Rauch SL, Kim H, Makris N, Cosgrove GR, Cassem EH, Savage CR, Price B, **Nierenberg, AA**, Shera D, Baer L, Buchbinder B, Caviness VS, Jenike MA, Kennedy DN. Volumetric reduction in caudate nucleus following stereotactic placement of lesions in the anterior cingulate cortex in humans: A morphometric magnetic resonance imaging study. *Journal of Neurosurgery* 93:1019-25 (2000)
73. Stahl SM, **Nierenberg, AA**, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. *J Clin Psychiatry* 62:17-23 (2001)
74. Ochsner KN, Kosslyn SM, Cosgrove GR, Cassem EH, Price BH, **Nierenberg, AA**. Deficits in visual cognition and attention following bilateral anterior cingulotomy. *Neuropsychologia* 39:219-230 (2001)
75. Leon AC, Blier P, Culpepper L, Gorman JM, Hirschfeld RMA, **Nierenberg, AA**, Roose SP, Rosenbaum JF, Stahl AM, Trivedi MH. An ideal trial to test differential onset of antidepressant effect. *J Clin Psychiatry* 62:34-36 (2001)
76. Mischoulon D, McColl R, Horwath S, Lagomasino IT, Alpert JE, **Nierenberg, AA**, Fava M. Management of major depression in the primary care setting. *Psychotherapy and Psychosomatics* 70:103-107 (2001).
77. Price BH, Baral I, Cosgrove GR, Rauch SL, **Nierenberg, AA**, Jenike MA, Cassem EH. Improvement in self-mutilation following limbic leucotomy: A series of five consecutive cases. *J Clin Psychiatry* 62:925-932 (2001).
78. Lavori PW, Rush JA, Wisniewski S, Fava M, Kupfer DJ, **Nierenberg, AA**, Quitkin F, Thase ME, Trivedi MH. Strengthening clinical effectiveness trials: equipoise-stratified randomization. *Biological Psychiatry* 50 :792-801(2001).
79. Spillman MK, Van der Does AJ, Rankin MA, Vuolo RD, Alpert JE, **Nierenberg, AA**, Rosenbaum JF, Hayden D, Schoenfeld D, Fava M. Tryptophan depletion in SSRI-recovered depressed outpatients. *Psychopharmacology* (2001) 155:123-127
80. Kornbluh R, Papakostas GI, Petersen T, Neault NB, **Nierenberg, AA**, Rosenbaum JF, Fava M. A survey prescribing preferences in the treatment of refractory depression: recent trends. *Psychopharmacology Bulletin* (2001) 35: 150-156
81. Rauch SL, Dougherty DD, Cosgrove GR, Cassem EH, Alpert NM, Price BH, **Nierenberg, AA**, Mayberg HS, Baer L, Jenike MA, Fischman AJ. Cerebral metabolic

- predictors of responses to anterior cingulotomy for obsessive compulsive disorder. *Biological Psychiatry* 50:659-667 (2001)
82. Peterson T, Bottonari K, Alpert JE, Fava M, **Nierenberg, AA**. Use of the five-factor inventory in characterizing patients with major depressive disorder. *Comprehensive Psychiatry* 42:488-493 (2001)
 83. Montoya A, Weiss AP, Ruiz-Lopez I, Price BH, **Nierenberg, AA**. El tratamiento de la depresion despues de la respuesta inicial a la terapia electroconvulsiva (Depression treatment after electroconvulsive therapy). *Archivos de Neurociencias* 2001: 6 (3): 135-143
 84. Thase ME, **Nierenberg, AA**, Keller MB, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: A placebo-controlled double-blind trial of recently remitted high-risk patients. *J Clin Psychiatry* 62: 782-788 (2001)
 85. Iosifescu D V. Howarth S. Alpert J E. **Nierenberg** A A. Worthington J J. Fava M. T3 blood levels and treatment outcome in depression. *International Journal of Psychiatry in Medicine*. (2001)31:367-73.
 86. **Nierenberg, AA**, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. *J Clin Psychiatry* 62 [Supple 16]: 5-9 (2001)
 87. Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, **Nierenberg AA**, Jenike MA, Rauch SL. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment refractory obsessive compulsive disorder. *Am J Psychiatry* (2002)159;2: 269-75
 88. Perlis RH. Fava M. **Nierenberg AA**. Pollack MH. Falk WE. Kienke AS. Rosenbaum JF. Strategies for Treatment of SSRI-Associated Sexual Dysfunction: A Survey of an Academic Psychopharmacology Practice. *Harvard Review of Psychiatry*. 10(2):109-14, 2002
 89. Petersen T. Papakostas GI. Bottonari K. Iacoviello B. Alpert JE. Fava M. **Nierenberg AA**. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. *Psychiatry Research*. 109(1):9-16, 2002.
 90. Yeung A. Howarth S. Chan R. Sonawalla S. **Nierenberg AA**. Fava M. Use of the Chinese version of the Beck Depression Inventory for screening depression in primary care. *Journal of Nervous & Mental Disease*. 190(2):94-9, 2002
 91. Petersen T. Dording C. Neault NB. Kornbluh R. Alpert JE. **Nierenberg AA**. Rosenbaum JF. Fava M. A survey of prescribing practices in the treatment of depression. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 26(1):177-87, 2002
 92. Yeung A. Neault N. Sonawalla S. Howarth S. Fava M. **Nierenberg AA**. Screening for major depression in Asian-Americans: a comparison of the Beck and the Chinese Depression Inventory. *Acta Psychiatrica Scandinavica*. 105(4):252-7, 2002
 93. Petersen T. Dording C. Neault NB. Kornbluh R. Alpert JE. **Nierenberg AA**. Rosenbaum JF. Fava M. A survey of prescribing practices in the treatment of depression. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 26:177-87, 2002
 94. Montoya A. Weiss AP. Price BH. Cassem EH. Dougherty DD. **Nierenberg AA**. Rauch SL. Cosgrove GR. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. *Neurosurgery*. 50(5):1043-9; discussion 1049-52;2002.
 95. **Nierenberg AA**, Phillips KA, Petersen TJ, Kelley KE, Alpert JE, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M. Body Dysmorphic disorder in outpatients with major depression. *J Affective Disorders* 69:141-148;2002.
 96. Murphy JM, **Nierenberg AA**, Monson RR, Laird NM, Sobol AM, Leighton AH. Self-disparagement as feature and forerunner of depression: findings from the Stirling County Study. *Comprehensive Psychiatry*. 43(1):13-21;2002.

97. Spillmann MK, Van der Does AJ, Rankin MA, Vuolo RD, Alpert JE, **Nierenberg AA**, Rosenbaum JF, Hayden D, Schoenfeld D, Fava M. Tryptophan depletion in SSRI-recovered depressed outpatients. *Psychopharmacology (Berl)*. 2001;155(2):123-7.
98. Murphy JM, **Nierenberg, AA**, Laird NM, Monson RR, Sobol AM, Leighton AH. Incidence of major depression: prediction from subthreshold categories in the Sterling County study. *J Affective Disorders* 68(2-3):251-9; 2002
99. Perlis RH, **Nierenberg AA**, Alpert JE, Pava, Matthews JD, Buchin J, Sickinger AH, Fava M. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. *J Clin Psychopharmacol* 22(5):474-80;2002
100. Petersen T, Gordon JA, Kant A, Fava M, Rosenbaum JF., **Nierenberg, AA**. Treatment resistant depression and axis II comorbidity. *Psychological Medicine*. 31:1223-9;2001.
101. Alpert JE, Mischoulon D, Rubenstein GEF, Bottonari K, **Nierenberg AA**, Fava M. Folinic acid as an adjunctive treatment for SSRI-refractory depression. *Annals of Clin Psychiatry* 35:150-6;2001.
102. Pollack M, Rapaport M, Fayyad R, Otto M, **Nierenberg AA**, Clary C. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. *J Psychiatric Research* 36:229-236;2002.
103. Fava M. Farabaugh AH. Sickinger AH. Wright E. Alpert JE. Sonawalla S. **Nierenberg AA**. Worthington JJ 3rd. Personality disorders and depression. *Psychological Medicine*. 32:1049-57, 2002
104. Tedlow J. Smith M. Neault N. Polania L. Alpert J. **Nierenberg A**. Fava M. Melancholia and axis II comorbidity. *Comprehensive Psychiatry*. 43:331-5, 2002
105. Otto MW. **Nierenberg AA**. Assay sensitivity, failed clinical trials, and the conduct of science. *Psychotherapy & Psychosomatics*. 71:241-3, 2002
106. Montgomery SA. Bech P. Blier P. Möller HJ. **Nierenberg AA**. Pinder RM. Quitkin FM. Reimnitz PE. Rosenbaum JF. Rush AJ. Stassen HH. Thase ME. Selecting methodologies for the evaluation of differences in time to response between antidepressants. *Journal of Clinical Psychiatry*. 63:694-9, 2002
107. Fava M, Alpert JE, **Nierenberg, AA**, Worthington JJ, Rosenbaum JF: Double-blind study of high-dose fluoxetine vs. lithium or desipramine augmentation of fluoxetine in partial and non-responders to fluoxetine. *J Clinical Psychopharmacol* 22:379-87, 2002
108. Petersen T. Hughes M. Papakostas GI. Kant A. Fava M. Rosenbaum JF. **Nierenberg AA**. Treatment-Resistant Depression and Axis II Comorbidity. *Psychotherapy & Psychosomatics*. 71:269-74, 2002
109. Frankle WG, Perlis R, Grandin LD, Deckersbach T, Gray SM, Sachs GS, **Nierenberg AA**. Bipolar depression: relationship between episode length and antidepressant treatment. *Psychol Med Psychological Medicine*. 32:1417-23, 2002
110. Papakostas GI, Petersen T, Mischoulon D, Hughes M, Alpert JE, **Nierenberg AA**, Rosenbaum JF, Fava M: Serum cholesterol and serotonergic function in major depressive disorder. *Psychiatry Research* 118:137-145; 2003
111. Fava M, Rush AJ, Trivedi MH, **Nierenberg AA**, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. *Psychiatric Clinics of North America*. 26:457-94,2003
112. Sachs GS. Thase ME. Otto MW. Bauer M. Miklowitz D. Wisniewski SR. Lavori P. Lebowitz B. Rudorfer M. Frank E. **Nierenberg AA**. Fava M. Bowden C. Ketter T. Marangell L. Calabrese J. Kupfer D. Rosenbaum JF. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). *Biological Psychiatry*. 53:1028-42, 2003
113. Papakostas GI, Petersen T, Mischoulon D, Hughes M, Alpert JE, Fava M, **Nierenberg AA**. Functioning and interpersonal relationships as predictors of

- response in treatment resistant depression. *Comprehensive Psychiatry* 44: 44-50; 2003
114. **Nierenberg AA**, Papakostas GI, Petersen T, Worthington JJ, Tedlow J, Alpert JE, Fava M. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants *J Clin Psychopharmacology* 23: 92-95, 2003
 115. **Nierenberg AA**, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M. Nortriptyline for treatment resistant depression. *J Clin Psychiatry* 64: 35-39; 2003
 116. **Nierenberg AA**. Predictors of response to antidepressants: General principles and clinical implications. *Psychiatric Clinics NA* 2003;26:345-352
 117. Papakostas GI, Petersen T, Pava J, Worthington JJ IIIrd, Alpert JE, Fava M, **Nierenberg AA**: Hopelessness and Suicide in Treatment-Resistant Depression. *J Nervous Mental Disorder* 191:444-9;2003
 118. Papakostas GI, Petersen T, Iosifescu DV, Alpert JE, Rosenbaum JF, Fava M, **Nierenberg AA**. Axis III co-morbidity in Treatment-Resistant Depression. *Psychiatry Research* 118:183-188;2003.
 119. Papakostas GI, Petersen T, Sonawalla SB, Merens W, Alpert JE, Iosifescu DV, Fava M, **Nierenberg**. Serum Cholesterol in Treatment Resistant Depression. *Neuropsychobiology* 47:146-151;2003
 120. Ostacher MJ, Eisner L, **Nierenberg AA**. Mirtazapine in the treatment of mood and anxiety disorders. *Neurotherapeutics* 3(4), 425-433 (2003)
 121. Dougherty DD, Weiss AP, Cosgrove GR, Alpert NM, Cassem EH, Nierenberg AA, Price BH, Mayberg HS, Fischman AJ, Rauch SL. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. *J Neurosurg* 99:1010-1017;2003.
 122. Papkostas GI, Peterson T, Mahal Y, Mischoulon D, **Nierenberg AA**, Fava M. Quality of life in major depressive disorder: A review of the literature. *General Hospital Psychiatry* (accepted for publication).
 123. Papakostas GI, Peterson T, Montoya H, **Nierenberg AA**, Alpert JE, Fava M. Treatment related adverse events and outcomes in a clinical trial of fluoxetine for depression. *Annals of Clinical Psychiatry* (accepted for publication).
 124. Papakosta GI, Peterson T, **Nierenberg AA**, Murakami JL, alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation in selective serotonin reuptake inhibitors for SSRI resistant major depressive disorder. *J Clin Psych* 65:217-21, 2004
 125. Papakostas GI, Petersen T, Pava J, Alpert JE, Rosenbaum JF, Fava M, **Nierenberg AA**. Psychiatric comorbidity among responders and nonresponders to nortriptyline in treatment resistant depression. *J Clin Psychiatry* (accepted for publication).
 126. Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Alpert JE, **Nierenberg AA**, Fava M: Somatic Symptoms in Treatment-Resistant Depression. *Psychiatry Research* 118 (1) 146-151; 2003
 127. Alpert JE, Petersen T, Roffi P, Papakostas GI, Freed R, Smith MM, spector AR, **Nierenberg AA**, Rosenbaum JF, Fava M. Behavioral and emotional disturbances in the offspring of depressed patients with anger attacks. *Psychotherapy and Psychosomatics* 72 (2): 102-106; 2003
 128. Deckersbach T, Perlis RH, Frankle WG, Gray SM, Grandin L, Dougherty DD, **Nierenberg AA**, Sachs GS. Presence of irritability during depressive episodes in bipolar disorder. *CNS Spectrums* 2004;9:227-231
 129. Perlis RH. Iosifescu DV. Alpert J. **Nierenberg AA**. Rosenbaum JF. Fava M. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. *Psychosomatics*. 45(3):224-9, 2004
 130. Papakostas GI, Petersen T, Pava J, Worthington JJ IIIrd, Alpert JE, Fava M, **Nierenberg AA**: A pilot, open study of sertraline in treatment-resistant depression. *Int Clin Psychopharmacology* 18:293-6;2003

131. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, **Nierenberg AA**, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G. STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. *Controlled Clin Trials* 2004;25:119-142.
132. Perlis RH, Smoller JW, Fava MF, **Nierenberg AA**, Sachs GS. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. *J Affective Disorders* 79:291-295; 2004
133. Perlis RH, Alpert J, **Nierenberg AA**, Mischoulon D, Yeung A, Rosenbaum JF, Fava M. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. *Acta Psychiatrica Scandinavica* 108:432-438;2003.
134. Papakostas GI, Petersen TJ, Farabaugh AH, Murakami JL, Pava JA, Alpert JE, Fava M, **Nierenberg AA**. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. *J Clin Psychiatry* 64:1357-1361;2003.
135. Iosifescu DV, **Nierenberg AA**, Alpert JE, Smith M, Bitran S, Dording C, Fava M. The impact of medical comorbidity on acute treatment in major depressive disorder. *Am J Psychiatry*. 2003;160:2122-2127.
136. Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, Bowden CL, Sachs GS, **Nierenberg AA**, for the STEP-BD investigators. Long Term Implications of Early Onset in Bipolar Disorder: Data from the First 1000 STEP-BD Participants. *Biological Psychiatry* 2004;55:875-881
137. **Nierenberg AA**, Quitkin FM, Kremer CM, Thase ME and the Relapse Prevention Study Group. Placebo-Controlled Continuation Treatment with Mirtazapine: Acute Pattern of Response Predicts Relapse. *Neuropsychopharmacology* 2004;29:1012-1018
138. Yeung A, Chang D, Gresham RL, **Nierenberg AA**, Fava M. Illness beliefs of depressed Chinese American patients in primary care. *J Nerv Mental Disease* 192 (4): 324-327 ;2004
139. Yeung A, Chan R, Gresham RL, Sonawalla S, Mischoulon D, Wong E, **Nierenberg AA**, Fava M. Prevalence of Major Depressive Disorder among Chinese-Americans in Primary Care. *General Hospital Psychiatry* 26:24-30;2004
140. **Nierenberg AA**, Trivedi MH, Ritz L, Burroughs D, Greist J, Sackeim H, Kornstein S, Schwartz T, Stegman D, Fava M, Wisniewski S. Suicide Risk Management for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study: Applied NIMH Guidelines. *Journal of Psychiatry Research*. 2004;38;583-589
141. Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, **Nierenberg AA**, Fava M: Psychosocial Functioning during the Treatment of Major Depressive Disorder with Fluoxetine. *J Clin Psychopharmacology* 2004;24:507-511
142. Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Alpert JE, **Nierenberg AA**, Fava M: Obesity among outpatients with major depressive disorder. *International Journal of Neuropsychopharmacology* 2004;7:1-5
143. Papakostas GI, Petersen T, Hughes ME, **Nierenberg AA**, Alpert JE, Fava M: Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. *Psychiatry Research*. 2004;126(3): 287-290.
144. Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, **Nierenberg AA**, Calabrese JR, Sachs GS, Pollack, MH for STEP-BD Investigators. Pharmacotherapy for Bipolar Disorder and Comorbid Conditions: Baseline Data From STEP-BD. *J Clin Psychopharmacol* 2004;24:512-520

145. Iosifescu DV, **Nierenberg AA**, Alpert JE, Papakostas GI, Perlis RH, Sonawalla S, Fava M. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. *Psychosomatics*. 45:419-25, 2004
146. Petersen T, Papakostas GI, Mischoulon D, Mahal Y, Alpert JE, Fava M, **Nierenberg AA**: Quality of Life in Treatment-Resistant Depression. *European Psychiatry* (accepted for publication)
147. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagdayu K, Frank E, Sachs GS, **Nierenberg AA**, Thase ME and Pollack MH. Anxiety Disorder Comorbidity in Bipolar Disorder: Data from the First 500 STEP-BD Participants. *Am J Psychiatry* 161:2222-9, 2004
148. Alpert JE, Papakostas GI, Petersen T, Mischoulon D, Worthington JJ III, Burns A, Bottiglieri T, **Nierenberg AA**, Fava M: Oral S-Adenosyl Methionin (SAME) for Antidepressant Augmentation. *J Clin Psychopharmacology* 24:661-4, 2004
149. Iosifescu DV, Papakostas GI, Lyoo IK, Lee HK, Renshaw PF, Alpert JE, Nierenberg A, Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). *Psychiatry Res*. 2005 Dec 30;140(3):291-9.
150. Papakostas GI, Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Alpert JE, **Nierenberg AA**, Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). *Psychiatry Res*. 2005 Dec 30;140(3):301-7. Epub 2005 Nov 16.
151. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, **Nierenberg AA**, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. *Int J Neuropsychopharmacol*. 2005 Dec;8(4):523-8. Epub 2005 May 9.
152. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, **Nierenberg AA**. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. *Am J Psychiatry*. 2005 Oct;162(10):1957-60.
153. Perlis RH, Delbello MP, Miyahara S, Wisniewski SR, Sachs GS, **Nierenberg AA**; STEP-BD investigators. Revisiting depressive-prone bipolar disorder: polarity of initial mood episode and disease course among bipolar I systematic treatment enhancement program for bipolar disorder participants. *Biol Psychiatry*. 2005 Oct 1;58(7):549-53. Epub 2005 Sep 28.
154. Henin A, Biederman J, Mick E, Sachs GS, Hirshfeld-Becker DR, Siegel RS, McMurrich S, Grandin L, **Nierenberg AA**. Psychopathology in the offspring of parents with bipolar disorder: a controlled study. *Biol Psychiatry*. 2005 Oct 1;58(7):554-61.
155. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, **Nierenberg AA**. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2005 Oct;66(10):1326-30.
156. Fava M, Alpert J, **Nierenberg AA**, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. *J Clin Psychopharmacol*. 2005 Oct;25(5):441-7.
157. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, **Nierenberg AA**, Fava M. An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report. *Biol Psychiatry*. 2005 Sep 28; [Epub ahead of print]
158. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, **Nierenberg AA**, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-

- resistant depression: a randomized, controlled acute phase trial. *Biol Psychiatry*. 2005 Sep 1;58(5):347-54.
159. Simon NM, Pollack MH, Fischmann D, Perlman CA, Muriel AC, Moore CW, **Nierenberg AA**, Shear MK. Complicated grief and its correlates in patients with bipolar disorder. *J Clin Psychiatry*. 2005 Sep;66(9):1105-10.
 160. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, **Nierenberg AA**, Fava M. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. *Psychosom Med*. 2005 Sep-Oct;67(5):703-6.
 161. Iosifescu DV, **Nierenberg AA**, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2005 Aug;66(8):1038-42.
 162. Novick JS, Stewart JW, Wisniewski SR, Cook IA, Manev R, **Nierenberg AA**, Rosenbaum JF, Shores-Wilson K, Balasubramani GK, Biggs MM, Zisook S, Rush AJ; STAR*D investigators. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. *J Clin Psychiatry*. 2005 Aug;66(8):1002-11.
 163. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, **Nierenberg AA**, Fava M. Empirical testing of two models for staging antidepressant treatment resistance. *J Clin Psychopharmacol*. 2005 Aug;25(4):336-41.
 164. Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, **Nierenberg AA**, Fava M, Posternak MA. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. *Ann Clin Psychiatry*. 2005 Jul-Sep;17(3):161-5.
 165. Simon NM, Otto MW, Fischmann D, Racette S, **Nierenberg AA**, Pollack MH, Smoller JW. Panic disorder and bipolar disorder: anxiety sensitivity as a potential mediator of panic during manic states. *J Affect Disord*. 2005 Jul;87(1):101-5.
 166. **Nierenberg AA**, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N, Pollack MH, Ostacher MJ, Yan L, Siegel R, Sachs GS; STEP-BD Investigators. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. *Biol Psychiatry*. 2005 Jun 1;57(11):1467-73.
 167. Murck H, Fava M, Alpert J, **Nierenberg AA**, Mischoulon D, Otto MW, Zajecka J, Mannel M, Rosenbaum JF. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. *Int J Neuropsychopharmacol*. 2005 Jun;8(2):215-21.
 168. Weiss RD, Ostacher MJ, Otto MW, Calabrese JR, Fossey M, Wisniewski SR, Bowden CL, **Nierenberg AA**, Pollack MH, Salloum IM, Simon NM, Thase ME, Sachs GS; for STEP-BD Investigators. Does recovery from substance use disorder matter in patients with bipolar disorder? *J Clin Psychiatry*. 2005 Jun;66(6):730-5.
 169. Deckersbach T, Savage CR, Dougherty DD, Bohne A, Loh R, **Nierenberg A**, Sachs G, Rauch SL. Spontaneous and directed application of verbal learning strategies in bipolar disorder and obsessive-compulsive disorder. *Bipolar Disord*. 2005 Apr;7(2):166-75.
 170. Hollon SD, Jarrett RB, **Nierenberg AA**, Thase ME, Trivedi M, Rush AJ. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? *J Clin Psychiatry*. 2005 Apr;66(4):455-68.

171. Papakostas GI, Petersen T, Iosifescu DV, Burns AM, **Nierenberg AA**, Alpert JE, Rosenbaum JF, Fava M. Obesity among outpatients with major depressive disorder. *Int J Neuropsychopharmacol*. 2005 Mar;8(1):59-63.
172. Mansour HA, Talkowski ME, Wood J, Pless L, Bamne M, Chowdari KV, Allen M, Bowden CL, Calabrese J, El-Mallakh RS, Fagiolini A, Faraone SV, Fossey MD, Friedman ES, Gyulai L, Hauser P, Ketter TA, Loftis JM, Marangell LB, Miklowitz DJ, **Nierenberg AA**, Patel J, Sachs GS, Sklar P, Smoller JW, Thase ME, Frank E, Kupfer DJ, Nimgaonkar VL. Serotonin gene polymorphisms and bipolar I disorder: focus on the serotonin transporter. *Ann Med*. 2005;37(8):590-602.
173. Yeung A, Kung WW, Murakami JL, Mischoulon D, Alpert JE, **Nierenberg AA**, Fava M. Outcomes of recognizing depressed Chinese American patients in primary care. *Int J Psychiatry Med*. 2005;35(3):213-24.
174. Perlis RH, Brown E, Baker RW, **Nierenberg AA**. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. *Am J Psychiatry*. 2006 Feb;163(2):225-31.
175. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, **Nierenberg AA**, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). *Am J Psychiatry*. 2006 Feb;163(2):217-24.
176. **Nierenberg AA**, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. *Am J Psychiatry*. 2006 Feb;163(2):210-6.
177. Eden Evins A, Demopulos C, **Nierenberg A**, Culhane MA, Eisner L, Sachs G. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. *Bipolar Disord*. 2006 Feb;8(1):75-80.
178. Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Perlis RH, Papakostas GI, **Nierenberg AA**, Fava M. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. *Br J Psychiatry*. 2006 Feb;188:180-5.
179. Hollon SD, Shelton RC, Wisniewski S, Warden D, Biggs MM, Friedman ES, Husain M, Kupfer DJ, **Nierenberg AA**, Petersen TJ, Shores-Wilson K, Rush AJ. Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. *J Psychiatr Res*. 2006 Feb;40(1):59-69.
180. Deckersbach T, Dougherty DD, Savage C, McMurrich S, Fischman AJ, **Nierenberg A**, Sachs G, Rauch SL. Impaired recruitment of the dorsolateral prefrontal cortex and hippocampus during encoding in bipolar disorder. *Biol Psychiatry*. 2006 Jan 15;59(2):138-46.
181. Trivedi MH, Rush AJ, Wisniewski SR, **Nierenberg AA**, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry*. 2006 Jan;163(1):28-40.
182. Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M, Berman SR, Farabaugh A, Luther J, **Nierenberg AA**, Lis J, Sackeim H. Factors Associated with Health-Related Quality of Life Among Outpatients with Major Depressive Disorder: A STARD Report. *J Clin Psychiatry* 2006;67:185-191
183. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, **Nierenberg AA**, for the STAR*D Investigators: Self-rated global measure of the frequency, intensity, and burden of side effects. *J Psychiatr Pract* 2006;12:71-79
184. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin FM, Warden D, Ritz L, **Nierenberg A**, Niederehe G, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ. Comparison of Citalopram Augmentation with Bupropion-SR and Buspirone

- Following SSRI Failure for Depressed Outpatients: A STAR*D Report. *NEJM* 2006;354:1243-52
185. Rush AJ, Trivedi MH, Wisniewski SR, Stewart J, **Nierenberg A**, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M. A Comparison of Bupropion-SR, Sertraline, and Venlafaxine-XR Following SSRI Failure for Depressed Outpatients: A STAR*D Report. *NEJM* 2006;354:1231-42
 186. Otto MW., Simon NM, Wisniewski SR, Miklowitz DJ, Kogan J, Reilly-Harrington NA, Frank E, **Nierenberg AA**, Marangell L, Sagduyu KA, Weiss RD, Miyahara S, Thase ME., Sachs GS, Pollack MH for STEP-BD Investigators. One-Year Longitudinal Outcome for Bipolar Patients With and Without Anxiety Disorders: Data from the First 1000 Participants in the Systematic Treatment Enhancement Program. *British J Psychiatry* 2006;189, 20-25.
 187. Wolff N, Perlick DA, Kaczynski R, Calabrese J, **Nierenberg A**, Micklowitz DJ. Modeling costs and burden of informal caregiving for persons with bipolar disorder. *J Ment Health Policy Econ* 2006;9(2):99-110.
 188. Khan AY, Carrithers J, Preskorn SH, Wisniewski SR, Lear R, Rush AJ, Stegman D, Kelley C, Kreiner K, **Nierenberg AA**, Fava M. Clinical and demographic factors associated with DSM-IV melancholic depression. *Annals Clin Psychiatry* (in press).
 189. Ghaemi SN, Hsu D, Thase ME, Wisniewski SR, **Nierenberg AA**, Miyahara S, Sachs G, for the STEP-BD Investigators. Psychotropic drug prescription patterns in bipolar disorder: Data from the first 500 STEP-BD participants (accepted for publication).
 190. McGrath PJ, Stewart JW, Quitkin FW, Chen Y, Alpert JE, **Nierenberg AA**, Fava M, Jianfeng C, Petkova E. A Prospective Study of Predictors of Relapse during Fluoxetine Treatment of Major Depression. *Am J Psychiatry* (in press)
 191. Evins AE, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, **Nierenberg AA**, Sachs GS. Inositol Augmentation of Lithium or Valproate for Bipolar Depression *Biological Psychiatry* (in press).
 192. **Nierenberg, A.A.**, Trivedi, M., Fava, M., Biggs, M.M., Shores-Wilson, K., Wisniewski, S.R., Balasubramani, G.K. and Rush, A.J. Family history of mood disorder and characteristics of major depressive disorder: a STAR*D study. *Journal of Psychiatric Research, J Psychiatr Res.* 2007 Apr-Jun;41(3-4):214-21. Epub 2006 May 11.
 193. Pollack MH, Simon NM, Fagiolini A, Pitman R, McNally RJ, **Nierenberg AA**, Miyahara S, Sachs G, Perlman C, Ghaemi SN, Thase ME, Otto MW. Persistent PTSD in Bipolar Patients Following September 11th. *J Clin Psychiatry* (in press).
 194. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, **Nierenberg AA**, Fava M, Wong KK. Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging. *Biological Psychiatry* (in press)
 195. Petersen T, Papakostas GI, Alpert JE, Mahal Y, Buchin J, Farabaugh A, Matthews J, **Nierenberg AA**, Pava JA, Fava M: The Role of Cognitive-Behavioral Therapy and Fluoxetine in Prevention of Recurrence of Major Depressive Disorder. *Cognitive Therapy and Research* (accepted for publication).
 196. Fava M, Rush AJ, Wisniewski SR, **Nierenberg AA**, Alpert J, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JL, Niederehe G, Ritz L, Trivedi MH, For the STAR*D Trial Team. A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. *Am J Psychiatry* (in press).
 197. Simon NM, Pollack MH, Ostacher MJ, Zalta AK, Chow C, Fischmann D, Demopulos CM, **Nierenberg AA**, Otto MW. Understanding the Link Between Anxiety Symptoms and Suicidal Ideation and Behaviors In Outpatients with Bipolar Disorder. *Journal of Affective Disorders* (in press)
 198. Ostacher MJ, **Nierenberg AA**, Perlis RH, Eidelman P, Borrelli DJ, Tran TB, Ericson GM, Weiss RD, Sachs GS. The association between smoking, suicidal behavior,

- comorbidity, and course of illness in bipolar disorder. *J Clin Psychiatry* 2006;67:1907-1911
199. **Nierenberg AA**, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ. A Comparison of Lithium and Thyroid Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. *Am J Psychiatry* (in press).
 200. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, **Nierenberg AA**, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ. A Comparison of Tranylcypromine to the Combination of Venlafaxine-XR Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. *Am J Psychiatry* (in press).
 201. Henin A, Biederman J, Mick E, Hirshfeld-Becker DR, Sachs GS, Wu, Y, Yan L, Ogutha J, **Nierenberg AA**. Childhood antecedent disorders to bipolar disorder in adults: A controlled study. *J Affect Disord* 2007 Apr;99(1-3):51-7. Epub 2006 Oct 12.
 202. Iosifescu DV, Renshaw PF, Dougherty DD, Lyoo IK, Lee HK, Fraguas R, Cassano P, **Nierenberg AA**, Fava M. Major Depressive Disorder with Anger Attacks and Subcortical MRI White Matter Hyperintensities. *Journal of Nervous and Mental Disease J Nerv Ment Dis.* 2007 Feb;195(2):175-8.
 203. Rush AJ, Trivedi MH, Wisniewski SR, **Nierenberg AA**, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry* 2006; 163(11):1905-1917
 204. Simon NM, Zalta AK, Otto MW, Ostacher MJ, Fischmann D, Chow CW, Thompson EH, Stevens JC, Demopulos CM, **Nierenberg AA**, Pollack MH. The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. *J Psychiatr Res.* 2007 Apr-Jun;41(3-4):255-64. Epub 2006 Oct 18.
 205. **Nierenberg AA**, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. *Curr Med Res Opin.* 2007 Feb;23(2):401-16.
 206. Kobak KA, Kane JM, Thase ME, **Nierenberg AA**. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? *J Clin Psychopharmacol.* 2007 Feb;27(1):1-5.
 207. Iosifescu DV, Renshaw PF, Dougherty DD, Lyoo IK, Lee HK, Fraguas R, Cassano P, **Nierenberg AA**, Fava M. Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. *J Nerv Ment Dis.* 2007 Feb;195(2):175-8.
 208. Papakostas GI, Petersen T, Sklarsky KG, **Nierenberg AA**, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. *Psychiatry Res.* 2007 Jan 15;149(1-3):195-200. Epub 2006 Dec 8.
 209. Simon NM, Pollack MH, Ostacher MJ, Zalta AK, Chow CW, Fischmann D, Demopulos CM, **Nierenberg AA**, Otto MW. Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder. *J Affect Disord.* 2007 Jan;97(1-3):91-9. Epub 2006 Jul 3.
 210. Michelson D, Adler LA, Amsterdam JD, Dunner DL, **Nierenberg AA**, Reimherr FW, Schatzberg AF, Kesley DK, Williams DW. Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study. *J Clin Psychiatry* 2007;68:582-587.
 211. Sachs GS, **Nierenberg AA**, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman E, Bowden C, Fossey M, Ostacher M, Ketter T, Patel J, Hauser P, Rapport

- D, Martinez J, Allen M, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. *New England Journal of Medicine* 2007; 356: 1711-1722.
212. Tamada RS, Amaral JA, Issler CK, **Nierenberg AA**, Lafer B. Antidepressant treatment-emergent affective switch in bipolar disorder: a prospective case-control study of outcome. *Rev Bras Psiquiatr.* 2006 Dec;28(4):297-300.
 213. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN; **Nierenberg AA**, Calabrese JR, Marangell LB, Gyulai L, Araga M, Gonzalez JM, Shirley ER, Thase ME, Sachs GS. Psychosocial Treatments for Bipolar Depression: A 1-Year Randomized Trial From the Systematic Treatment Enhancement Program. *Arch Gen Psychiatry.* 2007;64:419-426.
 214. Michelson D, Adler LA, Amsterdam JD, Dunner DL, **Nierenberg AA**, Reimherr FW, Schatzberg AF, Kelsey DK, Williams DW. Addition of atomoxetine for depression incompletely responsive to sertraline: A randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007;68:582-587
 215. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, **Nierenberg AA**, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ. Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. *Am J Psychiatry* 2007 164: 739-752
 216. Reilly-Harrington NA, Deckersbach T, Knauz R, Wu Y, Tran T, Eidelman P, Lund HG, Sachs G, **Nierenberg AA**. Cognitive behavioral therapy for rapid-cycling bipolar disorder: a pilot study. *J Psychiatric Practice* 2007;13:291-297
 217. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI , Pollack MH, **Nierenberg AA**, Fava M, Wong KK. A Detailed Examination of Cytokine Abnormalities in Major Depressive Disorder. *European Neuropsychopharmacology* (in press)
 218. Taylor CT, Hirshfeld-Becker DR, Ostacher MJ, Chow CW, LeBeau RT, Pollack MH, **Nierenberg AA**, and Simon NM. Anxiety is Associated with Impulsivity in Bipolar Disorder. *Journal of Anxiety Disorders* (in press)
 219. Zisook S, Lesser I, Stewart JW, Wisniewski SR, Balasubramani GK, Fava M, Gilmer WS, Dresselhaus TR, Thase ME, **Nierenberg AA**, Trivedi MH, Rush AJ. Effect of age at onset on the course of major depressive disorder. *Am J Psychiatry.* 2007 Oct;164(10):1539-46.
 220. Warden D, Trivedi MH, Wisniewski SR, Davis L, **Nierenberg AA**, Gaynes BN, Zisook S, Hollon SD, Balasubramani GK, Howland R, Fava M, Stewart JW, Rush AJ. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. *Am J Psychiatry.* 2007 Aug;164(8):1189-97.
 221. **Nierenberg AA**, Alpert JE, Gaynes BN, Warden D, Wisniewski SR, Biggs MM, Trivedi MH, Barkin JL, Rush AJ. Family History of Completed Suicide and Characteristics of Major Depressive Disorder: A STAR*D (Sequenced Treatment Alternatives to Relieve Depression) Study. *J Affective Disorders* (accepted for publication).
 222. Taylor CT, Hirshfeld-Becker DR, Ostacher MJ, Chow CW, Lebeau RT, Pollack MH, **Nierenberg AA**, Simon NM. Anxiety is associated with impulsivity in bipolar disorder. *J Anxiety Disord.* 2007 Sep 11; Epub ahead of print
 223. Howland RH, Schettler PJ, Rapaport MH, Mischoulon D, Schneider T, Fasiczka A, Delrahim K, Maddux R, Lightfoot M, **Nierenberg AA**. Clinical features and functioning of patients with minor depression. *Psychotherapy Psychosomatics* 2008;77(6):384-9.
 224. **Nierenberg AA**, Smoller J, Eidelman P, Wu Y, Tilley C. Critical Thinking about Adverse Drug Effects: Lessons from the Psychology of Risk and Medical Decision-Making for Clinical Psychopharmacology. *Psychother Psychosom* 2008;77:201-208
 225. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, McGrath PJ, Thase ME, Klinkman M, **Nierenberg AA**, Yates WR, Fava M. Primary Versus

- Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D. *J Gen Intern Med.* 2008 Feb 5; Epub ahead of print
226. Iosifescu DV, Bolo NR, **Nierenberg AA**, Jensen JE, Fava M, Renshaw PF. Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder. *Biol Psychiatry.* 2008 Jan 17; Epub ahead of print
 227. **Nierenberg AA**, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. *Biol Psychiatry* 2008 Sep 15;64(6):455-60.
 228. Deckersbach T, Rauch S, Buhlmann U, Ostacher MJ, Beucke JC, **Nierenberg AA**, Sachs G, Dougherty DD. An fMRI Investigation of Working Memory and Sadness in Females with Bipolar Disorder: A Brief Report. *Bipolar Disorders* (in press)
 229. Lipkovich I, Mallinckrodt C, Prakash A, **Nierenberg A**. Addressing Methodological Issues in Studying Antidepressant Onset Efficacy Using Pre-Specified Sensitivity Analyses. *Psychopharm Bulletin* (in press).
 230. Blais MA, Frank RG, **Nierenberg AA**, et al.: Measuring Outcomes Makes Good Sense. *Psychiatric Services* 60:112-112, 2009.
 231. Deckersbach T, Rauch SL, Buhlmann U, et al.: An fMRI investigation of working memory and sadness in females with bipolar disorder: a brief report. *Bipolar Disorders* 10:928-942, 2008.
 232. Ei-Mallakh RS, Ghaemi SN, Sagduyu K, et al.: Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. *Journal of Affective Disorders* 111:372-377, 2008.
 233. **Nierenberg AA**, Akiskal HS, Angst J, Hirschfeld RM, Merikangas KR, Petukhova M, Kessler RC. Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS-R). *Mol Psychiatry.* 2009 Jun 30. Epub ahead of print
 234. Stewart JW, McGrath PJ, Fava M, Wisniewski SR, Zisook S, Cook I, **Nierenberg AA**, Trivedi MH, Balasubramani GK, Warden D, Lesser I, John Rush A. Do atypical features affect outcome in depressed outpatients treated with citalopram? *Int J Neuropsychopharmacol.* 2009 Apr 3:1-16.
 235. Fan J, Ionita-Laza I, McQueen MB, Devlin B, Purcell S, Faraone SV, Allen MH, Bowden CL, Calabrese JR, Fossey MD, Friedman ES, Gyulai L, Hauser P, Ketter TB, Marangell LB, Miklowitz DJ, **Nierenberg AA**, Patel JK, Sachs GS, Thase ME, Molay FB, Escamilla MA, Nimgaonkar VL, Sklar P, Laird NM, Smoller JW. Linkage disequilibrium mapping of the chromosome 6q21-22.31 bipolar I disorder susceptibility locus. *Am J Med Genet B Neuropsychiatr Genet.* 2009 Mar 23. Epub ahead of print PubMed PMID: 19308960.
 236. McGrath PJ, Khan AY, Trivedi MH, et al.: Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features: A STAR*D Report. *Journal of Clinical Psychiatry* 69:1847-1855, 2008.
 237. Amsterdam JD, Williams D, Michelson D, Adler LA, Dunner DL, **Nierenberg AA**, Reimherr FW, Schatzberg AF: Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. *Neuropsychobiology* 2009;59:227-233.
 238. Blais MA, Frank RG, **Nierenberg AA**, Rauch SL: Measuring outcomes makes good sense. *Psychiatric Services* 2009;60:112-112.
 239. Dording CM, Sinicropi-Yao L, Papakostas G, Matthews JD, **Nierenberg AA**, Fava M, Mischoulon D: The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. *Nordic Journal of Psychiatry* 2009;63:420-425.
 240. Friedman ES, Wisniewski SR, Gilmer W, **Nierenberg AA**, Rush AJ, Fava M, Zisook S, Balasubramani GK, Trivedi MH: Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with

- citalopram: Results of the nimh star*d trial. *Depression and Anxiety* 2009;26:612-621.
241. Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB, Calabrese JR, **Nierenberg AA**, Sachs GS: Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: Findings from the step-bd. *American Journal of Psychiatry* 2009;166:173-181.
 242. Husain MM, Rush J, Wisniewski SR, McClintock SM, Fava M, **Nierenberg AA**, Davis L, Balasubramani GK, Young E, Albala AA, Trivedi MH: Family history of depression and therapeutic outcome: Findings from star*d. *Journal of Clinical Psychiatry* 2009;70:185-195.
 243. Iosifescu DV, Moore CM, Deckersbach T, Tilley CA, Ostacher MJ, Sachs GS, **Nierenberg AA**: Galantamine-er for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: A proof-of-concept study. *Cns Neuroscience & Therapeutics* 2009;15:309-319.
 244. Mansour HA, Talkowski ME, Wood J, Chowdari K, McClain L, Prasad K, Montrose D, Fagiolini A, Friedman ES, Allen MH, Bowden CL, Calabrese J, El-Mallakh RS, Escamilla M, Faraone SV, Fossey MD, Gyulai L, Loftis JM, Hauser P, Ketter TA, Marangell LB, Miklowitz DJ, **Nierenberg AA**, Patel J, Sachs GS, Sklar P, Smoller JW, Laird N, Keshavan M, Thase ME, Axelson D, Birmaher B, Lewis D, Monk T, Frank E, Kupfer DJ, Devlin B, Nimgaonkar VL: Association study of 21 circadian genes with bipolar i disorder, schizoaffective disorder, and schizophrenia. *Bipolar Disorders* 2009;11:701-710.
 245. **Nierenberg A**, Kennedy S, Lydiard RB, Rapaport MH: Efficacy, safety, and tolerability considerations in the novel treatment of major depressive disorder. *CNS Spectrums* 2009;14
 246. **Nierenberg AA**: Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. *Psychotherapy and Psychosomatics* 2009;78:391-393. Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Ketter TA, Calabrese JR, Thase ME, Bowden CL, Friedman ES, Ostacher MJ, Novak L, Iosifescu DV: Lithium treatment-moderate dose use study (litmus) for bipolar disorder: Rationale and design. *Clinical Trials* 2009;6:637-648.
 247. **Nierenberg AA**, Trivedi MH, Gaynes BN, Mitchell J, Davis LL, Husain MM, Wisniewski SR, Fava M, Warden D, Luther JF, van Nieuwenhuizen AO, Morris DW, Shelton RC, Rush AJ: Effectiveness study of venlafaxine-xr combined with aripiprazole for chronic or recurrent major depressive disorder. *Australian and New Zealand Journal of Psychiatry* 2009;43:956-967.
 248. Ostacher MJ, LeBeau RT, Perlis RH, **Nierenberg AA**, Lund HG, Moshier SJ, Sachs GS, Simon NM: Cigarette smoking is associated with suicidality in bipolar disorder. *Bipolar Disorders* 2009;11:766-771.
 249. Perlis RH, Dennehy EB, Miklowitz DJ, DelBello MP, Ostacher M, Calabrese JR, Ametrano RM, Wisniewski SR, Bowden CL, Thase ME, **Nierenberg AA**, Sachs G: Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: Results from the step-bd study. *Bipolar Disorders* 2009;11:391-400.
 250. Perlis RH, Ostacher MJ, Uher R, **Nierenberg AA**, Casamassima F, Kansky C, Calabrese JR, Thase M, Sachs GS: Stability of symptoms across major depressive episodes in bipolar disorder. *Bipolar Disorders* 2009;11:867-875.
 251. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, **Nierenberg AA**: Star*d revising conventional wisdom. *Cns Drugs* 2009;23:627-647.
 252. Segal J, Zira M, Mulligan M, Pirok E, Meinel M, Steel S, Iosifescu D, Deckersbach T, Fan A, **Nierenberg A**, Randolph C, Gilmer W: Evaluation of short-term memantine treatment in euthymic bipolar disorder. *Bipolar Disorders* 2009;11:78-79.
 253. Sherrill JT, Sommers DI, **Nierenberg AA**, Leon AC, Arndt S, Bandeen-Roche K, Greenhouse J, Guthrie D, Normand SL, Phillips KA, Shear MK, Woolson R: Integrating statistical and clinical research elements in intervention-related grant

- applications: Summary from an nimh workshop. *Academic Psychiatry* 2009;33:221-228.
254. Warden D, Rush AJ, Wisniewski SR, Lesser IM, Kornstein SG, Balasubramani GK, Thase ME, Preskorn SH, **Nierenberg AA**, Young EA, Shores-Wilson K, Trivedi MH: What predicts attrition in second step medication treatments for depression?: A star*d report. *International Journal of Neuropsychopharmacology* 2009;12:459-473.
255. Warden D, Rush AJ, Wisniewski SR, Lesser IM, Thase ME, Balasubramani GK, Shores-Wilson K, **Nierenberg AA**, Trivedi MH: Income and attrition in the treatment of depression: A star*d report. *Depression and Anxiety* 2009;26:622-633.

256. Wisniewski SR, Rush AJ, **Nierenberg AA**, Gaynes BN, Warden D, Luther JF, McGrath PJ, Lavori PW, Thase ME, Fava M, Trivedi MH: Can phase iii trial results of antidepressant medications be generalized to clinical practice? A star*d report. *American Journal of Psychiatry* 2009;166:599-607.
257. **Nierenberg AA**, Rapaport MH, Schettler PJ, Howland RH, Smith JA, Edwards D, Schneider T, Mischoulon D. Deficits in Psychological Well-Being and Quality-of-Life in Minor Depression: Implications for DSM-V. *CNS Neurosci Ther.* 2010 Mar 4. [Epub ahead of print] PubMed PMID: 20236139.
258. Perlis RH, Ostacher M, Fava M, **Nierenberg AA**, Sachs GS, Rosenbaum JF. Assuring that double-blind is blind. *Am J Psychiatry.* 2010 Mar;167(3):250-2. PubMed PMID: 20194487.
259. Ostacher MJ, Perlis RH, **Nierenberg AA**, Calabrese J, Stange JP, Salloum I, Weiss RD, Sachs GS; STEP-BD Investigators. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Am J Psychiatry.* 2010 Mar;167(3):289-97. Epub 2009 Dec 15. PubMed PMID: 20008948.
260. Perlis RH, Ostacher MJ, Miklowitz DJ, Hay A, **Nierenberg AA**, Thase ME, Sachs GS. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. *J Clin Psychiatry.* 2010 Mar;71(3):296-303. PubMed PMID: 20331931.
261. Daly EJ, Trivedi MH, Wisniewski SR, **Nierenberg AA**, Gaynes BN, Warden D, Morris DW, Luther JF, Farabaugh A, Cook I, Rush AJ. Health-related quality of life in depression: a STAR*D report. *Ann Clin Psychiatry.* 2010 Feb;22(1):43-55. PubMed PMID: 20196982.
262. Stewart JW, McGrath PJ, Fava M, Wisniewski SR, Zisook S, Cook I, **Nierenberg AA**, Trivedi MH, Balasubramani GK, Warden D, Lesser I, John Rush A. Do atypical features affect outcome in depressed outpatients treated with citalopram? *Int J Neuropsychopharmacol.* 2010 Feb;13(1):15-30. Epub 2009 Apr 3. PubMed PMID: 19341509.
263. Perlis RH, Ostacher MJ, Miklowitz DJ, Smoller JW, Dennehy EB, Cowperthwait C, **Nierenberg AA**, Thase ME, Sachs GS. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. *J Clin Psychiatry.* 2010 Feb;71(2):194-200. PubMed PMID: 20193647.
264. Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, Marchant B, Michelson D, **Nierenberg A**, Schatzberg A, Feldman P. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. *Psychiatry Res.* 2010 Jan 30;175(1-2):67-73. Epub 2009 Dec 6. PubMed PMID: 19969374.
265. **Nierenberg AA**, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. *Psychol Med.* 2010 Jan;40(1):41-50. Epub 2009 May 22. PubMed PMID: 19460188.
266. Sylvia LG, Ametrano RM, **Nierenberg AA**. Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. *Psychother Psychosom.* 2010;79(2):87-96. Epub 2009 Dec 24. PubMed PMID: 20051706.
267. Posternak MA, Baer L, **Nierenberg AA**, Fava M. Response rates to fluoxetine in subjects who initially show no improvement. *J Clin Psychiatry.* 2011 May 31. [Epub ahead of print] PubMed PMID: 21672502.

268. Rapaport MH, **Nierenberg AA**, Howland R, Dording C, Schettler PJ, Mischoulon D. The treatment of minor depression with St. John's Wort or citalopram: Failure to show benefit over placebo. *J Psychiatr Res.* 2011 Jul;45(7):931-41. Epub 2011 May 31. PubMed PMID: 21632064.
269. Bobo WV, Chen H, Trivedi MH, Stewart JW, **Nierenberg AA**, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. *J Affect Disord.* 2011 May 19. Epub ahead of print PubMed PMID:21601287.
273. Sylvia LG, **Nierenberg AA**, Stange JP, Peckham AD, Deckersbach T. Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. *J Psychiatr Pract.* 2011 May;17(3):224-32. PubMed PMID:21587004.
274. Rush AJ, Trivedi MH, Stewart JW, **Nierenberg AA**, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. *Am J Psychiatry.* 2011 May 2. Epub ahead of print PubMed PMID: 21536692.
275. Hodgkin D, Volpe-Vartanian J, Merrick EL, Horgan CM, **Nierenberg AA**, Frank RG, Lee S. Customization in prescribing for bipolar disorder. *Health Econ.* 2011 Apr 19. doi: 10.1002/hec.1737. Epub ahead of print PubMed PMID: 21506194.
276. **Nierenberg AA**, Leon AC, Price LH, Shelton RC, Trivedi MH. The current crisis of confidence in antidepressants. *J Clin Psychiatry.* 2011 Jan;72(1):27-33. PubMed PMID: 21272514.
277. McClintock SM, Husain MM, Wisniewski SR, **Nierenberg AA**, Stewart JW, Trivedi MH, Cook I, Morris D, Warden D, Rush AJ. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. *J Clin Psychopharmacol.* 2011 Apr;31(2):180-6. PubMed PMID: 21346613.
278. Dias RS, Lafer B, Russo C, Del Debbio A, **Nierenberg AA**, Sachs GS, Joffe H. Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD. *Am J Psychiatry.* 2011 Apr;168(4):386-94. Epub 2011 Feb 15. PubMed PMID: 21324951.
279. Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, **Nierenberg AA**. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. *Depress Anxiety.* 2011 Feb;28(2):137-44. doi: 10.1002/da.20768. Epub 2010 Dec 13. PubMed PMID: 21284066.
280. Barnett JH, Huang J, Perlis RH, Young MM, Rosenbaum JF, **Nierenberg AA**, et al. Personality and bipolar disorder: dissecting state and trait associations between mood and personality. *Psychol Med.* 2011;41(8):1593-604.
281. Deckersbach T, Stange JP, **Nierenberg AA**. Norms for Performance in the Workplace in Healthy People: Data from the National Comorbidity Survey Replication Study. *CNS Spectr.* 2011.
282. Dias RS, Lafer B, Russo C, Del Debbio A, **Nierenberg AA**, Sachs GS, et al. Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD. *Am J Psychiatry.* 2011;168(4):386-94.
293. Stange JP, Eisner LR, Holzel BK, Peckham AD, Dougherty DD, Rauch SL, et al. Mindfulness-based cognitive therapy for bipolar disorder: effects on cognitive functioning. *J Psychiatr Pract.* 2011;17(6):410-9.
294. Sylvia LG, **Nierenberg AA**, Stange JP, Peckham AD, Deckersbach T. Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. *J Psychiatr Pract.* 2011;17(3):224-32.

295. Targum SD, **Nierenberg A**. The complexity of "mixed" depression: a common clinical presentation. *Innov Clin Neurosci*. 2011;8(6):38-42.
296. Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. *J Clin Psychiatry*. 2011;72(6):757-64.
297. Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, et al. Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. *J Clin Psychiatry*. 2011;72(6):765-74.
298. Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, et al. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. *J Clin Psychiatry*. 2011;72(10):1322-32.
299. Bowden CL, Perlis RH, Thase ME, Ketter TA, Ostacher MM, Calabrese JR, et al. Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD). *CNS Neurosci Ther*. 2012;18(3):243-9.
300. Chan HN, Rush AJ, **Nierenberg AA**, Trivedi M, Wisniewski SR, Balasubramani GK, et al. Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. *Int J Neuropsychopharmacol*. 2012;15(10):1387-99.
301. Deckersbach T, Holzel BK, Eisner LR, Stange JP, Peckham AD, Dougherty DD, et al. Mindfulness-based cognitive therapy for nonremitted patients with bipolar disorder. *CNS Neurosci Ther*. 2012;18(2):133-41.
302. Hodgkin D, Volpe-Vartanian J, Merrick EL, Horgan CM, **Nierenberg AA**, Frank RG, et al. Customization in prescribing for bipolar disorder. *Health Econ*. 2012;21(6):653-68.
303. Magalhaes PV, Kapczinski F, **Nierenberg AA**, Deckersbach T, Weisinger D, Dodd S, et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. *Acta Psychiatr Scand*. 2012;125(4):303-8.
304. Rush AJ, Wisniewski SR, Zisook S, Fava M, Sung SC, Haley CL, et al. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. *Psychol Med*. 2012;42(6):1131-49.
305. Sylvia LG, Dupuy JM, Ostacher MJ, Cowperthwait CM, Hay AC, Sachs GS, et al. Sleep disturbance in euthymic bipolar patients. *J Psychopharmacol*. 2012;26(8):1108-12.
306. Sylvia LG, Reilly-Harrington NA, Leon AC, Kansky CI, Ketter TA, Calabrese JR, et al. Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder. *Clin Trials*. 2012;9(1):94-101.
307. Kessler RC, Calabrese JR, Farley PA, Gruber MJ, Jewell MA, Katon W, Keck PE, **Nierenberg AA**, Sampson NA, Shear MK, Shillington AC, Stein MB, Thase ME, Wittchen HU. Composite International Diagnostic Interview screening scales for DSM-IV anxiety and mood disorders. *Psychol Med*. 2013 Aug;43(8):1625-37.
308. Magalhaes PV, Dodd S, **Nierenberg AA**, Berk M. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Aust N Z J Psychiatry*. 2012;46(11):1058-67.
309. Fava M, Targum SD, **Nierenberg AA**, Bleicher LS, Carter TA, Wedel PC, et al. An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery. *J Psychiatr Res*. 2012;46(12):1553-63.
310. **Nierenberg AA**, Bentley KH, Farabaugh AH, Fava M, Deckersbach T. The absence of depressive symptoms is not the presence of wellness: Validation of the Clinical Positive Affect Scale. *Aust N Z J Psychiatry*. 2012.

311. Cusin C, Hilton GQ, **Nierenberg AA**, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. *Am J Psychiatry*. 2012;169(8):868-9.
312. Ellard KK, Deckersbach T, Sylvia LG, **Nierenberg AA**, Barlow DH. Transdiagnostic treatment of bipolar disorder and comorbid anxiety with the unified protocol: a clinical replication series. *Behav Modif*. 2012;36(4):482-508.
313. Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, et al. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. *CNS Spectr*. 2012;17(2):76-86.
314. **Nierenberg AA**, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV. Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. *Aust N Z J Psychiatry*. 2012.
315. Sung SC, Haley CL, Wisniewski SR, Fava M, **Nierenberg AA**, Warden D, et al. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. *J Clin Psychiatry*. 2012;73(7):967-76.
316. Bystritsky A, **Nierenberg AA**, Feusner JD, Rabinovich M. Computational non-linear dynamical psychiatry: a new methodological paradigm for diagnosis and course of illness. *J Psychiatr Res*. 2012;46(4):428-35.
317. Baek JH, Eisner LR, **Nierenberg AA**. Smoking and suicidality in subjects with major depressive disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Affect Disord*. 2013 Jul 1.
318. Baek JH, Eisner LR, **Nierenberg AA**. Smoking and Suicidality in Subjects with Bipolar Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (Nesarc). *Depress Anxiety*. 2013 May 8.
319. Baek JH, Kinrys G, **Nierenberg AA**. Lithium tremor revisited: pathophysiology and treatment. *Acta Psychiatr Scand*. 2013 Jul 3.
320. Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, Zhao H, Bowden C, Calabrese JR, Friedman ES, Ketter TA, Iosifescu DV, Reilly-Harrington NA, Ostacher M, Thase ME, **Nierenberg A**. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). *Pharmacogenomics J*. 2013 May 14.
321. Ebert MH, Findling RL, Gelenberg AJ, Kane JM, **Nierenberg AA**, Tariot PN. The effects of the Affordable Care Act on the practice of psychiatry. *J Clin Psychiatry*. 2013 Apr;74(4):357-61; quiz 62.
322. Friedman ES, Calabrese JR, Ketter TA, Leon AC, Thase ME, Bowden CL, Sylvia LG, Ostracher MJ, Severe J, Iosifescu DV, **Nierenberg AA**. Using comparative effectiveness design to improve the generalizability of bipolar treatment trials data: Contrasting LiTMUS baseline data with pre-existing placebo controlled trials. *J Affect Disord*. 2013 Jul 8.
323. Fung V, Price M, Busch AB, Landrum MB, Fireman B, **Nierenberg A**, Dow WH, Hui R, Frank R, Newhouse JP, Hsu J. Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs. *Med Care*. 2013 Jul;51(7):614-21.
324. Kemp DE, Sylvia LG, Calabrese JR, **Nierenberg AA**, Thase ME, Reilly-Harrington NA, Ostacher MJ, Leon AC, Ketter TA, Friedman ES, Bowden CL, Rabideau DJ, Pencina M, Iosifescu DV. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. *Acta Psychiatr Scand*. 2013 Mar 7.
325. **Nierenberg AA**, Friedman ES, Bowden CL, Sylvia LG, Thase ME, Ketter T, Ostacher MJ, Leon AC, Reilly-Harrington N, Iosifescu DV, Pencina M, Severe JB, Calabrese JR. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a

- randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. *Am J Psychiatry*. 2013 Jan 1;170(1):102-10..
326. Stange JP, Sylvia LG, da Silva Magalhaes PV, Miklowitz DJ, Otto MW, Frank E, Berk M, **Nierenberg AA**, Deckersbach T. Extreme attributions predict the course of bipolar depression: results from the STEP-BD randomized controlled trial of psychosocial treatment. *J Clin Psychiatry*. 2013 Mar;74(3):249-55.
 327. Stange JP, Sylvia LG, Magalhaes PV, Frank E, Otto MW, Miklowitz DJ, Berk M, **Nierenberg AA**, Deckersbach T. Extreme attributions predict transition from depression to mania or hypomania in bipolar disorder. *J Psychiatr Res*. 2013 Jun 20.
 328. Sylvia LG, Hay A, Ostacher MJ, Miklowitz DJ, **Nierenberg AA**, Thase ME, Sachs GS, Deckersbach T, Perlis RH. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. *J Clin Psychopharmacol*. 2013 Jun;33(3):343-50.
 329. Sylvia LG, Peters AT, Deckersbach T, **Nierenberg AA**. Nutrient-based therapies for bipolar disorder: a systematic review. *Psychother Psychosom*. 2013;82(1):10-9.
 330. Trivedi MH, Morris DW, Wisniewski SR, Lesser I, **Nierenberg AA**, Daly E, Kurian BT, Gaynes BN, Balasubramani GK, Rush AJ. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. *Am J Psychiatry*. 2013 Jun 1;170(6):633-41.
 331. Trivedi MH, Morris DW, Wisniewski SR, **Nierenberg AA**, Gaynes BN, Kurian BT, Warden D, Stegman D, Shores-Wilson K, Rush AJ. Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. *Can J Psychiatry*. 2013 Feb;58(2):113-22.
 332. Baek JH, Bernstein EE, **Nierenberg AA**. One-carbon metabolism and bipolar disorder. *Aust N Z J Psychiatry*. 2013 Nov;47(11):1013-8.
 333. Kessler RC, Calabrese JR, Farley PA, Gruber MJ, Jewell MA, Katon W, Keck PE, **Nierenberg AA**, Sampson NA, Shear MK, Shillington AC, Stein MB, Thase ME, Wittchen HU. Composite International Diagnostic Interview screening scales for DSM-IV anxiety and mood disorders. *Psychol Med*. 2013 Aug;43(8):1625-37.
 334. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, Gonzalez-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vazquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valenti M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martinez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, **Nierenberg AA**, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, Macqueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. *Am J Psychiatry*. 2013 Nov 1;170(11):1249-62.
 335. Sarris J, **Nierenberg AA**, Schweitzer I, Alpert JE, Rosenbaum JF, Iovieno N, Covino J, Fava M, Mischoulon D. Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. *J Clin Psychopharmacol*. 2013 Dec;33(6):827-30.
 336. Sylvia LG, Friedman ES, Kocsis JH, Bernstein EE, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Bobo WV, Kamali M, McInnis MG, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Calabrese JR, Thase ME, Reilly-Harrington NA, Singh V, Rabideau DJ, **Nierenberg AA**. Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. *J Affect Disord*. 2013 Nov;151(2):722-7.
 337. Sylvia LG, Thase ME, Reilly-Harrington NA, Salcedo S, Brody B, Kinrys G, Kemp D, Shelton RC, McElroy SL, Kocsis JH, Bobo WV, Kamali M, McInnis M, Friedman E, Tohen M, Bowden CL, Ketter TA, Singh V, Calabrese J, **Nierenberg AA**, Rabideau

- DJ, Elson CM, Deckersbach T. Psychotherapy use in bipolar disorder: Association with functioning and illness severity. *Aust N Z J Psychiatry*. 2015 Feb 13. pii:0004867415569803. [Epub ahead of print] PubMed PMID: 25680360.
338. Bernstein EE, **Nierenberg AA**, Deckersbach T, Sylvia LG. Eating behavior and obesity in bipolar disorder. *Aust N Z J Psychiatry*. 2015 Jan 13. pii:0004867414565479. [Epub ahead of print] PubMed PMID: 25586751.
- 339: Freed RD, Tompson MC, Wang CH, Otto MW, Hirshfeld-Becker DR, **Nierenberg AA**, Henin A. Family functioning in the context of parental bipolar disorder: Associations with offspring age, sex, and psychopathology. *J Fam Psychol*. 2015 Feb;29(1):108-18. doi: 10.1037/fam0000048. Epub 2014 Dec 22. PubMed PMID:25528073.
- 340: Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, **Nierenberg AA**, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M. Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study. *J Clin Psychopharmacol*. 2015 Feb;35(1):68-74. doi:10.1097/JCP.0000000000000257. PubMed PMID: 25514063.
- 341: **Nierenberg AA**, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI. Predictors of placebo response in bipolar depression. *Int Clin Psychopharmacol*. 2015 Mar;30(2):59-66. doi: 10.1097/YIC.0000000000000058. PubMed PMID: 25438027.
- 342: Thase ME, Fava M, **Nierenberg AA**. Depression: addressing partial response after first line antidepressant treatment. *J Clin Psychiatry*. 2014 Sep;75(9):978-80. doi: 10.4088/JCP.13018co4c. PubMed PMID: 25295423.
- 343: Mischoulon D, **Nierenberg AA**, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. *J Clin Psychiatry*. 2015 Jan;76(1):54-61. doi: 10.4088/JCP.14m08986. PubMed PMID:25272149.
- 344: Sylvia LG, Rabideau DJ, **Nierenberg AA**, Bowden CL, Friedman ES, Iosifescu DV, Thase ME, Ketter T, Greiter EA, Calabrese JR, Leon AC, Ostacher MJ, Reilly-Harrington N. The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. *J Affect Disord*. 2014 Dec 1;169:144-8. doi: 10.1016/j.jad.2014.08.019. Epub 2014 Aug 20. PubMed PMID: 25194782; PubMed Central PMCID: PMC4172551.
- 345: Baek JH, Kang ES, Fava M, Mischoulon D, Nierenberg AA, Lee D, Heo JY, Jeon HJ. Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. *J Affect Disord*. 2014 Dec 1;169:112-7. doi: 10.1016/j.jad.2014.08.009. Epub 2014 Aug 17. PubMed PMID: 25189990.
- 346: Sylvia LG, Shelton RC, Kemp DE, Bernstein EE, Friedman ES, Brody BD, McElroy SL, Singh V, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Thase ME, Reilly-Harrington NA, **Nierenberg AA**, Rabideau DJ, Kinrys G, Kocsis JH, Bobo WV, Kamali M, McInnis MG, Calabrese JR. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). *Bipolar Disord*. 2014 Aug 16. doi:10.1111/bdi.12243. [Epub ahead of print] PubMed PMID: 25130321.
- 347: Calabrese JR, Fava M, Garibaldi G, Grunze H, Krystal AD, Laughren T, Macfadden W, Marin R, **Nierenberg AA**, Tohen M. Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. *J Affect Disord*. 2014 Oct 15;168:439-51. doi:10.1016/j.jad.2014.06.056. Epub 2014 Jul 10. PubMed PMID: 25113957.
- 348: Peters A, Sylvia LG, Magalhães PV, Miklowitz DJ, Frank E, Otto MW, Hansen NS, Dougherty DD, Berk M, **Nierenberg AA**, Deckersbach T. Age at onset, course of illness and response to psychotherapy in bipolar disorder: results from

- the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Psychol Med.* 2014 Dec;44(16):3455-67. doi: 10.1017/S0033291714000804. Epub 2014 Apr 10. PubMed PMID: 25066366.
- 349: Wardenaar KJ, van Loo HM, Cai T, Fava M, Gruber MJ, Li J, de Jonge P, **Nierenberg AA**, Petukhova MV, Rose S, Sampson NA, Schoevers RA, Wilcox MA, Alonso J, Bromet EJ, Bunting B, Florescu SE, Fukao A, Gureje O, Hu C, Huang YQ, KaramAN, Levinson D, Medina Mora ME, Posada-Villa J, Scott KM, Taib NI, Viana MC, Xavier M, Zarkov Z, Kessler RC. The effects of co-morbidity in defining major depression subtypes associated with long-term course and severity. *Psychol Med.* 2014 Nov;44(15):3289-302. doi: 10.1017/S0033291714000993. Epub 2014 Jul 17. PubMed PMID: 25066141; PubMed Central PMCID: PMC4180779.
- 350: Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, **Nierenberg AA**, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M. Corrigendum to "Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the bipolar CHOICE trial" [*J. Affect. Disord.* 161 (2014) 30-35]. *J Affect Disord.* 2014 Jul 3;167C:259-260. doi: 10.1016/j.jad.2014.06.025. [Epub ahead of print] PubMed PMID: 24998842.
- 351: Baek JH, **Nierenberg AA**, Kinrys G. Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder. *Aust N Z J Psychiatry.* 2014 Jun 19;48(8):705-715. [Epub ahead of print] PubMed PMID: 24947278.
- 352: Rabideau DJ, **Nierenberg AA**, Sylvia LG, Friedman ES, Bowden CL, Thase ME, Ketter TA, Ostacher MJ, Reilly-Harrington N, Iosifescu DV, Calabrese JR, Leon AC, Schoenfeld DA. A novel application of the Intent to Attend assessment to reduce bias due to missing data in a randomized controlled clinical trial. *Clin Trials.* 2014 May 28;11(4):494-502. [Epub ahead of print] PubMed PMID: 24872362; PubMed Central PMCID: PMC4247354.
- 353: Citrome L, Karagianis J, Maguire GA, **Nierenberg AA**. Pharmaism: a tale of two perspectives. *Int J Clin Pract.* 2014 Jun;68(6):659-61. doi: 10.1111/ijcp.12460. PubMed PMID: 24837087.
- 354: PCORnet PPRN Consortium, Daugherty SE, Wahba S, Fleurence R. Patient-powered research networks: building capacity for conducting patient-centered *clinical outcomes research.* *J Am Med Inform Assoc.* 2014 Jul-Aug;21(4):583-6. doi:10.1136/amiajnl-2014-002758. Epub 2014 May 12. PubMed PMID: 24821741; PubMed Central PMCID: PMC4078295.
- 355: Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, **Nierenberg AA**, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M. Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial. *J Affect Disord.* 2014 Jun;161:30-5. doi: 10.1016/j.jad.2014.02.046. Epub 2014 Mar 13. PubMed PMID: 24751304; PubMed Central PMCID: PMC4113323.
- 356: Baek JH, Eisner LR, **Nierenberg AA**. Epidemiology and course of unipolar mania: results from the national epidemiologic survey on alcohol and related conditions (NESARC). *Depress Anxiety.* 2014 Sep;31(9):746-55. doi: 10.1002/da.22261. Epub 2014 Mar 27. PubMed PMID: 24677651.
- 357: Peters AT, Peckham AD, Stange JP, Sylvia LG, Hansen NS, Salcedo S, Rauch SL, **Nierenberg AA**, Dougherty DD, Deckersbach T. Correlates of real world executive dysfunction in bipolar I disorder. *J Psychiatr Res.* 2014 Jun;53:87-93. doi:10.1016/j.jpsychires.2014.02.018. Epub 2014 Mar 2. PubMed PMID: 24655587; PubMed Central PMCID: PMC4045408

- 358: Freed RD, Tompson MC, Otto MW, **Nierenberg AA**, Hirshfeld-Becker D, Wang CH, Henin A. Early risk factors for psychopathology in offspring of parents with bipolar disorder: the role of obstetric complications and maternal comorbid anxiety. *Depress Anxiety*. 2014 Jul;31(7):583-90. doi: 10.1002/da.22254. Epub 2014 Mar 18. PubMed PMID: 24643978.
- 359: Sylvia LG, Salcedo S, Bianchi MT, Urdahl A, **Nierenberg AA**, Deckersbach T. A Novel Home Sleep Monitoring Device and Brief Sleep Intervention for Bipolar Disorder: Feasibility, Tolerability, and Preliminary Effectiveness. *Cognit Ther Res*. 2014 Feb 1;38(1):55-61. PubMed PMID: 24511171; PubMed Central PMCID: PMC3913189.
- 360: Stange JP, Sylvia LG, da Silva Magalhães PV, Miklowitz DJ, Otto MW, Frank E, Berk M, Hansen NS, Dougherty DD, **Nierenberg AA**, Deckersbach T. Extreme attributions predict suicidal ideation and suicide attempts in bipolar disorder: prospective data from STEP-BD. *World Psychiatry*. 2014 Feb;13(1):95-6. doi:10.1002/wps.20093. PubMed PMID: 24497260; PubMed Central PMCID: PMC3918031.
- 361: Baek JH, Kang ES, Fava M, Mischoulon D, **Nierenberg AA**, Yu BH, Lee D, Jeon HJ. Serum lipids, recent suicide attempt and recent suicide status in patients with major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014 Jun 3;51:113-8. doi: 10.1016/j.pnpbp.2014.01.018. Epub 2014 Feb 2. PubMed PMID: 24495778.
- 362: **Nierenberg AA**, Sylvia LG, Leon AC, Reilly-Harrington NA, Shesler LW, McElroy SL, Friedman ES, Thase ME, Shelton RC, Bowden CL, Tohen M, Singh V, Deckersbach T, Ketter TA, Kocsis JH, McInnis MG, Schoenfeld D, Bobo WV, Calabrese JR; Bipolar CHOICE Study Group. Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. *Clin Trials*. 2014 Feb;11(1):114-27. doi:10.1177/1740774513512184. Epub 2013 Dec 17. PubMed PMID: 24346608
- 363: Sylvia LG, Reilly-Harrington NA, Leon AC, Kansky CI, Calabrese JR, Bowden CL, Ketter TA, Friedman ES, Iosifescu DV, Thase ME, Ostacher MJ, Keyes M, Rabideau D, **Nierenberg AA**. Medication adherence in a comparative effectiveness trial for bipolar disorder. *Acta Psychiatr Scand*. 2014 May;129(5):359-65. doi:10.1111/acps.12202. Epub 2013 Oct 3. PubMed PMID: 24117232; PubMed Central PMCID: PMC3975824
- 364: Deckersbach T, Peters AT, Sylvia L, Urdahl A, Magalhães PV, Otto MW, Frank E, Miklowitz DJ, Berk M, Kinrys G, **Nierenberg A**. Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD. *Am J Psychiatry*. 2014 Feb;171(2):178-86. doi: 10.1176/appi.ajp.2013.13020225. PubMed PMID: 24077657; PubMed Central PMCID: PMC3946300.
- 365: Friedman ES, Calabrese JR, Ketter TA, Leon AC, Thase ME, Bowden CL, Sylvia LG, Ostracher MJ, Severe J, Iosifescu DV, **Nierenberg AA**, Reilly-Harrington NA. Using comparative effectiveness design to improve the generalizability of bipolar treatment trials data: contrasting LiTMUS baseline data with pre-existing placebo controlled trials. *J Affect Disord*. 2014 Jan;152-154:97-104. doi:10.1016/j.jad.2013.05.052. Epub 2013 Jul 8. PubMed PMID: 23845385.
- 366: Baek JH, Kinrys G, **Nierenberg AA**. Lithium tremor revisited: pathophysiology and treatment. *Acta Psychiatr Scand*. 2014 Jan;129(1):17-23. doi:10.1111/acps.12171. Epub 2013 Jul 3. Review. PubMed PMID: 23834617.
367. Berk M, Nierenberg AA. Three paths to drug discovery in psychiatry. *Am J Psychiatry*. 2015 May 1;172(5):412-4. doi: 10.1176/appi.ajp.2014.14070858. PubMed PMID: 25930130.
368. Nierenberg AA, Sylvia L, Doederlein A, Edgman-Levitan S, Muskin A, Jewell L, Walker M, Goodman D, Farahbakhsh M, Hearing C, Tovey R, Deckersbach T. Improving the care of patients who have treatment-resistant depression: the promise of the PCORnet Mood Network. *J Clin Psychiatry*. 2015 Apr;76(4):e528-30. doi: 10.4088/JCP.14com09570. PubMed PMID: 25919850.

369. Nierenberg AA, McIntyre RS, Sachs GS. Improving outcomes in patients with bipolar depression: a comprehensive review. *J Clin Psychiatry*. 2015 Mar;76(3):e10. doi: 10.4088/JCP.13091ip1. PubMed PMID: 25830453.
370. Gonzalez Arnold J, Salcedo S, Ketter TA, Calabrese JR, Rabideau DJ, Nierenberg AA, Bazan M, Leon AC, Friedman ES, Iosifescu D, Sylvia LG, Ostacher M, Thase M, Reilly-Harrington NA, Bowden CL. An exploratory study of responses to low-dose lithium in African Americans and Hispanics. *J Affect Disord*. 2015 Jun 1;178:224-8. doi: 10.1016/j.jad.2015.02.035. Epub 2015 Mar 14. PubMed PMID: 25827507; PubMed Central PMCID: PMC4397978.
371. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. *Mol Psychiatry*. 2015 Mar 24. doi: 10.1038/mp.2015.22. [Epub ahead of print] PubMed PMID: 25802980.
372. Sylvia LG, Thase ME, Reilly-Harrington NA, Salcedo S, Brody B, Kinrys G, Kemp D, Shelton RC, McElroy SL, Kocsis JH, Bobo WV, Kamali M, McInnis M, Friedman E, Tohen M, Bowden CL, Ketter TA, Singh V, Calabrese J, Nierenberg AA, Rabideau DJ, Elson CM, Deckersbach T. Psychotherapy use in bipolar disorder: Association with functioning and illness severity. *Aust N Z J Psychiatry*. 2015 May;49(5):453-61. doi: 10.1177/0004867415569803. Epub 2015 Feb 13. PubMed PMID: 25680360.
373. Bernstein EE, Nierenberg AA, Deckersbach T, Sylvia LG. Eating behavior and obesity in bipolar disorder. *Aust N Z J Psychiatry*. 2015 Jun;49(6):566-72. doi: 10.1177/0004867414565479. Epub 2015 Jan 13. PubMed PMID: 25586751.
374. Freed RD, Tompson MC, Wang CH, Otto MW, Hirshfeld-Becker DR, Nierenberg AA, Henin A. Family functioning in the context of parental bipolar disorder: associations with offspring age, sex, and psychopathology. *J Fam Psychol*. 2015 Feb;29(1):108-18. doi: 10.1037/fam0000048. Epub 2014 Dec 22. PubMed PMID: 25528073.
375. Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, Nierenberg AA, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M. Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study. *J Clin Psychopharmacol*. 2015 Feb;35(1):68-74. doi: 10.1097/JCP.0000000000000257. PubMed PMID: 25514063.
376. Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI. Predictors of placebo response in bipolar depression. *Int Clin Psychopharmacol*. 2015 Mar;30(2):59-66. doi: 10.1097/YIC.0000000000000058. PubMed PMID: 25438027.
377. Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. *J Clin Psychiatry*. 2015 Jan;76(1):54-61. doi: 10.4088/JCP.14m08986. PubMed PMID: 25272149.
378. Bernstein EE, Rabideau DJ, Gigler ME, Nierenberg AA, Deckersbach T, Sylvia LG. Patient perceptions of physical health and bipolar symptoms: The intersection of mental and physical health. *J Affect Disord*. 2016 Jan 1;189:203-6. doi: 10.1016/j.jad.2015.09.052. Epub 2015 Sep 30. PubMed PMID: 26451504; PubMed Central PMCID: PMC4641031.
379. Freed RD, Tompson MC, Otto MW, Nierenberg AA, Henin A. A latent class analysis of parental bipolar disorder: Examining associations with offspring psychopathology. *Psychiatry Res*. 2015 Dec 15;230(2):314-22. doi: 10.1016/j.psychres.2015.09.011. Epub 2015 Sep 12. PubMed PMID: 26394919.

380. Ostacher MJ, Nierenberg AA, Rabideau D, Reilly-Harrington NA, Sylvia LG, Gold AK, Shesler LW, Ketter TA, Bowden CL, Calabrese JR, Friedman ES, Iosifescu DV, Thase ME, Leon AC, Trivedi MH. A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). *J Psychiatr Res.* 2015 Dec;71:126-33. doi: 10.1016/j.jpsychires.2015.10.004. Epub 2015 Oct 9. PubMed PMID: 26476489.
381. Peters AT, Shesler LW, Sylvia L, da Silva Magalhaes PV, Miklowitz DJ, Otto MW, Frank E, Berk M, Dougherty DD, Nierenberg AA, Deckersbach T. Medical burden, body mass index and the outcome of psychosocial interventions for bipolar depression. *Aust N Z J Psychiatry.* 2015 Nov 20. pii: 0004867415616694. [Epub ahead of print] PubMed PMID: 26590023.
382. Baek JH, Heo JY, Fava M, Mischoulon D, Nierenberg A, Hong JP, Roh S, Jeon HJ. Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. *J Affect Disord.* 2015 Nov 15;187:183-7. doi: 10.1016/j.jad.2015.08.006. Epub 2015 Aug 28. PubMed PMID: 26342171.
383. Nierenberg AA, Hearing CM, Sande Mathias I, Young LT, Sylvia LG. Getting to wellness: The potential of the athletic model of marginal gains for the treatment of bipolar disorder. *Aust N Z J Psychiatry.* 2015 Oct 12. pii: 0004867415607364. [Epub ahead of print] Review. PubMed PMID: 26460331.
384. Nierenberg AA, Sylvia LG, Ellard KK, Ghaznavi S, Deckersbach T. What happens now? the importance of naturalistic course after first mania. *J Clin Psychiatry.* 2015 Sep;76(9):e1161-3. doi: 10.4088/JCP.14com09596. PubMed PMID: 26455693.
385. McElroy SL, Kemp DE, Friedman ES, Reilly-Harrington NA, Sylvia LG, Calabrese JR, Rabideau DJ, Ketter TA, Thase ME, Singh V, Tohen M, Bowden CL, Bernstein EE, Brody BD, Deckersbach T, Kocsis JH, Kinrys G, Bobo WV, Kamali M, McInnis MG, Leon AC, Faraone S, Nierenberg AA, Shelton RC. Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. *Acta Psychiatr Scand.* 2015 Jun 26. doi: 10.1111/acps.12460. [Epub ahead of print] PubMed PMID: 26114830.
386. Nierenberg AA, Ellard KK. Neurotic depression as the missing link: old wine with a new twist on anxiety and major depressive disorder. *Epidemiol Psychiatr Sci.* 2015 Jun;24(3):230-2. doi: 10.1017/S2045796015000323. PubMed PMID: 25997898.
387. Cassano P, Cusin C, Mischoulon D, Hamblin MR, De Taboada L, Pisoni A, Chang T, Yeung A, Ionescu DF, Petrie SR, Nierenberg AA, Fava M, Iosifescu DV. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. *Psychiatry J.* 2015;2015:352979. doi: 10.1155/2015/352979. Epub 2015 Aug 19. PubMed PMID: 26356811; PubMed Central PMCID: PMC4556873.

Reviews and Educationally Relevant Publications:

1. **Nierenberg, AA**, White K. What next? A review of pharmacologic strategies for treatment resistant depression. *Psychopharmacol Bull* 26:429-460 (1990).
2. **Nierenberg, AA**. A systematic approach to treatment resistant depression. *J Clin Psychiatry Monograph* 10:5-10 (1992).
3. **Nierenberg, AA**, Rosenbaum JF. Antidepressant augmentation strategies II: Lithium augmentation. *American Society of Clinical Psychopharmacology Progress Notes* 3:3-4 (1992).
4. **Nierenberg, AA**. Rational polypharmacy for depression. *Directions in Psychiatry.* Dec (1993).

5. **Nierenberg, AA.** Antidepressant augmentation strategies 3. Thyroid Augmentation. American Society of Clinical Psychopharmacology Progress Notes 4:2 (1993).
6. **Nierenberg, AA,** Rosenbaum JF. Antidepressant augmentation strategies 4. Dopamine agonists and stimulants. American Society of Clinical Psychopharmacology Progress Notes 5:3-4 (1993).
7. Feighner JP, **Nierenberg, AA.** Advances in managing major depression. Psychiatric Times Advances in Psychiatric Medicine 12:1-4 (1995)
8. **Nierenberg, AA.** Treatment resistant depression. Currents in Affective Disorders (August 1995)
9. **Nierenberg, AA.** Review of selected studies in depression. Depressive Disorders: Index and Reviews: 1:2 (1996)
10. **Nierenberg, AA.** Review of selected studies in depression. Depressive Disorders: Index and Reviews: 1:3 (1996).
11. **Nierenberg, AA.** SSRIs and relapse or recurrence in depression. [response to letter to the editor]. Primary Psychiatry 5:22 (1998)
12. **Nierenberg, AA.** Shock therapy for depression. Health News 1998: 4:2:3
13. **Nierenberg, A.** Should you take St. John's Wort? Health News 4:4-5 (1998)
14. **Nierenberg, AA.** Critique of St. John's Wort as an herbal antidepressant. HealthNews (from the publishers of the New England Journal of Medicine) 4:4 (1998).
15. **Nierenberg, AA,** McColl RD. Management options for refractory depression. Am J Med:101:45S-52S
16. **Nierenberg, AA.** Relapse and recurrence prevention with the new generation of antidepressants. Depressive Disorders: Index and Reviews:1 (2):8-9, 1996
17. **Nierenberg, AA.** St. John's Wort: A putative over-the-counter herbal antidepressant. J of Depressive Disorders: Index and Review 1998 Vol 3;2, 3 16-17.
18. **Nierenberg, AA,** Wright EC. Evolution of remission as the new standard in the treatment of depression (review). J Clin Psychiatry 60 Suppl 22:7-11 (1999)
19. **Nierenberg, AA.** Management of patients on antidepressants. J Clin Psychiatry (accepted for publication).
20. **Nierenberg, AA.** Long-term management of chronic depression. J Clin Psychiatry 2001: 62; Suppl 6:17-21 .
21. Frankle WG, **Nierenberg AA.** An overview of the management of the side effects associated with newer treatments for mood disorders. J Clin Psychiatry (accepted for publication).
22. **Nierenberg AA,** Gray S, Grandin L. Mood disorders and suicide. J Clin Psychiatry 2002;62[supple 25]:27-30
23. **Nierenberg AA.** Do some antidepressants work faster than others? J Clin Psychiatry 2001 62 [Suppl 15]:22-25
24. **Nierenberg AA.** Relationship between mood disorder and suicide. J Clin Psychiatry; CNS Discourses (2001)
25. **Nierenberg AA.** Current perspectives on the diagnosis and treatment of major depressive disorder. Am J of Managed Care. 7 [Supple 11]:S353-366 (2001)
26. Carlson K, Chae C, Cohen L, Frigoletto F, Heislein D, Kaplan L, **Nierenberg AA,** Schiff I, Shifren J. Answers to frequently asked questions about women's health. Massachusetts General Hospital Women's Health Program (2002)
27. Alpert JE, **Nierenberg AA.** Treatment-resistant depression; newer alternatives. Current Psychiatry (2002) 1:11-20
28. Hirschfeld RMA, **Nierenberg AA,** Gorman JM, Roose SP, Leon AC, Blier P, Culpepper L, Rosenbaum JF, Stahl SM, Trivedi MH. Debate and discussion - Do some antidepressants have a faster onset of action than others? J Clin Psychiatry 62: 37-40 Suppl. 4 2001

29. **Nierenberg AA**, Peterson TJ, Alpert JE. Prevention of relapse and and recurrence in depression: The role of long-term pharmacotherapy and psychotherapy. *J Clin Psych* 64 [Suppl 15] 13-17 (2003).
30. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, **Nierenberg AA**, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. *Gen Hosp Psychiatry* 2004;26:13-17
31. **Nierenberg AA**, Eidelman P, Wu Y, Joseph M. In: (Nierenberg AA, guest editor) Depression: An update for the clinician. Focus: The Journal of Lifelong Learning in Psychiatry. 3:3-12 (2005)
32. **Nierenberg AA**, Sonino N. From clinical observations to clinimetrics: A tribute to Alvan R. Feinstein, M.D. *Psychother Psychosom* 73:131-133;2004
33. Marangell LB, Suppes T, Ketter TA, Dennehy E, Zboyan H, Kertz K, **Nierenberg A**, Calabrese J, Wisniewski S, Sachs G. Omega-3 Fatty Acids in Bipolar Disorder: Clinical and Research Considerations. *Prostaglandins Leukotrienes & Essential Fatty Acids* (in press)
34. Huffman JC, **Nierenberg AA**. Psychopharmythyology: Not so slowly: How quickly do antidepressants work? *Curbside Consultant* 4:2-3 (October/November 2005)
35. **Nierenberg AA**, Ostacher MJ, Borrelli DJ, Iosifescu DV, Perlis RH, Desrosiers A, Armistead MS, Calkins AW, Sachs GS. The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry.*J Clin Psychiatry*. 2006;67 Suppl 11:3-7.
36. **Nierenberg AA**. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolarI depression compared to lamotrigine. *Evid Based Ment Health*. 2007 Feb;10(1):12
37. **Nierenberg AA**. A counter proposal to manage financial conflicts of interest in academic psychiatry. *World Psychiatry*. 2007 Feb;6(1):34-6.
38. Iosifescu DV, **Nierenberg AA** (Eds). *New Developments in Depression Research*. Psychiatric Clinics NA. 2007:30:1.
39. **Nierenberg AA**, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. *Psychiatr Clin North Am*. 2007 Mar;30(1):13-29.
40. **Nierenberg AA**, Targum SD. Revisiting the clinical utility of cytochrome p450 in practice. *Psychiatry* 2007. 4:28-30.
41. **Nierenberg AA**. The Cutting Edge: Lessons from STEP-BD for the Treatment of Bipolar Depression. *Depression and Anxiety* 2009;26:106-109.
42. **Nierenberg A**, Kennedy S, Lydiard RB, et al.: EFFICACY, SAFETY, AND TOLERABILITY CONSIDERATIONS IN THE NOVEL TREATMENT OF MAJOR DEPRESSIVE DISORDER. *Cns Spectrums* 14:1-+, 2009.
43. **Nierenberg AA**: An Analysis of the Efficacy of Treatments for Bipolar Depression. *Journal of Clinical Psychiatry* 69:4-8, 2008.
44. **Nierenberg AA**: LESSONS FROM STEP-BD FOR THE TREATMENT OF BIPOLAR DEPRESSION. *Depression and Anxiety* 26:106-109, 2009.
45. **Nierenberg AA**. Diagnosing and treating patients with symptoms of depression. *J Clin Psychiatry*. 2009 Mar 20;70(3)
46. **Nierenberg A**. Major depressive disorder: barriers to treatment. *CNS Spectr*. 2009 Mar;14(3 Suppl 5):5-7. PubMed PMID: 19407716.
47. **Nierenberg AA**. Lessons from STEP-BD for the treatment of bipolar depression. *Depress Anxiety*. 2009;26(2):106-9. PubMed PMID: 19177467.
48. Blais MA, Frank RG, **Nierenberg AA**, Rauch SL. Measuring outcomes makes good sense. *Psychiatr Serv*. 2009 Jan;60(1):112. PubMed PMID: 19114580.
49. **Nierenberg A**, Kennedy S, Lydiard RB, Rapaport MH. EFFICACY, SAFETY, AND TOLERABILITY CONSIDERATIONS IN THE NOVEL TREATMENT OF MAJOR DEPRESSIVE DISORDER. *Cns Spectrums*. Mar 2009;14(3)

50. Adler LD, **Nierenberg AA**. Review of medication adherence in children and adults with ADHD. *Postgrad Med*. 2010 Jan;122(1):184-91. Review. PubMed PMID:20107302.
51. Dupuy JM, Ostacher MJ, Huffman J, Perlis RH, **Nierenberg AA**. A critical review of pharmacotherapy for major depressive disorder. *Int J Neuropsychopharmacol*. 2011 Feb 24:1-15. [Epub ahead of print] PubMed PMID: 21349226.
52. **Nierenberg AA**. Alternatives to antidepressants in treating acute bipolar depression. *J Clin Psychiatry*. 2011 Jan;72(1):e03. PubMed PMID: 21272510.
53. Kane JM, Leon AC, **Nierenberg AA**, Correll C. Fifty years of clinical research in neuropsychopharmacology. In *ACNP 50 Years: 50th Anniversary Compendium 1961-2011*. 2011;61-64
54. **Nierenberg AA**. Alternatives to antidepressants in treating acute bipolar depression. *J Clin Psychiatry*. 2011;72(1):e03.
55. **Nierenberg AA**, Leon AC, Price LH, Shelton RC, Trivedi MH. Crisis of confidence: antidepressant risk versus benefit. *J Clin Psychiatry*. 2011;72(3):e11.
56. **Nierenberg AA**, Leon AC, Price LH, Shelton RC, Trivedi MH. The current crisis of confidence in antidepressants. *J Clin Psychiatry*. 2011;72(1):27-33.
57. Peters AT, **Nierenberg AA**. Stepping back to step forward: lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *J Clin Psychiatry*. 2011;72(10):1429-31.

Editorials:

1. **Nierenberg AA**. A new era for CNS Spectrums. *CNS Spectrums*. 2009 May;14(5):232-3.
2. **Nierenberg AA**. Distress: To treat or not to treat. *CNS Spectrums*. 2009;14(7):344-345
3. **Nierenberg AA**. Uncertainty and Practical Reasoning in Clinical Psychiatry and Neuropsychiatry. *Cns Spectrums*. Jun 2009;14(6):284-285.
4. **Nierenberg AA**. Psychiatry and Neuropsychiatry as a Craft. *CNS Spectrums*. Aug 2009;14(8):408-409.
5. **Nierenberg AA**. The Long Tale of the Short Arm of the Promoter Region for the Gene that Encodes the Serotonin Uptake Protein. *CNS Spectrums*. Sep 2009;14(9):462-463.
6. **Nierenberg AA**. The Contribution of Clinical Trials in Psychiatry: A Basic Science of Clinical Care. *CNS Spectrums*. Oct 2009;14(10):528-529.
7. **Nierenberg AA**. Failure to Integrate Brain and Mind (or Blaming Descartes to Understand a Very Modern Dilemma about Explanatory Models, Psychiatric Treatment, and Underfunding of Clinical Care and Research). *CNS Spectrums*. Nov 2009;14(11):599-600.

Chapters:

1. **Nierenberg AA**, Keck PE, Samson J, Rothschild AJ, Schatzberg AF. Methodologic considerations for the study of treatment-resistant depression. In: Amsterdam JD (ed). *Refractory depression*. New York, Raven Press 1-12 (1991).
2. **Nierenberg AA**, Sachs GS, Stoll AL, Rybakowsky J, Matkowski K, Cole AJ, Scott J. Alternative approaches in refractory bipolar depression. In: Nolen W, Zohar J, Roose S, Amsterdam JD (eds). *Refractory Depression: Current Strategies and Future Directions*. Cinchester, John Wiley and Sons 169-174 (1994).
3. Rosenbaum JF, Fava M, **Nierenberg AA**, Sachs GS. Treatment resistant mood disorders. In: Gabbard G (ed). *Treatment of Psychiatric Disorders*. Washington DC. American Psychiatric Press 1275-1328 (1995).

4. **Nierenberg AA**, Kolsky A. Management of patients on psychotropic medications. In: Stern TA, Herman JB, Slavin PL (eds). The MGH Guide to Psychiatry in Primary Care. McGraw-Hill. New York 479-482 (1998).
5. Newman J, **Nierenberg AA**. SSRIs: Distinctive actions? Distinctive differences? In: Stanford C (ed). The SSRIs: A Multidisciplinary Appraisal. College of London University Press. London (1999).
6. Newman J, **Nierenberg AA**. A critical comparison of SSRIs. In: Lafer B, (ed). Depression Across the Life Cycle. Sao Paulo (2000)
7. Mischoulon D, **Nierenberg AA**. Natural medications in psychiatry. In: Stern TA, Herman JB, editors. Psychiatry Update and Board Preparation. New York: McGraw-Hill; 1999:399-408.
8. Rosenbaum JF, Fava M, **Nierenberg AA**, Sachs GS. Treatment resistant mood disorders. In: Gabbard GO (ed). Treatment of Psychiatric Disorders III. Washington DC. American Psychiatric Press 1307-1383 (2001).
9. Alpert JE, **Nierenberg AA**. Psychopharmacological approaches to prevention and treatment of relapse recurrence. In Alpert JE, Fava M (ed). Handbook of Chronic Depression. Marcel Dekker New York, NY (accepted for publication).
10. **Nierenberg AA**, Mischoulon D, DeCecco L. St. John's Wort: A Critique of Antidepressant Efficacy and Possible Mechanisms of Action. Mischoulon D, Rosenbaum JF (eds). Natural Medications for Psychiatric Disorders. Lippincott Williams & Wilkins (2002)
11. Mischoulon D, **Nierenberg A**. Complementary Therapies. In: Potokar J, Thase M (Eds.). Advances in Management and Treatment of Depression. Martin Dunitz Ltd. London, 2002.
12. **Nierenberg AA**, Kolsky A. Management of patients on psychotropic medications. In: Stern TA, Herman JB, Slavin PL (eds). The MGH Guide to Psychiatry in Primary Care (Second Edition). McGraw-Hill. New York 2003.
13. Mischoulon D, **Nierenberg AA**. Natural Medications in Psychiatry. In: (Stern T, Herman J (ed) MGH Psychiatry Update and Board Preparation (Second Edition) McGraw-Hill. New York 2003.
14. Ostacher M, Huffman J, Perlis R, **Nierenberg AA**. Evidence-based pharmacotherapy of major depressive disorder. In: Stein D (ed) Evidence Based Psychopharmacology. Cambridge University Press, London 2006.
15. **Nierenberg AA**, Ostacher M, Delgado P, Gelenberg A, Sachs GS, Rosenbaum JF, Fava M. Antidepressant and Antimanic Medications. In: Gabbard GO (ed). Treatment of Psychiatric Disorders IV. Washington DC. American Psychiatric Press 2007:385-407.
16. **Nierenberg AA**, Mischoulon D, DeCecco L. St. John's Wort: A Critique of Antidepressant Efficacy and Possible Mechanisms of Action. Mischoulon D, Rosenbaum JF (eds). Natural Medications for Psychiatric Disorders, 2nd Edition. Lippincott Williams & Wilkins (2008)

Books:

1. Amsterdam JD, Hornig M, **Nierenberg, AA** (eds). Treatment Resistant Mood Disorders. Cambridge University Press. London, 2001.
2. **Nierenberg AA**, Sussman N, Trivedi M. Prevention of Depressive Relapse. Science Press, London 2003.
3. Deckersbach T, Holzel B, Eisner L, Lazar SW, **Nierenberg AA**. Mindfulness-Based Cognitive Behavioral Therapy for Bipolar Disorder. Guilford Press. New York, 2014.
4. Tohen M, Bowden CL, **Nierenberg AA**, Geddes JR (eds). Clinical Trial Design Challenges in Mood Disorders. Academic Press. London, 2015.

Non-Print Materials:

1. Salzman C, **Nierenberg, AA**, Rosenbaum JF. Panic and Agoraphobia Disorders (audiotape). American College of Psychiatry-Psychiatric Update Audiotape. Port Washington, NY, Medical Information Systems, Inc., 11:6 (1991).
2. **Nierenberg, AA**. Lithium use in unipolar illness (audiotape). In: Spotlight on Lithium. Glendale, CA, Audio-Digest Foundation (1991).
3. **Nierenberg, AA**. Diagnosis and treatment of depression (video). Cambridge, MA, Competent Assurance Systems (1991).
4. Kayton W, **Nierenberg, AA**. Recognition of depression (audiotape). Management of Depression in Primary Care Practice, Indianapolis, Dista Products Company, Division of Eli Lilly and Company, 1 (1991).
5. **Nierenberg, AA**. Clinical simulation for the management of depression (interactive booklet). Newark, Medical Informatics. (1992).
6. Jefferson JW, **Nierenberg, AA**, Zisook S, Weisler RH, Akiskal HS, Settle EC, Segraves RT. Management of patients who are nonresponders or nontolerators of initial antidepressant therapy (video). Medical Information Resources Division of Physicians Postgraduate Press, Inc. (1992).
7. **Nierenberg, AA**, Preskorn S, Glazer W. The Clinical Management of Depression: Guidelines for Treatment. psychLINK Live Television Interactive Conference. IMN Group, Reston, VA (1994)
8. **Nierenberg, AA**. Overcoming treatment-resistant depression (audiotape). Glendale CA, Audio Digest; 24 (1995)
9. **Nierenberg, AA**. Depression. Susan Wornick Consumer Show (live television call-in broadcast). New England Cable News. December 4 (1995)
10. **Nierenberg, AA**. Relapse and Recurrence Prevention in the Post-TCA Era. Depressive Disorders: Index and Reviews Tele-Lecture Volume 1, Number 2 (1996)
11. **Nierenberg, AA**, Blier P, Stoll A, Belmaker RH. Cutting-Edge polypharmacy for mood disorders (Audiotape) APA 98APA-S84B, 1998
12. Amsterdam JD, Greden JF, **Nierenberg, AA**, Thase ME. Treatment-resistant depression. (Audiotape). Journal of Clinical Psychiatry Intercom. August 2000
13. Feighner JP, **Nierenberg AA**, Stahl SM. Antidepressants for the next decade (Audiotape). Psychiatric Update 21: 2001
14. Rush AJ, Greden JF, Kornstein SG, **Nierenberg AA**, Sackeim HA. Recognizing treatment-resistant depression (Audio CD). J Clin Psychiatry 4:2001
15. Thase M, **Nierenberg AA**, Rapaport M. The Future Treatment of Depression (Audiotape). Psychiatric Update 23:2003
16. **Nierenberg AA**. Treatment of Bipolar Depression (Webcast). The Journal of Clinical Psychiatry Pub Web. Vol. 1, No. 2:2005
17. **Nierenberg AA**, Marangell LB, Miklowitz DJ, Perlis RH. Bipolar disorder beyond episodes: The challenge of sustained wellness. Massachusetts General Hospital Psychiatry Academy PsychLink Satellite Broadcast 2006. Archived on www.mghcme.org

Abstracts:

1. **Nierenberg, AA**, Keck PE, Jr., Schatzberg AF, Rothschild AJ, Samson J. Catecholamine, cortisol, and psychosocial correlates of refractory depression. Philadelphia, *First International Conference on Refractory Depression* (1988).
2. Aaronson ST, **Nierenberg, AA**, Keck PE, McElroy SL, Grady T, Tynes L. A simple refractory depression scale. San Francisco, *Society for Biological Psychiatry* (1989)
3. **Nierenberg, AA**, Amsterdam JD. The spectrum of treatment resistant bipolar depression. Amsterdam, The Netherlands, *Second International Conference on Refractory Depression* (1992)

4. Myers JE, Abraham ME, Borus JS, Alpert JE, **Nierenberg, AA** and Fava M. Reproductive histories in depressed women. *Philadelphia, American Psychiatric Association* (1994)
5. Adler LA, **Nierenberg, AA**, Fava M, Hannibal J, Rotrosen J. Training raters to assess neuroleptic-induced akathisia using standardized videotapes. *Philadelphia, Society of Biological Psychiatry* (1994)
6. Meyers J, Abraham M, Borus J, Alpert JE, **Nierenberg, AA**, Fava M. Major depression and reproductive function in women. *American Psychiatric Association Annual Meeting, Miami FL* (1995).
7. **Nierenberg, AA**. Drug combinations in refractory depression. *Third International Conference on Refractory Depression, Napa CA* (1995).
8. **Nierenberg, AA**, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Does early nonresponse to fluoxetine predict poor 8-week outcome?: A replication study. 36th Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton FL (1996)
9. Uribe M, Keefe BR, Vega NA, **Nierenberg, AA**, Mischoulon D, Tedlow JR, Fava M: Comorbid conditions fail to predict patterns of response to fluoxetine. *151st Annual Meeting of the American Psychiatric Association*. Toronto, Ontario, Canada (1998).
10. Alpert JE, Baer HJ, Keefe BR, **Nierenberg, AA**, Rosenbaum JF, Biederman J, Fava M: Delinquent behavior among children of parents with depressive subtypes. *151st Annual Meeting of the American Psychiatric Association*. Toronto, Ontario, Canada (1998).
11. **Nierenberg, AA**, Wang PS, Rosenbaum JF, Fava M, Levin R, Avorn J: Black women receive fewer SSRI antidepressants. *151st Annual Meeting of the American Psychiatric Association*. Toronto, Ontario, Canada (1998).
12. Worthington JJ, Keefe BR, **Nierenberg, AA**, Alpert JE, Pava J, Rosenbaum JF, Fava M: Sociodemographic and clinical predictors of lifetime history of alcohol and drug abuse in depressed outpatients. *151st Annual Meeting of the American Psychiatric Association*. Toronto, Ontario, Canada (1998).
13. O'Sullivan R, Kizilbash L, Alpert J, **Nierenberg, A**, Keuthen N, Fava M. Trichotillomania Among Depressed Adults: Prevalence And Psychiatric Comorbidity. *152nd Annual Meeting of the American Psychiatric Association, Washington D.C.* (1999).
14. Weiss A, **Nierenberg, AA**. Pharmacological treatment after ECT failure. *Association for Convulsive Therapy Annual Meeting, Washington D.C.* (1999).
15. Fava M, Alpert JE, **Nierenberg, AA**, Russell JM, O'Boyle M, Camilleri A, Harrison WM. A validation study of a computerized management system for the diagnosis and treatment of depression. *153rd Annual Meeting of the American Psychiatric Association, Chicago, IL* (2000).
16. **Nierenberg, AA**. Divergence of practice from evidence for refractory depression. *153rd Annual Meeting of the American Psychiatric Association, Chicago, IL* (2000).
17. **Nierenberg, AA**. Can we predict what initial treatment to select and when to change treatment. *22nd CINP Congress, Brussels, Belgium* (2000).
18. **Nierenberg, AA**, Smoller JW, White CN, Guille C, Bitran S, Neault NB, Sachs GS, Fava M, Rosenbaum JF. Unipolar compared with bipolar depression: Similar depressive subtypes. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
19. **Nierenberg, AA**. When to augment antidepressants. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
20. **Nierenberg, AA**. Next generation of MAO inhibitors. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
21. Mischoulon D, Bitran S, Bottonari KA, Worthington JJ, Alpert JE, Fava M, **Nierenberg, AA**. HTP axis dysregulation and response to antidepressant treatment in resistant depression. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).

22. Gray SM, Perlis RH, Yan LJ, Orsini CMJ, Deckersbach T, Sachs GS, **Nierenberg, AA**. Prevalence and prognostic significance of atypical features in bipolar depression. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
23. Yan LJ, Perlis RH, Gray SM, Grandin LD, Orsini CMJ, **Nierenberg, AA**, Sachs GS. Residual symptoms in recovered bipolar patients. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
24. Grandin LD, Frankle WG, Orsini CMJ, Yan LJ, Deckersbach T, Sachs GS, **Nierenberg, AA**. A naturalistic study of the use of atypical antipsychotics in the treatment of bipolar disorder. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
25. Dording CM, Dececco LM, Gresham RL, Pava JA, Alpert JE, **Nierenberg, AA**, Fava M. Self-silencing behaviors in a depressed population: improvement following antidepressant treatment. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
26. Orsini CMJ, Frankle WG, Grandin LD, Gray SM, Yan LJ, **Nierenberg, AA**, Sachs GS. Lithium versus valproic acid: A comparison of the long-term treatment of bipolar illness. *154th Annual Meeting of the American Psychiatric Association, New Orleans, LA* (2001).
27. Wills MM, Lawson WB, Ogutha J, Yan LJ, Flowers J, **Nierenberg AA**, Sachs GS, Comparison of African Americans and Caucasians Entering the Systematic Treatment enhancement Program for Bipolar Disorder. *American Psychiatric Association Annual Meeting, Philadelphia, PA* (2002)
28. Cassano P, Iosifescu DV, Simon N, Murakami J, Alpert J, **Nierenberg AA**, Fava M. Panic Symptoms in Major Depressive Disorder. *New Clinical Drug Evaluation Unit Annual Meeting* (2003)
29. **Nierenberg AA**, Thase ME, Bowden, CL, Smoller J, Insel T. Update on STEP-BD Results and the Bipolar Trials Network. 46th ACNP Annual Meeting in Boca Raton, Florida, December 9-13, 2007

Book Reviews and Letters:

1. **Nierenberg, AA**. Psychiatric Aspects of Epilepsy. *Am J Psychiatry* 143-105 (1986).

Letters:

2. **Nierenberg, AA**, Jekel J, Singer B. Is standard deviation always the right choice? *Am J Psychiatry* (letter) 143:1198-1199 (1986).
3. **Nierenberg, AA**. One antidepressant fails: What next? A survey of northeastern psychiatrists: rejoinder. *J Clin Psychiatry* (letter) 53:417 (1992).
4. **Nierenberg, AA**. Early non-response to fluoxetine as a predictor of poor eight week outcome: rejoinder. *Am J Psychiatry*: (accepted for publication)
5. Grush LR, **Nierenberg, A**, Keefe B, Cohen LS. St. John's Wort during pregnancy. *JAMA* (letter) 280:1566 (1998)
6. Ostacher MJ, Perlis RH, **Nierenberg AA**. Dr. Ostacher and Colleagues Reply. *J Clin Psychiatry*. 2007 Sep;68(9):1447-1448.
7. Tamada RS, Amaral JA, Issler CK, Lafer B, **Nierenberg AA**. Reply to Dr. Kauer-Sant'Anna and Dr. Yatham's letter "comment on 'Antidepressant treatment-emergent affective switch in bipolar disorder: a prospective case-control study of outcome'" *Rev Bras Psiquiatr*. 2007 Mar;29(1):87-88.
8. **Nierenberg AA**. Response to Carlson letter. *Am J Psychiatry* 2013;170:559-60.

Appendix: National Presentations between 1985 and 2000

1985	"Clinical Epidemiology of Refractory Depression" Presented at Grand Rounds, Butler Hospital, Providence RI
1986	"The Clinical Epidemiology of Treatment Resistant Depression" Presented at Grand Rounds, Butler Hospital, Providence RI
1991	"Improving Skills in the Diagnosis of Depression" Presented at the Psychiatric Chapter of Central Georgia Regional Meeting, Macon, GA
1991	"Lithium Use with Unipolar Illness" Presented at The 19 th Annual Friends Hospital Clinical Conference Lithium in Clinical Practice, Philadelphia, PA
1992	"Treatment Resistant Depression: Definitions and Treatment Approaches" Presented at Grand Rounds, Hartford Hospital, Hartford, CT
1992	"Treatment Resistant Depression" Presented at the Greenbrier Eight Annual Psychopharmacologic Symposium, White Sulphur Springs, WV
1992	"Evaluation and Management of Treatment Resistant Depression" Presented at the Louisiana Psychiatric Association Spring Meeting, Lafayette, LA
1992	"Treatment of Resistant Depression" Presented at Vermont Psychiatric Association Spring Meeting, South Royalton, VT
1992	"Algorithm for Treatment Resistant Depression" Presented at Grand Rounds, University of Tennessee, Knoxville, TN
1992	"Algorithm for Treatment Resistant Depression" Presented at the Smokey Mountain Psychiatric Association, Knoxville, TN
1993	"Treatment Refractory Depression" Presented at Grand Rounds, Maine Medical Center, Portland, ME
1993	"Evaluation and Treatment of Resistant Depression" Presented at Grand Rounds, Jackson Brook Institute, Portland, ME
1993	"The Management of Treatment Refractory Depression" Presented at Grand Rounds, University of Cincinnati Medical Center, Cincinnati, OH
1993	"Issues in Treatment Resistant Depression" Presented at Grand Rounds, Plymouth Hospital, Plymouth, MA
1993	"Recurrent Depression" Presented at the Broward Psychiatric Society Meeting, Ft. Lauderdale, FL
1993	"Recognition and Treatment of Major Depression" Presented at the Annual Meeting of the New Hampshire Academy of Family Physicians, Concord, NH
1994	"SSRIs vs TCAs" Presented at Grand Rounds, Tampa Veterans Administration Hospital, Tampa, FL
1994	"Treatment of Severe Depression: Is there a difference between SSRIs and TCAs?" Presented at New Issues in Antidepressant Treatment Conference, Dallas, TX

- 1994 "The Next Generation of Antidepressants"
Presented at Grand Rounds, University of Vermont Medical School, Burlington, VT
- 1994 "The Next Generation of Antidepressants"
Presented at New York State Psychiatric Association Meeting, Plattsburgh, NY
- 1994 "The Treatment of Recurrent Depression"
Presented at Grand Rounds, Dartmouth-Hitchcock Memorial Hospital, Hanover, NH
- 1994 "Treatment Resistant Depression in the Age of SSRIs"
Presented at the First Staley Memorial Lecture, St. Francis Hospital, Pittsburgh, PA
- 1994 "Long-Term Management of Depression: How Long to Treat?"
Presented at Mood and Activity Disorders in Adults and Seniors Conference, University of South Florida College of Medicine, Tampa, FL
- 1994 "Treatment Resistant and Recurrent Depression: SSRI Issues"
Presented at Grand Rounds, William S. Hall Psychiatric Institute, Columbia, SC
- 1994 "A Rationale Approach to Antidepressant Drug Selection"
Presented at Midlands Psychiatric Association Meeting, Columbia, SC
- 1994 "Antidepressant Augmentation Strategies"
Presented at Grand Rounds, Department of Psychiatry, Maine Medical Center, Portland, ME
- 1994 "Polypharmacy in the Age of SSRIs"
Presented at Grand Rounds, Department of Psychiatry, Augusta Institute of Mental Health, Augusta, ME
- 1994 "Antidepressant Augmentation Strategies: An Update"
Presented at the Course on Refractory Depression, 150th Annual Meeting of the American Psychiatric Association, Philadelphia, PA (800 participants, 2 hrs)
- 1994 "New Issues in Antidepressant Treatment"
Presented at Grand Rounds, New Hampshire Hospital, Concord, NH
- 1994 "Diagnosis and Treatment of Biochemical Depression: New Therapeutic Options"
Presented at Grand Rounds St. Elizabeth's Hospital, Utica, NY
- 1994 "New Treatments in Depression"
Presented at CME Luncheon, Central Vermont Hospital, Montpelier, VT
- 1994 "Benefits and Risks of Venlafaxine"
Presented to the St. Vincents Hospital Medical Staff, Bridgeport, CT
- 1994 "An Update on Mood Disorders"
Presented at Grand Rounds, St. Vincent's Hospital, Harrison, NY
- 1994 "Venlafaxine for Treatment Resistant Unipolar Depression"
Presented at the Clinical Internationale Neuro-Psychopharmacologicum 14th Annual Congress, Washington, D.C. (200 participants, 1 hrs)
- 1994 "New Directions in the Psychopharmacology of Depression"
Presented at Grand Rounds, University of Tennessee Graduate School of Medicine, Knoxville, TN
- 1994 "New Antidepressants and Future Directions"

- Presented at Grand Rounds, Good Samaritan Hospital, Cincinnati, OH
- 1994 "New Directions in the Psychopharmacology of Mood Disorders"
Presented at Psychopharmacology Rounds, University of Cincinnati Medical School Department of Psychiatry, Cincinnati, OH
- 1994 "New Directions in Mood Disorders"
Presented at Grand Rounds, Mt. Sinai Hospital, New York, NY (100 participants, 1 hrs)
- 1994 "Treatment Resistant Depression in the '90s"
Presented to the NY Hospital Westchester Division Department of Psychiatry, Purchase, NY
- 1994 "Recognition and Management of Depression in Primary Care"
Presented at Medical Grand Rounds, St. Barnabus Hospital, Livingston, NJ
- 1994 "Recognition and Management of Depression in Primary Care"
Presented at Medical Grand Rounds, West Orange VAMC, West Orange, NJ
- 1994 "Treatment Resistant Depression in the '90s"
Presented at Grand Rounds, Lenox Hill Hospital, New York, NY
- 1994 "Treatment Resistant Depression"
Presented at Grand Rounds, St. Mary's Hospital, Lewiston, ME
- 1994 "Treatment Resistant Depression: An Update"
Presented at the Maine Psychiatric Nurses Association Annual Meeting, Freeport, ME
- 1994 "Treatment Resistant Affective Disorders"
Presented at Grand Rounds, Mayo Clinic, Rochester, MN (70 participants, 1 hrs)
- 1994 "New Directions in Psychopharmacology of Mood Disorders"
Presented at the Fall Meeting of the New Hampshire Psychiatric Society, Concord, NH
- 1994 "Treatment Resistant Depression in the 90's"
Presented at Grand Rounds, State University of New York at Buffalo, Buffalo, NY
- 1994 "Treatment Resistant Depression"
Presented at the conference "Mood Disorders: A Clinical Research Update", The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, (130 participants, 1 hrs)
- 1994 "New Antidepressants for the 90's"
Presented at Medical Grand Rounds, St. Joseph's Hospital, Nashua NH, 40 participants, 1 hour
- 1995 "Treatment Resistant Depression in the 90's"
Presented at Grand Rounds, NYU Medical Center, New York, NY (150 participants, 1 hrs)
- 1995 "Treatment Resistant Depression: A Practical Update"
Presented at Grand Round, Metropolitan Hospital, New York, NY 40 participants, 1 hour
- 1995 "Treatment Resistant Depression in the 90's"
Presented at Grand Rounds, Beth Israel Hospital, New York, NY
- 1995 "Advances in the Diagnosis and Treatment of Depression"
Presented at Medical Grand Rounds, Southern New Hampshire Medical Center, Nashua, NH
- 1995 "Newer Antidepressants: Benefits and Risks"
Presented at Grand Rounds, University of Illinois, Urbana, IL

- 1995 "Bringing Coals to Newcastle: Atypical vs. DSM-IV Melancholic Depression"
Presented at Grand Rounds, Columbia University Department of Psychiatry, New York, NY (75 participants, 1 hrs)
- 1995 "Treatment Resistant Depression"
Presented at Marvelous Medicines, Magical Cures, and the Mental Health Jungle of Managed Care Conference, University of Wisconsin Medical School and the Dean Foundation for Health, Research, and Education, Madison, WI (120 participants, 1 hrs)
- 1995 "Refractory Depression"
Presented at Riverside Hospital University of Ohio CME series, Columbus, OH
- 1995 "Treatment of Depression"
Presented at Medical Grand Rounds, Riverside Hospital, University of Ohio Medical School, Columbus, OH
- 1995 "Problems in the Long-Term Treatment of Depression"
Presented at Grand Rounds, Tulane Medical School Department of Psychiatry, New Orleans, LA
- 1995 "Treatment Resistant Depression"
Presented at Grand Rounds, Malcolm Grow Medical Center, Andrews Air Force Base, MD
- 1995 "Resistant Unipolar Depression"
Presented at Psychopharmacology Rounds, Bethesda Naval Hospital, Bethesda, MD
- 1995 "Treatment Resistant Depression"
Presented at Grand Rounds, Allegheny General Hospital Department of Psychiatry, Pittsburgh, PA
- 1995 "Augmentation Strategies in Refractory Depression"
Presented at the American Psychiatric Association Annual Meeting Refractory Depression Course, Miami, FL (800 participants, 1 hrs)
- 1995 "Sexual Side Effects of Antidepressants: A Quality of Life Issue"
Presented at Depression: From the Laboratory to the Clinic to the Community Symposium, Brown University Department of Psychiatry, Providence, RI
- 1995 "An Update on New Antidepressants"
Presented at Grand Rounds, Dartmouth-Hitchcock Memorial Hospital, Hanover, NH
- 1995 "Treatment Resistant Depression in 1995"
Presented at Major Affective Disorders: State-of-the-Art Update Conference, Hospital of Saint Raphael, New Haven, CT
- 1995 "New Directions in the Psychopharmacology of Depression"
Presented at Medical Grand Rounds, Manchester VA Medical Center, Manchester, VT
- 1995 "Treatment Resistant Depression"
Presented at the Update on Clinical Psychopharmacology, American Psychiatric Association Annual Institute of Psychiatric Services, Boston, MA
- 1995 "An Update on Treatment Resistant Depression"
Presented at the First Annual Mood Disorders Conference, George Washington University, Washington, D.C. (60 participants, 1 hrs)
- 1995 "Treatment Resistant Depression"
Presented at Grand Rounds, Milwaukee College of Medicine,

- Milwaukee, WI
- 1995 "Treatment Resistant Depression"
Presented at Grand Rounds, Milwaukee VA Medical Center, Milwaukee, WI
- 1995 "Recent Advances in the Management of Acute and Treatment-Resistant Depression"
Presented at the Department of Psychiatry and Biobehavioral Science Grand Rounds, Neuropsychiatric Institute and Hospital, Center for the Health Sciences, University of California, Los Angeles, CA (40 participants, 1 hrs)
- 1995 "Predictors of Antidepressant Response: The Holy Grail?"
Presented at Contemporary Clinical Psychopharmacology: Relating Basic and Clinical Science - In Honor of Jonathan O. Cole, MD. American College of Neuropsychopharmacology Annual Meeting Satellite, San Juan, Puerto Rico (50 participants, 1 hrs)
- 1996 "Treatment Resistant Depression"
Presented at the Cleveland Psychiatric Society, Cleveland, OH (40 participants, 1 hrs)
- 1996 Invited Expert Participant, "Consensus Conference for Preferred Practices for the Management of Depression", State of Texas Mental Health and Mental Retardation Division, Galveston, TX (70 participants, 1 hrs)
- 1996 "Treatment Resistant Depression"
Presented at MetroHealth Medical Center Grand Rounds, Cleveland, OH
- 1996 "Issues in the Long-Term Treatment of Depression"
Presented at Grand Rounds, Cleveland Clinic, Cleveland, OH
- 1996 "Long Term Treatment of Depression in the Real World"
Presented at the Western New York State Psychiatric Association Meeting, Buffalo, NY (60 participants, 1 hrs)
- 1996 "Clinical Consultation for Treatment Resistant Depression"
Presented at the Southern New Jersey Psychiatric Association Meeting, Cherry Hill, NJ
- 1996 "Expert Consultation for Difficult Patients"
UMDNJ-Department of Psychiatry, Cherry Hill, NJ (50 participants, 1 hrs)
- 1996 "Better Outcomes for Treatment Resistant Depression"
Presented at the Eastern Missouri Psychiatric Society Meeting, St. Louis, MO
- 1996 "Pharmacological Strategies for the Management of Refractory Depression"
Presented at Grand Rounds, St. Louis University Psychiatry, St. Louis, MO
- 1996 "Depression in Primary Care: What do you really have to know?"
Presented at Grand Rounds, Austin Diagnostic and Medical Center, Austin, TX
- 1996 "An Update on Treatment Refractory Depression"
Presented at Grand Rounds, Austin Travis County Mental Health and Mental Retardation Center, Austin, TX
- 1996 "Management of Treatment Resistant Depression"
Presented at Grand Rounds, Veterans Administration Medical Center at Waco, TX

- 1996 "Case Conference: Treatment Resistant Depression"
Presented at Grand Rounds, Malcolm Grow Medical Center,
Andrews Air Force Base, MD
- 1996 "Contemporary Management of Refractory Depression"
Presented at Grand Rounds, Department of Psychiatry,
Uniformed Services University School of Medicine, Bethesda,
MD (35 participants, 1 hrs)
- 1997 "Psychostimulant Augmentation:
Presented at An Update of Antidepressant Augmentation,
Journal of Clinical Psychiatry Symposium, New York NY
- 1997 "Pharmacology of Treatment Resistant Depression"
Presented at Grand Rounds, St. Luke's Hospital, New York, NY
- 1997 "Dysthymia"
Presented at Grand Rounds, Buffalo Psychiatric Center, Buffalo,
NY
- 1997 "Depression"
Presented at Medical Grand Rounds, Frisbee Memorial Hospital,
North Conway, NH
- 1997 "Treatment Resistant Depression"
Presented at Grand Rounds, Hampstead Hospital, NH
- 1997 "Long-Term Course of Depression"
Presented at Grand Rounds, University of Connecticut
Psychiatry Grand Rounds, Hartford, CT (50 participants, 1 hrs)
- 1997 "Benefits of Treatment of Depression"
Presented at the conference on Depression in the Workplace:
Achieving Productivity and Workplace Peace, Minneapolis, MN
- 1997 "Strategies and Tactics in the Treatment of Depression"
Presented at Medical Grand Rounds, North Shore Hospital,
Manhasset, NY
- 1997 "An Overview of Antidepressants"
Presented at the Rockville Psychiatry Group
Psychopharmacology Meeting, Washington, D.C.
- 1997 "Treatment Resistant Depression"
Presented at Grand Rounds, Brattleboro Hospital, Brattleboro,
VT
- 1998 "Treatment Resistant Depression"
Presented at Grand Rounds, Middlesex Hospital, Middletown, CT
- 1998 "A Critique of Pharmacological Strategies for Treatment
Resistant Depression"
Presented at Grand Rounds, Department of Psychiatry, Baylor
Medical School, Houston, TX (70 participants, 1 hrs)
- 1998 "A Critique of Pharmacological Strategies for Treatment
Resistant Depression"
Presented at Grand Rounds, Department of Psychiatry, St.
Raphael Hospital, New Haven, CT
- 1998 "Treatment Resistant Depression"
Presented at Grand Rounds, Department of Psychiatry,
Bridgeport Mental Health Center, Bridgeport, CT
- 1998 "Treatment Resistant Depression"
Presented at Grand Rounds, Finch University of the Health
Sciences, Chicago, IL
- 1998 "Management of Patients on Antidepressants"
Presented at the Conference on Antidepressants and Sexual
Dysfunction, New York, NY

- 1998 "An Overview of Treatment Resistant Depression"
Presented at the Symposium on Treatment Resistant Depression, American Psychiatric Association Annual Meeting, Toronto, Canada (500 participants, 1 hrs)
- 1998 "Predictors of Response to Antidepressants"
Presented at the Symposium on Predictors and Antidepressants, American Psychiatric Association Annual Meeting, Toronto, Canada (800 participants, 1 hrs)
- 1998 "A Critical Look at Lithium Augmentation"
Presented at the Symposium on Cutting Edge Polypharmacy for Mood Disorders, American Psychiatric Association Annual Meeting, Toronto, Canada (500 participants, 1 hrs)
- 1998 "Minority Patients Receive Less SSRIs"
Presented at New Research, American Psychiatric Association Annual Meeting, Toronto, Canada
- 1998 "Atypical Depression"
Presented at the Symposium on Subtypes of Depression, American Psychiatric Association Institute on Health Services
- 1998 "Beyond Major Depression"
Presented at Grand Rounds, Department of Psychiatry, St. Francis Medical Center, Pittsburgh, PA
- 1998 "Beyond Major Depression"
Presented at Grand Rounds, Department of Psychiatry, Allegheny Medical Center, Pittsburgh, PA
- 1998 "Sexual Dysfunction and Depression"
Presented at the National Mental Health Association Meeting Symposium Depression Research Update, New York, NY
- 1999 "Sexual Dysfunction and Antidepressants"
Presented at the Danbury Hospital Division of Behavioral Health Psychiatry Rounds, Danbury, CT
- 1999 "Remission as the New Standard in the Treatment of Depression and Anxiety"
Presented at the Working Group on Remission Conference, Dallas, TX (25 participants, 1 hrs)
- 1999 "Practical Issues in the Management of Treatment Resistant Depression"
Presented at Grand Rounds, University of Wisconsin Medical School Department of Psychiatry, Milwaukee, WI
- 1999 "Treatment Resistant Depression"
Presented at Grand Rounds, Loyola University Medical School, Chicago, IL
- 1999 "St. John's Wort"
Presented at the 2nd Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists, Lake Tahoe, NV
- 1999 "Treatment Resistant Depression Update"
Presented at Grand Rounds, University of Kansas Medical School Department of Psychiatry, Wichita, KA
- 1999 "A Critique of Treatment Resistant Depression"
Presented at Grand Rounds, Department of Psychiatry, Woodhull Hospital, Brooklyn, NY
- 1999 "Optimizing Management of Depression"
Presented at "Therapeutic Advances in Treating Depression", Chicago, IL

- 1999 Invited participant, International Expert Meeting "The issue of onset of action in antidepressants: Methodology and Results", Boca Raton, FL
- 2000 Invited Presenter, Robert Wood Johnson Consensus Conference "Integrating Psychotherapy Into Medication Algorithms for Mood Disorders", Dallas TX (50 participants, 1 hrs)
- 2000 "Women and Depression"
Presented at "What's New for the Blues?", Geisinger Health Systems, Danville, PA (40 participants, 1 hrs)
- 2000 "Treatment Resistant Depression"
Presented at the Eighth Annual Mood and Anxiety Disorder Conference, Georgetown University School of Medicine, Washington, D.C. (60 participants, 1 hrs)
- 2000 "Management of Antidepressant and Mood Stabilizer Side Effects"
Presented at An Update on the Pharmacotherapy of Mood Disorders, New York Presbyterian Hospital, Manhattan, New York (100 participants, 1 hrs)
- 2000 "Update on Reboxetine"
Presented at "Psychopharmacology Annual Review", New York University School of Medicine, New York, NY (150 participants, 1 hrs)
- 2000 Invited participant, "The Second Annual Luther B. Robinson Symposium on Mental Health: Disparities in Access to Mental Health Services for African Americans", Howard University, Washington, D.C. (200 participants, 1 hrs)

Invited Presentations Local between 1989 and 2000

- 1989 "The Use of Anticonvulsants in Psychiatry"
Presented at Grand Rounds, Worcester State Hospital, Worcester MA
- 1991 "Treatment of Resistant Depression"
Presented at Grand Rounds, Cape Cod Psychiatric Center, Hyannis MA
- 1992 "Treatment Resistant Depression"
Presented at Grand Rounds, Cambridge Hospital, Cambridge MA
- 1992 "Use of Antidepressants in Outpatients"
Presented at Grand Rounds, Lowell General Hospital, Lowell MA
- 1992 "Treatment Resistant Depression"
Presented at Grand Rounds, Spaulding Hospital, Boston MA
- 1992 "Treatment Resistant Depression"
Presented at Grand Rounds, Leonard Morse Hospital, Natick MA
- 1993 "The Recognition and Treatment of Depression"
Presented at Harvard Community Health Plan, Cambridge, MA
- 1993 "Polypharmacy for Unipolar Depression"
Presented at Manic Depressive and Depressive Association Meeting, Belmont, MA
- 1993 "Treatment of Resistant Depression: New Agents"
Presented at the University of Massachusetts Medical Center, Worcester MA
- 1993 "The Pharmacologic Management of Resistant Depression"
Presented at Grand Rounds, Danvers State Hospital, Danvers, MA

- 1993 "Causes and Management of Treatment Resistant Depression"
Presented at Grand Rounds, Atlanticare Hospital, Lynn, MA
- 1993 "Long Term Management of Recurrent Depression"
Presented at the Conference on Chronic Mental Disorders,
University of Massachusetts Medical Center, Worcester, MA
- 1993 "Recognition and Management of Depression"
Presented at the Massachusetts Pharmacists Meeting,
Burlington, MA
- 1993 "Treatment Resistant Depression"
Presented at Grand Rounds, Pembroke Hospital, Pembroke, MA
- 1994 "Recurrent Atypical Depression: Are Neurovegetative Symptoms
Stable?"
Presented at Harvard Research Day, Boston, MA
- 1994 "An Update of Treatment Resistant Depression"
Presented at the Psychopharmacology Conference, McLean
Hospital, Belmont, MA
- 1994 "Recurrent Depression: How Long to Treat?"
Presented at Grand Rounds, Massachusetts General Hospital,
Boston, MA
- 1994 "New Issues in Antidepressant Treatment"
Presented at the Quincy Medical Group, Quincy, MA
- 1994 "What's New in Antidepressant Treatment?"
Presented at Grand Rounds, New England Memorial Hospital,
Stoneham, MA
- 1994 "Treatment Resistant Depression in the 1990's"
Presented at Grand Rounds, Boston Veterans Administration
Medical Center, Boston, MA
- 1994 "New Issues in Antidepressant Treatment"
Presented at Grand Rounds, Lahey Clinic, Burlington, MA
- 1994 "How to Use an Article on Prognosis: A Critical Look at the
Literature"
Presented at the First Psychiatry Journal Club, Massachusetts
General Hospital, Boston, MA
- 1994 "Treatment Resistant Depression"
Presented at Psychopharmacology Lecture,
Psychopharmacology Unit, Massachusetts General Hospital,
Boston, MA
- 1994 "Promises and Pitfalls of Polypharmacy for Mood Disorders"
Presented at the Manic Depressive and Depressive Association
Meeting, McLean Hospital, Belmont, MA
- 1994 "New Directions in the Treatment of Depression"
Presented at Grand Rounds, Faulkner Hospital, Boston, MA
- 1994 "Sexual and Other Side Effects of Antidepressants"
Presented at the McLean Hospital CME Conference
"Understanding and Managing Complex Problems in
Depression: Sleep, Sex, Chronicity and Psychosis", Harvard
University, Cambridge, MA
- 1994 "Antidepressants: Current Issues and New Drugs"
Presented at the Harvard Medical School CME Course
"Psychopharmacology", Harvard University, Boston, MA
- 1994 "Treatment Resistance: Relapse and Recurrence"
Presented at the Harvard Medical School CME Course
"Psychopharmacology", Harvard University, Boston, MA, 1 hour,
710 participants

- 1994 "Epidemiology of Depression"
Presented at the Psychiatric Epidemiology Course, School of Public Health, Harvard University, Boston, MA, 3 hours, 25 students
- 1994 "Dosing of SSRI Antidepressants"
Presented at the Massachusetts Medicaid Drug Utilization Review Board, Massachusetts Medical Society, Waltham, MA, 1 hour, 20 participants
- 1994 "Treatment Resistant Depression"
Presented at Tufts University Department of Psychiatry Grand Rounds, Boston, MA, 1 hour, 30 participants
- 1994 "Treatment Resistant Depression in the 90's"
Presented at Harvard Community Health Plan, Medford, MA, 1 ½ hours, 10 participants
- 1994 "New Directions in the Management of Depression"
Presented at Grand Rounds, St. Elizabeth Hospital, Worcester, MA
- 1994 "Advances in Antidepressant Treatment"
Presented at Medical Grand Rounds, Newton Wellesley Hospital, Newton, MA, 50 participants, 1 hour
- 1995 "Treatment Resistant Depression: A case conference"
Presented at Harvard Community Health Center, Medford, MA, 1 ½ hours, 10 participants
- 1995 "Issues in the Treatment of Depression"
Presented at Harvard Community Health Center, Medford, MA
- 1995 "Treatment Resistant Depression in the '90s"
Presented at Grand Rounds, Norwood Hospital, Norwood, MA
- 1995 "Venlafaxine: Risks and Benefits"
Presented at Grand Rounds, Massachusetts Mental Health Center, Boston, MA
- 1995 "Treatment Resistant Depression in the '90s"
Presented at Harvard Community Health Center, Wellesley, MA
- 1995 "DSM-IV Mood Disorders: What's new, what's different, what's the same as DSM-III-R?" Presented at Grand Rounds, Harvard Community Health Center, Brookline, MA
- 1995 "Treatment Resistant Depression in the '90s"
Presented at Grand Rounds, Tewksbury Hospital, Hawthorne, MA
- 1995 "New Directions in the Pharmacotherapy of Depression"
Presented at Grand Rounds, Sommerville Hospital, Sommerville, MA
- 1995 "Clinical Comparison of Antidepressants"
Presented at Massachusetts General Hospital Pharmacy Department Continuing Education Program, Boston, MA
- 1995 "Depression Treatment"
Presented at Massachusetts General Hospital Medicine-Psychiatry Lectures, Boston, MA
- 1995 "New Perspectives on Antidepressants"
Presented at the Psychopharmacology Seminar, Cambridge Hospital, Cambridge, MA
- 1995 "New Issues in Acute and Long Term Antidepressant Treatment"
Presented at Medical Staff CME Meeting, Bournewood Hospital, Brookline, MA

- 1996 "Pharmacological Management of Treatment Resistant Depression"
Presented at the Psychopharmacology Symposium, Brookside Hospital, Andover, MA
- 1996 "Treatment Resistant Depression"
Presented at Psychopharmacology Rounds, Brigham and Women's Hospital, Boston, MA
- 1996 "Treatment Resistant Depression"
Presented at Psychopharmacology '96: State of the Art Therapies, McLean Hospital, Belmont, MA
- 1996 "A Matter of Time and Antidepressants: Acute and Long-Term Issues"
Presented at Grand Rounds, McLean Hospital, Belmont, MA
- 1996 "Risks and Benefits of Antidepressants"
Presented at Staff Conference, MGH Chelsea Memorial Health Center, Chelsea, MA
- 1996 "Relapse Prevention of Depression"
Presented at the Massachusetts Department of Mental Health Conference, Kennedy Library, Boston, MA
- 1996 "Long-Term Treatment of Depression"
Presented at Massachusetts Psychiatric Society Annual Psychopharmacology Conference, Boston, MA
- 1996 "Nefazodone"
Presented at Chelsea Medical Center, Chelsea, MA
- 1996 "Everything You Wanted to Know about Nefazodone"
Presented at Grand Rounds, Department of Psychiatry, University of Massachusetts, Worcester MA
- 1997 "Course of Depression: Relapse and Recurrence"
Presented at Grand Rounds, Massachusetts Mental Health Center, Boston, MA
- 1997 "An Overview of Depression"
Presented at Medical Grand Rounds, Lowell General Hospital, Lowell, MA
- 1997 "Treatment Resistant Depression"
Presented at Psychiatric Grand Rounds, Berkshire Medical Center, Pittsfield, MA
- 1997 "An Overview of Antidepressants"
Presented at the Harvard Medical School 8th Annual Summer Series, North Falmouth, MA
- 1998 "St. John's Wort: A Critique of a Putative Herbal Antidepressant"
Presented at Grand Rounds, Massachusetts General Hospital Department of Psychiatry, Boston, MA
- 1998 "New Treatments for Treatment Resistant Depression"
Presented at the Robert Sovner Memorial Symposium, Harvard Vanguard Medical Center, Medford, MA
- 1998 "Treatment Resistant Depression"
Presented at Grand Rounds, University of Massachusetts Department of Psychiatry, Worcester, MA
- 1998 "Treatment Resistant Depression"
Presented at Psychopharmacology Rounds, McLean Hospital, Belmont, MA
- 1998 "What is the Threshold for the Treatment of Depression?"

- Presented at Grand Rounds, Department of Psychiatry, Heritage Hospital, Somerville, MA
- 1998 "A Critical Overview of Antidepressants"
Presented at Grand Rounds, Department of Psychiatry, Cape Cod Hospital, Cape Cod, MA
- 1998 "An Overview of Antidepressants"
Presented at the Harvard Medical School 9th Annual Summer Series, North Falmouth, MA
- 1998 "Newer Antidepressants"
Presented at the American College of Clinical Pharmacology 17th Frontiers Symposium: An Update in Clinical Pharmacology, Boston, MA
- 1998 "Depression in the Elderly"
Presented at Grand Rounds, Family Practice Residency Program, Malden Hospital, Malden, MA
- 1999 "Nutritional supplements and Herbal remedies: Help or hype? St. John's Wort"
Presented at the Complementary Medicine Seminar, Kenneth B. Schwartz Center and Women's Health Associates, Massachusetts General Hospital, Boston, MA
- 1999 "A Critical Look at the Treatment of Treatment Resistant Depression: Confluence and Discrepancies between the Literature and the Clinic"
Presented at Tufts University School of Medicine New England Medical Center Psychiatric Institute Science Lecture Series, Boston, MA
- 1999 "Treatment-Resistant Depression: An Update"
Presented at the Massachusetts Mental Health Center Psychopharmacology and Neurobiology Guest Lecture Series, Boston, MA
- 1999 "Depressive Spectrum Disorders"
Presented at Grand Rounds, Department of Psychiatry, Massachusetts General Hospital, Boston MA
- 1999 "An Overview of Antidepressants"
Presented at the Harvard Medical School 10th Annual Summer Series, North Falmouth, MA
- 1999 "Norepinephrine and Depression: Back to the Future"
Presented at Academic Conference, 1 hour 60 participants, McLean Hospital, Belmont, MA
- 1999 "Treatment Resistant Depression"
Presented at Advanced Clinical Training, Massachusetts General Hospital, Boston, MA
- 2000 "The Psychopharmacological Treatment of Depression"
Presented at Case Discussions of Depression Conference, McLean Hospital, Belmont, MA (12 participants, 1 hrs)
- 2000 "St. John's Wort"
Presented at National Depressive and Manic Depressive Association National Meeting, Boston, MA (150 participants, 1 hrs)
- 2000 "Long Term Treatment of Depression in the Real World"
Presented at Grand Rounds, Newton Wellesley Hospital, Department of Psychiatry, Newton, MA (70 participants, 1 hrs)
- 2000 "Update on Depression"

2000 Presented at Harvard Pigrim Healthcare Program, Cambridge, MA (15 participants, 1 hrs)
"Essential Psychopharmacology"
2000 Presented at the Harvard Medical School 11th Annual Summer Series, North Falmouth, MA (15 participants, 40 hrs)
"Depression an Update"
Presented at Grand Rounds, Melsrose-Wakefield Hospital, Melrose, MA (30 participants, 1 hrs)